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Title of Thesis Studies on Louping-ill Virus Vaccine
Studies were undertaken to define the optimum dosage regimen for commercial louping-
ill virus vaccine, to investigate the susceptibility of vaccinated yet seronegative
sheep to challenge with live louping-ill virus and to determine the storage characteristics
of the vaccine at refrigerated and room temperatures.
Vaccination studies confirmed that two 1ml doses were required to provoke an
adequate immune response in the majority of animals and maximum antibody titres were
produced when an interval of two to eight weeks between injections was employed.
Vaccinated animals were clinically resistant to experimental challenge although in
animals exhibiting minimal or undetectable post-vaccinal antibody titres viraemias of
low intensity were demonstrated. Circulating virus was not detected in animals with
pre-challenge antibody titres greater than 1/10. Studies concerning vaccine stability
demonstrated that both the virus antigen concentrate and the emulsified final vaccine
were immunologically unstable following storage for periods of less than six months.
Production of louping-ill virus vaccine was therefore reappraised in an attempt
to improve vaccine potency and stability and to produce a one-dose vaccine capable
of consistently producing a satisfactory immune response in sheep.
Optimal conditions for the growth of louping-ill virus in BHK-21 cell monolayer
cultures were determined experimentally and using this technique under commercial
conditions titres of harvests ranged from 8.5 logiopfu/ml to 6.1 log-^Qpfu/ml. A
direct correlation between the preinactivation infectivity titres of virus suspensions
and the immunogenicity of resulting vaccines was demonstrated and a threshold titre of
8.0 logiQpfu/ml determined. Harvests with preinactivation infectivity titres below
the threshold produced unacceptable vaccines. Concentration of virus antigen was
therefore required to consistently produce potent louping-ill virus vaccine.
The present commercial vaccine is manufactured by concentrating inactivated virus
harvests by methanol precipitation. A study of the efficacy of this concentration
technique demonstrated however that there was no increase in the immunogenicity of
concentrated virus harvests compared to unconcentrated virus harvests and in several
instances concentration resulted in vaccines of decreased potency. The low potency
characteristic of the commercial vaccine may therefore be partly attributable to the
ineffectiveness of this technique for concentrating viral antigen.
Concentration by methods other than methanol precipitation were examined; these
were ultrafiltration and precipitation with polyethylene glycol. Vaccines produced
from virus antigen concentrated by ultrafiltration and prepared under both experimental
and commercial conditions of production were consistently more immunogenic than
corresponding vaccines prepared by concentrating viral antigen by methanol precipitation
or polyethylene glycol precipitation. A single 1ml dose and two 1ml doses of vaccine
prepared by ultrafiltration produced a satisfactory immune response in sheep and cattle
respectively and antibody titres remained constant for at least six months.
Stability studies with vaccine prepared by ultrafiltration and stored at refrigerated
temperatures demonstrated that although the immunogenicity of the emulsified final vaccine
progressively declined over a six month period, immunogenicity of the virus antigen
concentrate remained stable. Further work therefore is required to improve stability of
the final vaccine and it is suggested that this be designed to evaluate the use of





Louping-ill is a tick transmitted encephalomyelitis primarily
affecting sheep. The causative agent is recognised as a member of
the group of closely related tick-borne flaviviruses belonging to the
family of viruses known as the Togaviridae (Andrewes , Pereira and
Wildy, 1978).
In the 19th and early 20th centuries the term 'louping-ill' was
commonly used by shepherds in Scotland and parts of north England to
describe a group of disease conditions in sheep that included pyaemic
spinal meningitis, gastritis, woolball, joint-ill and pneumonia
(Cleishbottam, 1816; Duncan, 1807; M'Fadyean, 1894, 1900). Pool,
Brownlee and Wilson (1930) , following a systematic investigation of
louping-ill, described the first successful in series transmission
of 'true' louping-ill in sheep by intracerebral inoculation with
material from the central nervous system of an affected animal.
The common vector of louping-ill proved to be the tick Ixodes
ricinus , trans-stadial but not transovarial transmission being
demonstrated by MacLeod and Gordon (1932) . Experimental transmission
by certain non-British species of ticks has also been demonstrated
and these include Rhipicephalus appendiculatus (Alexander and Neitz,
1933) and Hyalomma anatolicum (Swanepoel, 1968). I. ricinus is
capable of feeding on any vertebrate species (Arthur, 1963) and there
is evidence that several wild vertebrate species are naturally
infected with louping-ill: shrew (Sorex craneus), wood mouse
(Apodemus sylvaticus) (Smith, Varma and McMahon, 1964), red deer
(Cervus elaphus) (Dunn, 1960; Adam, Beasley and Blewett, 1977),
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red grouse (Lagopus lagopus scoticus) (Williams, Thorburn and Ziffo,
1963; Reid and Boyce, 1974) , and roe deer (Capreolus capreolus)
(Reid, Barlow, Boyce and Inglis, 1976).
Infection of the tick is effected by only those vertebrate species
that develop viraemias in excess of the threshold titre required to
establish virus in the tick (Beasley, Campbell and Reid, 1978).
Following a study of the course of infection in a number of candidate
hosts Reid (1978), suggested that only sheep were likely to develop
viraemias of a sufficient intensity to regularly transmit virus to
the tick, and concluded that sheep were probably primarily responsible
for the maintenance of louping-ill in nature.
Although clinical disease is generally associated with sheep,
naturally occurring disease in other domestic animals has also been
described: cattle (Dunn, 1952), horses (Fletcher and Galloway, 1937;
Timoney, 1980), pigs (Bannatyne, Wilson, Reid, Buxton and Pow, 1980)
and dogs (MacKenzie, Smith and Muir, 1973). Man is also susceptible
to louping-ill infection and as a result of occupational associations
with the virus incidences of infection have been reported in laboratory
workers (Rivers and Schwentker, 1933, 1934; Edward, 1948b, Webb,
Connolly, Kane, O'Reilly and Simpson, 1968) and in butchers and
abattoir workers (Williams and Thorburn, 1962; Lawson, Manderson and
Hurst, 1949). The number of cases of natural infection in man which
has been recorded has remained small (Davison, Neubauer and Hurst,
1948; Brewis Neubauer and Hurst, 1949; Likar and Dane, 1958; Ross,
1961).
Experimentally louping-ill infection has been studied in
laboratory animals (Alston and Gibson, 1931; Czarkowska-Gladney and
Hurst, 1931; Hurst, 1931; Gre^ikova, Albrecht and Ernek, 1961; Webster
and Fite, 1933; Doherty, 1969a, 1969b; Zlotnik, Carter and Grant,
1971), in domestic species (Pool, Brownlee and Wilson, 1930; Brownlee
and Wilson, 1932; Dunn, 1952; Dow and McFerran, 1964; Reid and Doherty
1971a, 1971b) and captive wild species (Findlay and Elton, 1933,
Seamer and Zlotnik, 1970; Reid 1975b, 1978; Reid, Moss, Pow and Buxton
1980).
Elford and Galloway (1933) using colloidal membranes estimated
the size of louping-ill virus to be 15-20 millimicrons and Lepine
(1931) demonstrated that the optimal pH for viral stability was
7.5 - 8.5. The virus is inactivated by treatment with formalin
(Gordon, Brownlee, Wilson and MacLeod, 1932), bile salts (Smith, 1939),
ethyl ether (Andrewes and Horstmann, 1949), heat (Lepine, 1931),
saponin and sodium lauryl sulphate (Burnet and Lush, 1940).
The disease in sheep is biphasic. In the first febrile phase
virus multiplies and can be readily detected in the blood of the
animal. The second febrile phase follows a few days later coupled
with, in a proportion of cases, incoordination, paralysis and death.
Gordon, Brownlee, Wilson and MacLeod (1932) and Edward (1947a)
demonstrated that experimental infection of animals by the intra¬
cerebral route results in death. Following subcutaneous injection
and in the naturally occurring disease the outcome of infection is
variable although viral invasion of the central nervous system has
been shown to be an inevitable consequence following both intra¬
cerebral and peripheral inoculation (Zlotnik, Keppie and Grant, 1970;
Doherty and Reid, 1971a). Reid and Doherty (1971b) demonstrated
that following peripheral challenge the level of circulating virus
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increases exponentially for two to three days and then declines
rapidly. The decline and cessation of viraemia is associated with
the appearance of humoral antibody. Antibody specific to louping-ill
virus is also produced locally in the central nervous system and the
rate of appearance parallels that of serum antibody (Reid, Doherty
and Dawson, 1971). Reid and Doherty (1971b) therefore suggested that
the variable outcome of infection following peripheral challenge is
dependent on the magnitude and duration of viraemia and the rate at
which the immune system is activated.
Symptoms of louping-ill in sheep are caused by damage to the
Purkinje cells of the cerebellum and the motor nuclei, vestibular
nuclei and the anterior horn cells of the spinal cord (Doherty and
Reid, 1971a). The symptoms of louping-ill disease vary according to
the host (Schwentker, Rivers and Finkelstein, 1933). In monkeys
ataxia is predominant and is caused by widespread disintegration of
the Purkinje cells, in mice, however, the outstanding symptoms are
incoordination, weakness and paralysis caused by destruction of cells
in the cerebrum and spinal cord.
On tick infected pastures where louping-ill is enzootic, heavy
losses, as high as 60 per cent of the flock, may be experienced.
Losses occur in spring and autumn coinciding with the periods of
maximum tick activity. New stock and young sheep returning to tick
infected pastures after overwintering on tick-free ground are
particularly vulnerable (Pool, Brownlee and Wilson, 1930).
Three principal strategies have been attempted to combat louping-
ill; these are treatment, serum prophylaxis and vaccination.
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Laidlaw (1872) first described a treatment for affected animals
recommending a glass of good whisky for ewes and complete immersion
in cold water for afflicted lambs; the latter treatment was said to
have been used with considerable success.
Prophylactic immunization of lambs using hyper-immune louping-
ill antiserum obtained from either sheep or horses was described by
Wilson and Gordon (1948). The duration of passive immunity conferred
by the sheep antiserum was approximately four weeks and was longer
than that resulting from the horse antiserum. As a result of the
short duration of immunity the technique was limited in value although
in controlled field experiments high-titred sheep antiserum was shown
to effect an appreciable reduction in lamb mortality.
The first attempt at vaccination of susceptible animals was
described by Gordon, Brownlee, Wilson and MacLeod (1932). They
investigated the use of live virus based on the observation of Greig,
Brownlee, Wilson and Gordon (1931) that sheep inoculated subcutaneously
with live virus were subsequently immune, but following field trials
it was concluded that the method was particularly hazardous.
Interest then focused on the production of an inactivated virus
vaccine using methods similar to those of Laidlaw and Dunkin (1928)
for dog distemper vaccine. In 1931, a vaccine consisting of a
formalinized 10 per cent suspension of brain, spinal cord and spleen
tissues taken from experimentally infected sheep was subjected to
field trials to assess immunological efficiency and innocuity
(Gordon, 1934). Controlled large-scale field trials from 1931-1934
showed that an average mortality of 9 per cent in unvaccinated
animals was reduced to less than one per cent in vaccinated animals
6.
(Gordon, 1946). A vaccine dose schedule of two injections was
required to produce detectable levels of neutralizing antibody and
to protect sheep against challenge with live virus (Wilson and
Gordon, 1948; Edward, 1947b).
The vaccine was issued commercially in 1935 as three separate
batches and subsequently over 20,000 doses per annum were distributed.
A potential hazard in this technique of vaccine production, i.e. the
presence of adventitious agents in sheep tissue, became a reality in
1937 when a proportion of Blackface sheep inoculated in 1935 with
Batch 2 vaccine developed scrapie, a disease hitherto unknown in this
breed. On investigation it was found that eight Cheviot lambs, born
from ewes that had been in contact with scrapie infection had been
included in the 114 sheep that had been used to make this batch of
vaccine and it was presumed that although the lambs were apparently
healthy they had been in the incubative stage of a scrapie infection
(Gordon, 1946).
The vaccine was used without further incident until 1968 when it
became apparent that the manufacturing methods involved constituted
a serious hazard to production staff, and the vaccine was withdrawn
from the market.
Edward (1947b, 1948a) developed louping-ill vaccines from infected
chick embryo and infected mouse brain. Both vaccines were shown to
protect sheep against challenge with live virus but the chick embryo
vaccine proved to be unstable and lost immunogenicity following 17
weeks of storage. The mouse brain vaccine, although never considered
for commercial use, was used over a period of 10 years to protect at
risk personnel involved in the production of commercial louping-ill
vaccine.
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Wilson (1945) and Edward (1947a) attempted to attenuate the
virus by repeated passage in cultured minced chick embryo and chick
embryo respectively. Attempts were however unsuccessful as virus at
the 64th pass in chick embryo and the 170th pass in crude tissue
culture was still fully virulent for mice and sheep.
O'Reilly, Smith, McMahon, Wilson and Robertson (1965) investigated
the use of Langat virus strain TP-21 as a live vaccine for the
protection of sheep against louping-ill. The antibody responses
following vaccination were however low and its use as a vaccine was
not recommended.
Mayer, Bla&kovifc, Ernek and Libikova (1969) studying the immuno¬
genic and antigenic properties of a monkey and mouse attenuated clone,
designated Hy-Hk 28 '2' of the tick-borne encephalitis (Western
subtype) virus demonstrated that vaccination of sheep with a single
dose of this virus produced seroconversion in 85 per cent of animals
and that 11 months after vaccination animals were protected against
challenge with live louping-ill virus.
An inactivated vaccine based on louping-ill virus propagated in
secondary sheep kidney cell cultures was developed by Brotherston and
Boyce C1970); the infected sheep kidney tissue culture fluids were
treated with formalin and precipitated with cold methanol. The
precipitate was resuspended in saline and mixed with oil adjuvant to
form the finished vaccine. A single dose of this vaccine was shown
to elicit the production of haemagglutination inhibiting antibodies
and neutralizing antibodies and to protect sheep against challenge
with live virus (Brotherston, Bannatyne, Mathieson and Nicholson,
1971).
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This method of vaccine production was offered for commercial
exploitation and in 1971 a vaccine based on this technique of
preparation but with the exception that the virus was propagated in
BHK-21 cells was issued commercially. The current average annual
sales of the vaccine are in the region of 200,000 doses. The vaccine
was originally issued as a single dose vaccine but experience indicated
that the potency of this vaccine was considerably lower than that of
the experimental vaccine described by Brotherston and Boyce (1970).
Two doses of commercial vaccine are now required to consistently
provoke a satisfactory immune response. It has however been demons¬
trated that even following two doses of vaccine a proportion of sheep
remain seronegative. In addition regular potency testing of the
commercial vaccine indicated that the vaccine potency progressively
diminished as the storage period of the vaccine increased. The
stability characteristics of commercial vaccine at refrigerated
temperatures are undetermined.
A requirement therefore exists to define the time interval
between doses giving the maximum serological response, to determine
the relationship between antibody response and the protection
afforded and to determine the storage characteristics of the vaccine.
Louping-ill is probably the most important virus disease of
sheep affecting the hill farming areas of Scotland and northern
England. A double dose vaccination schedule, however effective at
protecting sheep from infection, is not readily accommodated within
the practical management policies of the hill farms. In addition as
a result of the two dose requirement vaccine production and purchase
costs are increased. An effective single dose vaccine would therefore
be considerably more attractive to both hill farmer and vaccine
9.
manufacturer.
In addition therefore a reappraisal of the present louping-ill
vaccine production procedure is also required in an attempt to develop
a vaccine capable of consistently provoking a satisfactory serological
response following a single dose.
The studies reported here were therefore undertaken with the aim
of defining the optimum dosage requirements and the stability of the
presently available vaccine, to determine the relationship between
antibody response and protection and to develop a single dose vaccine
of increased potency and stability.
10.
CHAPTER TWO
GENERAL MATERIALS AND METHODS
1. CELLS
The stable cell line BHK-21 (clone 13) (MacPherson and Stoker,
1962) was obtained from the Wellcome Research Laboratories, Beckenham,
at the 77th passage. All experimental work was performed using cells
between the 92nd and 112th pass levels. This was carried out by
preparing three tissue culture flasks* from cells at the 89th pass.
After 72 hours incubation, when a confluent monolayer had formed, the
BHK cell growth medium was decanted and the cells washed with
phosphate buffered saline (PBS) pH 7.2 without calcium or magnesium
(Dulbecco and Vogt, 1954). The cells were detached using 10ml of a
0.1 per cent Cw/v) trypsin - 0.05 per cent (w/v) versene solution.
The resulting cell suspension was centrifuged at 700g for 20 minutes
and the supernatant removed. BHK cell growth media containing 20 per
cent newborn calf serum (NBCS) and 10 per cent dimethyl sulphoxide
0
(DMSO) was then added to give a cell concentration of 5 x 10 cells/ml.
This cell suspension was then dispensed in 3ml volumes in screw-capped
bottles, placed in a polystyrene container and stored at -80°C.
After 24 hours the bottles were transferred for storage in liquid
nitrogen. Cells were removed at intervals and cultures prepared to
maintain a supply of cells at the required pass level.
Cells were grown in tissue culture flasks and passaged every
3-4 days at an expansion rate of 1:3. The medium was decanted and
*Flow Laboratories, Irvine.
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the cells washed and detached as described previously. The cells
from each flask were then redistributed in a further three bottles
in fresh cell growth media.
The BHK-21 (clone 13) R8 mycoplasma-free cell line, BHK-21
(R8MF) was obtained from the Wellcome Foundation, Pirbright, at the
118th passage. All experimental work was performed using cells
between the 123rd and 126th pass levels. This was achieved by
preparing a stock of cells at the 121st passage and treating them
as described above using BHK cell growth media supplemented with a
further 5 per cent (v/v) NBCS and 0.1 per cent (w/v) sodium
bicarbonate.
The BHK-21 (R8MF) cells were periodically checked for the presence
of mycoplasmas; this was kindly performed by Dr. G. E. Jones, Moredun
Research Institute, Edinburgh,
The IB/RS2 pig kidney (PK) cell line was obtained from the Animal
Virus Research Institute, Pirbright. Adsorption of Virus to PK
cells was achieved using cells between the 30th and 40th passage at
the Moredun Research Institute.
Cells were cultured in PK cell growth media and passaged every
3-4 days at an expansion rate of 1;4.
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2. MEDIA
BHK cell growth and virus growth media
1





















Reagents were obtained, with the exception of the serum, as stock
solutions from the Wellcome Research Laboratories, Beckenham.


























PK cell growth and virus growth media
Cell growth Virus growth
Basic salt solution Hanks Earles
Lactalbumin hydrolysate1 0.5% w/v 0.5% w/v
Adult bovine serum (inactivated) 10% v/v 10% v/v
Glucose 0.1% w/v 0.1% w/v
Sodium bicarbonate 0.02% w/v 0.2% w/v
1
Yeast Extract 0.001% w/v 0.01%, w/v
Folic acid - 0.0001% w/v
Penicillin 200 i.u./ml 400 i.u./ml
Streptomycin 100 pg/ml 200 pg/ml
. 2
Polymyxin 50 i.u,/ml -
3
Mycostatin 50 i.u./ml -
PKBA media
As for PK virus growth media substituting 0.5 per cent (w/v)
bovine serum albumin for the 10 per cent adult bovine serum.
3. VIRUS
The standard Moredun isolate of virus Li/31 was employed for all
laboratory procedures. The virus had been passaged intracerebrally
in mice five times and once in BHK-21 cells. Virus stocks for all
7
experiments were prepared by adsorbing 40ml of a 2 x 10 cells/ml
BHK-21 cell suspension at the 89th pass level with 20ml of virus
isolate Li/31.
~4)ifco Laboratories Ltd,, Detroit, Michigan, U.S.A.
2
Wellcome Foundation Ltd., London,
3
E.R. Squibb & Sons, Liverpool.
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Adsorption proceeded at 37 C for 60 minutes. Four Wheaton* roller
culture bottles were then each inoculated with 500ml of BHK virus
growth media and 15ml of the virus/cell suspension and incubated at
37°C on a roller apparatus rotating at 0.3 rpm. After three days the
infected fluids were decanted, pooled and centrifuged at 700g for
10 minutes at 4°C. The supernatant was distributed in 20ml volumes
in screw-capped bottles, designated Li/31/M5 BHK/2, and stored at
-80°C.
The Li/31 isolate at the 6th pass in mouse brain was used as
reference antigen in immunodiffusion tests. This was prepared by
-3
injecting 10 litters of one-day-old mice with 0.03ml of a 10
dilution of clarified mouse brain infected with Li/31/M5. A 26-gauge
needle was used for inoculation and 0.01ml was injected into the
cranium and 0.02ml deposited subcutaneously (s.c.). The brains of
the mice were harvested after five days and homogenized. A 10 ^
dilution of this preparation was then sonicated for 30 seconds using
a MSE 150 Watt Ultrasonic Disintegrator and then clarified at
o
10,000g for 30 minutes at 4 C. Normal mouse brains were homogenized,
diluted and sonicated in the same way.
The SB526 virus isolate at the 2nd pass in sucking mouse brain
(Reid and Doherty, 1971a) was used as inoculum in the challenge
experiment.
4. VIRUS, VIRUS ANTIGEN AND ANTIBODY QUANTITATION.
Assay of virus infectivity
Virus infectivity was determined by the plaque assay method
described by Reid and Doherty (1971b), using preformed monolayers of
*Jencons (Scientific) Ltd., Hemel Hempstead.
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the IB/RS2 pig kidney cell line. Undiluted and diluted preparations
of samples were inoculated onto four plates and results expressed as
mean plaque forming units (pfu) per ml.
Immunofluorescence
The proportion of cells infected with virus following adsorption
was determined by the direct immunofluorescence technique.
Preparation of fluorescein isothiocyanate (FITC) conjugated sheep
anti-louping-ill globulin.
A hyperimmune serum sample was produced according to the method
described by Doherty and Reid (1971b). A 5ml sample was dialysed
against 0.01M phosphate 0.03M sodium chloride buffer pH 7.6 and the
resultant serum applied to a Whatman DE/52 anion exchange column
(15 x 20cm) equilibrated with the same buffer. The fall-through
peak was pooled and concentrated by pressure dialysis against 0.05M
carbonate buffer pH 9 and the final protein concentration adjusted
to 20mg/ml, Celite with 10 per cent adsorbed FITC was added (2,5gm
per ml of IgG), stirred for 5 minutes at room temperature and
centrifuged at 1800g for 5 minutes at 4°C. The supernatant was then
applied to a Sephadex G25 column (1.5 x 10cm) equilibrated with IxPBS.
The first peak containing conjugated IgG was collected.
Optimal conditions for direct immunofluorescence were obtained
using the FITC sheep IgG conjugate at a dilution of 1/100. Pyrex
0
glass tubes containing coverslips were inoculated with 1.5 x 10
o
virus infected BHK-21 cells and incubated stationary at 37 C, At
intervals thereafter coverslips were removed, washed 3 times in PBS
and fixed in cold acetone for 5 minutes. They were overlaid with a
1/100 dilution of the FITC sheep IgG conjugate and incubated in a
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o
humid atmosphere at 37 C for one hour. The coverslips were then
washed twice in PBS, dried and mounted in buffered glycerol pH 8.4.
Examination for fluorescence was carried out using a Leitz* Ortholux 11
microscope fitted with a fluorescence vertical illuminator, the ultra¬
violet blue light being produced by a 50W high pressure mercury lamp.
Enumeration of infected cells was achieved by counting the number
of fluorescent cells in 20 fields selected at random from appropriate
coverslip preparations. The coverslips were then washed with water
to remove the mounting fluid and re-examined under the same microscope
readjusted to white light microscopy. Five fields with 50 per cent
cell cover were chosen and the number of cells counted, then 20 fields
were randomly selected and scanned for per cent cover. The percentage
of infected cells was thus determined. Control uninfected coverslips
were treated likewise.
Assay of haemagglutination (HA) activity
Haemagglutination activity in tissue culture harvests was assayed
using the techniques described by Clarke and Casals (1958).
Samples (0.4ml volumes) were prepared by extracting with 20
volumes of chilled acetone for 5 minutes. The samples were then
o
centrifuged at lOOOg for 15 minutes at 4 C, the supernatant removed
and the precipitate re-extracted with 20 volumes of a chilled mixture
of equal parts acetone and ether. Following centrifugation the
precipitate was dried on a vacuum air pump and resuspended in 0.4
per cent (w/v) bovalbumin borate saline (ph 9.0). The test was
performed using goose erythrocytes and a final pH of 6.2 - 6.4 in
standard leucite WHO plates.
*Ernst Leitz (Canada) Ltd., Midland, Ontario,
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Immunodiffus ion
Concentrated virus antigen preparations were examined by
immunodiffusion using double and radial diffusion methods.
For the double diffusion technique gels were prepared by pouring
15ml of one per cent Oxoid* Ionagar in PBS onto glass slides
(8.2 x 8,2cm). Six circular wells, 5mm in diameter, were cut
circumferentially around one well of the same diameter. All the wells
were spaced 5mm apart. A 1/8 dilution of a sheep hyperimmune
louping-ill antiserum, prepared according to the method described by
Doherty and Reid (1971b) was used as antibody and a clarified 1/10
dilution of Li/31/M6 infected sucking mouse brain homogenate used as
reference antigen. Normal mouse brain homogenate, BHK virus growth
media and BHK cellular extracts concentrated 10 fold were also
reacted against this antiserum. The concentrated BHK cellular
extracts were prepared by freezing and thawing uninfected 72 hour
monolayer cultures of BHK-21 cells, and concentrated by each of the
concentration methods described.
The charged plates were incubated in a humid atmosphere at room
temperature for 48 hours, then soaked in saline for 24 hours and
distilled water for a further 24 hours. They were then dried, fixed
with 2 per cent acetic acid for 5 minutes and stained with 0.5 per
cent amido-schwartz 10B in a methanol (9 parts)-glacial acetic acid
(1 part) mixture.
For the single radial diffusion technique antibody was
incorporated into the agar at a final dilution of 1/100 and poured
*0xoid Ltd .
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onto microscope slides (7.5 x 2.5cm). Four circular wells (2mm
diameter) spaced 1.5cm apart were cut. The charged plates were
incubated and stained as described previously.
Assay of haemagglutination-inhibiting (HAI) antibody.
Sera were pre-treated with kaolin to remove non-specific
inhibitors of haemagglutination and tested for HAI activity using
the method of Clarke and Casals (1958). The test was carried out in
standard leucite WHO plates using 4-8 haemagglutination units of an
acetone-ether extracted tissue culture antigen. To assess the
relative activity of the IgM and IgG antibody class, positive sera
were also treated at 64.5°C for 30 minutes (Reid and Doherty, 1971a)
and then examined for HAI activity.
19.
CHAPTER THREE
THE IMMUNIZATION OF SHEEP WITH COMMERCIAL LOUPING-ILL
VIRUS VACCINE; DEVELOPMENT OF ANTIBODY AND PROTECTION
AGAINST CHALLENGE WITH LIVE VIRUS
INTRODUCTION
Experience with the commercially produced louping-ill-virus vaccine
has indicated that a single dose of vaccine is often insufficient to
provoke a satisfactory serological response. Preparation and potency
testing of the commercial vaccine is described in Appendix 3.1.
This chapter describes the immune responses in sheep following the
administration of a second injection of commercial vaccine after
different time intervals and the effect of varying the dose volume.
The response to viral challenge of those sheep which produced little
or no antibody following vaccination is also examined.
MATERIALS AND METHODS
VACCINATION
Administration of a second dose of vaccine after different time
intervals
Ninety, 9 month old Scottish Blackface HAI-negative sheep, bred
and maintained in an area free of ticks were randomized into 9 equal
groups. Groups I - VIII were injected subcutaneously (s.c.) behind
the right shoulder with 1ml of commercial vaccine. Groups II - VIII
were then revaccinated with a further 1ml of vaccine after one, 2, 3,
4, 8, 16 and 24 weeks respectively. Sheep in group IX were unvaccinated
controls. Ten ml of blood were collected weekly for 4 weeks from all
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animals following primary vaccination. Groups I and IX were then
bled monthly for 7 months. Groups II to VIII were bled immediately
prior to revaccination, then weekly for 4 weeks and monthly until
completion of the experiment. The bloods were allowed to clot, the
o
sera removed and stored at -20 C until tested for HAI activity using
the method described in Chapter Two. A titre of <il0 was considered
a negative serological response.
For statistical analysis of the data reciprocal HAI titres were
transformed into logarithms to the base 10. Titres of < 10 were deemed
to have a logarithmic value of 0.7. Group I - VII means were compared
using an analysis of variance. Group VIII means which were excluded
from this analysis because the data were significantly less variable,
were compared with data from each of the other groups inturn using
a 2-sample t-test and halving the number of degrees of freedom when
required to allow for variance differences.
Administration of different dosage volumes
Twenty-one 9-month-old Cheviot HAI-negative sheep and 3 8-month-
old Finnish Landrace HAI-negative sheep bred and maintained in an area
free of ticks were randomized into 4 equal groups. They were injected
subcutaneously behind the right shoulder with varying volumes of
commercial vaccine and then revaccinated 21 days later. Groups A, C
and D were vaccinated with 2 doses of 1ml, 2 doses of 0.5ml and 2 doses
of 0.25ml respectively whilst group B were injected primarily with 1ml
and then revaccinated with a further 0.5ml of vaccine. Blood was
collected from all animals at weekly intervals for a period of 7 weeks
and the sera tested for HAI activity using the method described in
Chapter Two. The mean 21-day HAI titres and the mean 49-day HAI titres
from each of the 4 groups were compared using an analysis of variance.
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CHALLENGE OF VACCINATED SHEEP WITH LIVE VIRUS
In a group of vaccinated sheep a proportion of animals usually
remain completely seronegative or fail to produce a persistent antibody
response even after administration of 2 doses of vaccine (personal
observation). In an attempt to assess the degree of protection
afforded to such animals 26 of the 90 vaccinated sheep were challenged
with live virus. Ten of the 26 sheep were the unvaccinated control
sheep of group IX. The SB526 isolate of louping-ill virus was used as
inoculum. The clarified mouse brain homogenate was diluted and sheep
inoculated subcutaneously into the medial aspect of the right thigh
with 1ml of inoculum containing 6.0 pfu °f virus. The sheep
were bled immediately prior to challenge and then daily for 14 days.
On each occasion two tubes of blood were collected; one was allowed
to clot for serum separation whilst the other contained heparin.* The
heparinised bloods were centrifuged at 1500g for 20 minutes at 4°C,
the supernatants removed and stored at -80°C until assayed for virus
using the plaque assay method as described in Chapter Two. The sera
were stored at -20°C until assayed for HAI activity.
The animals were inspected every 12 hours for clinical signs and,
from those that died pieces of cerebrum, cerebellum and spinal cord were




Administration of a second dose of vaccine after different time intervals
The mean HAI titres of groups I - VIII 7 days after primary
vaccination and the mean titres of groups II - VIII immediately prior
*Pullarin Evans Medical Ltd., Liverpool.
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to revaccination are shown in Table 3.1. The numbers of animals
responding to primary vaccination are also indicated. Immediately
prior to administration of the second dose of vaccine a serological
response was detected in only 59 per cent of sheep in groups III -
VIII. The mean HAI titre of all animals in these groups at this
timewas 1/18 and there were no statistically significant differences
between the mean antibody titres of each group. A comparison of the
mean HAI titres of groups I - VIII at 7, 14, 21, 28 and 84 days
following initial (group I) and second ("groups II - VIII) Injection of
vaccine is shown in Table 3.2. The statistical differences between
the mean titres of group I and groups II - VIII sheep and the numbers
of sheep responding to vaccination are also indicated. The full results
are tabulated in Appendices 3.2 and 3.3.
Following injection of a single dose of vaccine an antibody response
was detected in only 4 sheep of group I and the maximum mean antibody
titre was 1/17. Eight of the group II sheep responded to revaccination
after an interval of one week with a maximum mean antibody titre of
1/29. There was no significant difference in the response of these
sheep and the response of group I sheep.
The secondary serological responses in groups III - VIII
developed quicker and to higher titres than the primary response in
group I sheep or the response in group II sheep. At 7, 14, 21, 28
and 84 days following revaccination antibody titres significantly
greater than those of group I were detected in groups III, V and VI.
The, highest mean antibody titres were consistently demonstrated in
sheep of group V with a maximum mean titre of 1/724 being attained
14 days following revaccination. Following administration of a
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second dose antibody titres significantly greater than those of
group I were detected on all sampling days except day 84 in groups
VII and VIII and only on days 7 and 21 in group IV. The control sheep
of group IX remained seronegative throughout the experiment.
Several of the 80 vaccinated sheep had either remained sero¬
negative throughout the experiment or had failed to produce a
persistent antibody response. Two such animals were chosen from each
of the vaccination groups I - VIII and together with the 10 control
unvaccinated animals from group IX were challenged with live virus.
The results are given in the next section.
Administration of different dose volumes
The HAI antibody responses 21 days after the first dose of vaccine
and 28 days following the second dose of vaccine in all groups are
tabulated in Table 3.3.
Twenty-eight days after revaccination a serological response was
detected in 50, 83, 67 and 83 per cent of animals in group A, B, C
and D respectively with corresponding mean antibody titres of 1/79,
1/50, 1/20 and 1/79.
There were no statistically significant differences between the
mean antibody titres of group A, B, C or D either at 21 days after
primary vaccination or at 28 days after revaccination.
CHALLENGE OF VACCINATED SHEEP WITH LIVE VIRUS
On the 16 sheep chosen from the vaccination groups I - VIII
(Experiment 1) HAI antibody titres immediately prior to challenge
were < 10 in 11 and 1/10 or 1/20 in the remaining 5.
Clinical response
Ataxia was observed in 4 of the 10 unvaccinated control sheep
(X333, X538, V875 and V876), 8 days after challenge. In two of these
affected sheep (X538, V875) symptoms progressed to death by 48 hours.
No signs of clinical infection were observed in any of the vaccinated
animals.
Viraemia
Virus was detected in the plasma of all but one of the 10
unvaccinated control sheep, in 9 of the 11 vaccinated but seronegative
animals and in 2 of the 5 vaccinated animals that had seroconverted
to maximum HAI titres of 1/10 or 1/20 (Table 3.4). The course of
viraemia in the unvaccinated animals, the seronegative vaccinates and
the seropositive vaccinates following challenge is illustrated in
Fig. 3.1. Mean levels of viraemia were consistently highest in the
unvaccinated controls and lowest in the vaccinated seropositive animals.
Maximal titres of circulating virus were found on days 3 and 4 following
challenge, ranging from 1.1 log^pfu/ml to 4.5 log^pfu/ml in the
vaccinated sheep and 1.6 log^^pfu/ml to 6.9 log^^pfu/ml in the
unvaccinated controls. The vaccinated animal with the maximum virus
titre of 4.5 log^^pfu/ml had been selected from vaccination group I
and had received a single dose of vaccine only. Viraemia was not
detected subsequent to day 5 in the vaccinated animals and day 6 in
the unvaccinated controls. The highest virus concentrations were
detected in the 2 unvaccinated animals that died and virus was
recovered from the brains of both these animals. The full data are
tabulated in Appendix 3.4.
The duration of viraemia was shorter and the magnitude of
circulating virus lower in the vaccinated animals than in the control
animals.
Figure 3.1
Comparison of the geometric mean titres of viraemia following
peripheral inoculation with louping-ill virus in:
(i) vaccinated sheep with reciprocal antibody titres of <10 (—O—)
(ii) vaccinated sheep with reciprocal antibody titres of ^10 (--▼—)
(iii) unvaccinated sheep (—)
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Antibody response
The development of HAI antibody following challenge in the
unvaccinated control animals, the seronegative vaccinates and the
seropositive vaccinates is illustrated in Fig. 3.2. The mean HAI
titres and the number of animals responding is given in Table 3.5.
The appearance of antibody correlated with a decline in circulating
virus. A rise in HAI antibody was first detected in 8 of the 16
vaccinated animals on day 5 following challenge. Thereafter antibody
titres increased in all animals and reached a maximum on day 9. The
antibody response was initially lower in the four animals selected
from vaccination groups I and II. Circulating HAI antibody developed
more slowly in the unvaccinated controls and was not detected until
the sixth day after challenge. Antibody titres then rose rapidly, and
peak values were attained on day 12.
Initial antibody activity in all animals was due to IgM. By day
10 antibody activity in the 16 vaccinated animals was almost totally
attributable to IgG whereas a substantial amount of IgM antibody
activity could still be detected 14 days following challenge in the
control unvaccinated animals. The full results are given in Appendix
3.5.
The development of HAI antibody was quicker and mean titres
higher in the vaccinated animals than in the unvaccinated control
animals.
DISCUSSION
Only 40 per cent of the animals vaccinated with a single dose of
commercial vaccine produced a detectable serological response and the
maximum mean antibody titre of these animals was 1/17. Revaccination
Figure 3.2
Comparison of the geometric mean reciprocal HAI antibody titres
following peripheral inoculation with louping-ill virus in:
(i) vaccinated sheep with reciprocal antibody titres of <10 (—0-
(ii) vaccinated sheep with reciprocal antibody titres of "^10 (--▼
(iii) unvaccinated sheep (—•—)
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one week after the initial dose failed to increase antibody titres
significantly. Revaccination at 2, 3, 4 and 8 weeks produced typical
secondary immune responses with antibody titres significantly higher
than those detected in sheep which received one dose of vaccine and
those revaccinated after one week. Administration of a second dose of
vaccine at 16 or 24 weeks significantly accelerated the rise in
antibody titres but these declined rapidly. The highest mean antibody
titres were consistently demonstrated in sheep revaccinated after an
interval of 4 weeks.
Two 1ml doses of commercial vaccine with an interval of 2 - 8
weeks between injections were therefore shown to be necessary to
provide a satisfactory level of immunity against infection with live
virus.
Although all 16 vaccinated animals were protected from clinical
disease following challenge with live virus, circulating virus was
detected in 11. Of these 11, 2 had pre-challenge HAI titres of 1/10
and the remainder were seronegative. Viraemia was not detected in the
remaining 5 animals. Of these animals 2 had pre-challenge HAI titres
of 1/20, one had a pre-challenge titre of 1/10, and the remaining 2
were seronegative. These animals did however become infected as
judged by the rise in antibody titre following challenge. Protection
against challenge is therefore afforded to animals with a vaccinal
HAI titre of 1/10 and circulatory virus is inhibited to undetectable
levels in animals with an HAI titre of 1/20.
Results obtained from protection studies in lambs that had
acquired passive immunity to louping-ill (Reid and Boyce, 1976) were
similar to those reported here. Lambs with low detectable titres of
29.
maternal antibody experienced infection following challenge but in
the absence of a detectable viraemia, whilst lambs in which maternal
antibody had declined to undetectable levels developed viraemias of
low intensity.
In studies on the susceptibility of sheep to sub-cutaneous
inoculation with live louping-ill virus, Reid and Doherty (1971b)
suggested a relationship between the magnitude and duration of viraemia,
the rate of the serum antibody response and survival. They demonstrated
that the intensity of viraemia was lower and of shorter duration and
serum antibody developed quicker in surviving animals compared to
animals succumbing to infection. Similarly in this study, following
challenge with live virus the magnitude and duration of viraemia is
reduced and the development of humoral antibody quicker in vaccinated
animals compared to both the surviving unvaccinated control animals
and those succumbing to infection. It is suggested therefore that
although vaccination may fail to consistently produce a detectable
serological response it does however sensitize the immune system to
viral antigen and thus produce an accelerated antibody response in
the event of subsequent exposure to virus.
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Table 3.1 The geometric mean reciprocal HAI titres and the



















































Table 3.2 The haemagglutination-inhibiting antibody response in
























































































The geometric mean reciprocal HAI titre following vaccination (Group I)
and revaccination (Groups II - VIII)
xx
The number of animals responding to vaccination/number of animals
vaccinated.
The statistical difference of the titres between Group I and any group
is indicated as follows
* p <0.050
** p < 0.010
*** p < 0.001
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Table 3.3 The geometric mean reciprocal HAI titres and the number of
animals responding to a single and double dose of varying
volumes of vaccine
Group
Vaccine* Response 21 days
































♦Second dose of vaccine administered 21 days following primary
vaccination
Mean - SE
Table3.4Meantitr s*ofvirusClogpfu/ml)dthnumberofnimalscirculatingvirufo lowichall nge SheepDayspostchallenge 3 Unvaccinatedco trols Vaccinates: titre<^10atchallenge Vaccinates: titre>10atchall nge1.2-0 18 8/10 1.2-0.12 3/11 0.9-.50 2/52.1-0.32 8/10 1.5-0 17 6/11 1.9 1/53.4-0.44 8/10 2.9-0.38 7/11 1.8-0.85 2/53.7-0.62
9/10
2.5-0.48 7/11 2.4 1/5
3.3-0.52 6/10 2.6-0.70 4/11 0.9 1/5
2.0 1/10
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Unvaccinatedcontrols Vaccinates: titre<10atchallenge Vaccinates: titre^10atchallenge
1.8
-0.20 5/11 1.9 3/5
2.2
-0.16 9/10 2.5 -0.15 11/11 3.0 -0.15 5/5
2.7
-0.18 10/10 3.0 ■0.12 11/11 3.3 -0.07 5/5
3.3 -0.12 10/10 3.3 -0.11 11/11 3.5 0.17 5/5
3.3
-0.15 10/10 3.6 0̂.14 "ll/ll 3.6 0.11 5/5
3.4 -0.10 10/10 3.6 -0.09 11/11 3.6 0.20 5/5
3.4
-0.15 10/10 3.7 -0.11 11/11 3.5 0.18 5/5
3.5
-0.16 10/10 3.7 -0.09 11/11 3.5 0.16 5/5
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CHAPTER FOUR
GROWTH OF LOUPING-ILL VIRUS IN BHK-21 CELLS
INTRODUCTION
Propagation of louping-ill virus was first demonstrated by
Rivers and Ward (1933) using minced chick embryo tissue suspended
in Tyrodes solution. Wilson (1945) also using this method showed
that virus titres were maximum 3-4 days following infection. The
replication of louping-ill virus in embryonated hens' eggs has been
reported by Burnet (1936) and Edward (1947a). Edward (1947a)
demonstrated that embryos at 6-10 days incubation were most
susceptible to virus and that following inoculation either into the
yolk sac or the embryo, the latter contained the higher concentration
of virus. Titres of virus were highest 3-4 days after inoculation.
The propagation of louping-ill virus in monolayer tissue culture by
other workers is summarised in Table 4.1.
Early attempts to produce vaccines from tissue culture propagated
virus were unrewarding (Wilson, 1945). However Brotherston and Boyce
(1970) developed an experimental louping-ill virus vaccine based on
propagation of the virus in secondary sheep kidney cells. For
commercial production of this vaccine virus is cultured in the
continuous BHK-21 clone 13 cell line (Appendix 3.1).
This chapter records an examination of the growth of louping-ill
virus in BHK-21 cells in an attempt to define optimal conditions for
virus replication.
Part I examines factors affecting the adsorption of virus.
Polyions such as Diethylaminoethyl-Dextran (DEAE-D) have been used
extensively in attempts to facilitate adsorption of virus to cells
and thus increase virus infectivity (Bijlenga and Van Den Bogaard,
1973; Shigeko, 1968; Rossi, 1971; McCutchan and Pagano, 1968; Stow
and Wilkie, 1976) and pretreatment of cell monolayers with dimethyl-
sulphoxide (DMSO) has been reported to enhance plaque formation
(Cleaver, 1974). The effect of pretreating BHK-21 cells with DEAE-D
and DMSO on virus adsorption was therefore examined.
Poste (1970, 1972) and Poste and Allison (1971) proposed that an
essential step in adsorption is the displacement of calcium ions from
sites within the surface membrane. Volkert and Horsfall (1947)
studying pneumonia virus of mice showed that the presence of trypsin
inhibited virus cell attachment. The effect of adsorption of louping-
ill virus to cell suspensions prepared without the use of trypsin and
a chelating agent was thus also investigated.
Part II examines the factors affecting growth of virus. Contamination
of cell cultures with mycoplasmas can cause either an increase in
virus yields (Singer, Kirschstein and Barile, 1969) a decrease in
virus yields (Butler and Leach, 1964; Singer, Fitzgerald, Barile and
Kirschstein, 1970) or no appreciable effect (Reed, 1971). The growth
of louping-ill virus both in mycoplasma-free and mycoplasma-contaminated
BHK-21 cells was therefore examined. The growth of louping-ill virus
in various types of culture vessels incubated both as stationary and
rolling cultures in BHK virus growth media and serum-free media was
also examined.
Viral infectivity of harvests grown in various types of culture
bottles was compared and their application for large scale virus
production discussed.
PART I ADSORPTION OF LOUPING-ILL VIRUS TO BHK-21 CELLS
MATERIALS AND METHODS
Cells were obtained by trypsinization of 3-day-old BHK-21 cell
cultures and counted using a Mod-Fuchs Rosenthal counting chamber.
Virus inoculum Li/31/M5 BHK/2 was prepared as described in Chapter
Two. Adsorption was carried out by either mixing virus and cells
together in suspension or by inoculating confluent cell monolayers.
ADSORPTION OF VIRUS TO CELLS IN A CELL SUSPENSION
Cell suspensions were prepared by resuspending trypsinized cells
in BHK virus growth media. The virus cell suspensions were incubated
in a water bath at 37.0 - 0.5°C and shaken at 15-minute intervals
throughout the adsorption period. Virus was incubated in an identical
fashion but without the addition of cells. Aliquots were removed
from the virus cell suspension throughout adsorption, centrifuged at
750g for 15 minutes at 4.0 i" 0.5°C and the deposited cells washed twice
in PBS and finally resuspended in 1ml of PK/BA media. The infected
cell suspensions and cell-free supernates were diluted and immediately
assayed for infected cells or free virus using the plaque method or
by direct immunofluorescence. The plaque method of assay was used on
the rationale that each infected cell will, in a similar fashion as
a free virus particle, become a centre of virus replication. When
plated onto a cell monolayer one infected cell will produce one
plaque. The number of plaques produced by a washed suspension of
infected cells will thus reflect the actual number of infected cells
if assay immediately follows sampling and before the cells have
started to release new virus. Assay of virus infected cells by the
plaque method and immunofluorescence were compared.
38,
ADSORPTION OF VIRUS TO CELLS IN A CELL MONOLAYER
Confluent cell monolayers were prepared by seeding Pyrex glass
0
tubes (15 x 150mm) with 10 cells in 1.5ml of BHK cell growth media
+ o
and incubating for 19 hours at 37.0 - 0.5 C on a roller drum rotating
at 0.2 rpm. The cells from 10 tubes were then trypsinized and counted
and the media poured from the remaining tubes. The cell monolayers
were inoculated with 1ml of virus diluted in BHK virus growth media
to give the required input multiplicity. The tubes were incubated on
o
a roller drum at 37 C for up to 90 minutes. At intervals throughout
adsorption 10 or more tubes were randomly selected, the virus inoculum
poured off and the cells removed by trypsinization. The trypsinized
cells were pooled, sedimented by centrifugation at 750g, washed twice
in PBS and finally resuspended in 1ml of PK/BA media. The cell
suspensions were assayed for infected cells using the plaque method.
Assay of infected cells by the plaque method
The plaque assay method used was as described in Chapter Two with
the exception that the 2 hour adsorption period prior to addition of
overlay was reduced to 30 minutes.
Assay of infected cells by direct immunofluorescence
The direct immunofluorescence technique used is described in
Chapter Two.
RESULTS
1. COMPARISON OF THE PLAQUE METHOD AND DIRECT IMMUNOFLUORESCENCE FOR
THE ASSAY OF INFECTED CELLS
BHK-21 cells suspended in BHK virus growth media were mixed with
virus inoculum to give an added multiplicity of 9 pfu/cell and
13 pfu/cell with a final cell concentration in the adsorbing suspension
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of 10 cells/ml. An aliquot was removed from each cell-virus
suspension after 90 and 120 minutes respectively of adsorption and
assayed in duplicate for infected cells using the plaque method. The
remaining cell-virus mixtures were washed twice to remove free
unadsorbed virus and the cells resuspended in BHK virus growth media.
6
Pyrex glass tubes containing coverslips were inoculated with 1.5 x 10
o
adsorbed cells and incubated as stationary cultures at 37 C. Cover-
slips removed between 10 and 11 hours post infection and treated with
FITC conjugated sheep anti- louping-ill globulin showed specific
fluorescence in a proportion of cells. The fluorescence was weak and
localised around the cell nucleus. The percentage of these infected
cells was determined as described in Chapter Two. Coverslips
removed between 11 and 24 hours post infection showed strong fluor¬
escence throughout the cytoplasm of all cells (Fig. 4.1).
With an adsorption period of 2 hours and an added multiplicity
of 9, 9 per cent of cells were infected and with a multiplicity of
13, 14.6 per cent of cells were shown to be infected using the plaque
assay method. The plaques were indistinguishable from plaques
produced by free virus particles. With an input multiplicity of
9 and 13 the percentage of infected cells determined by immuno¬
fluorescence was 7.3 and 8.4 respectively. The results were compared
statistically using the Mann-Whitney non-parametric test. The plaque
assay method detected a significantly higher (p<0.05) number of
infected cells than the immunofluorescence technique. In the following
studies the plaque method was routinely used for assay of infected
cells.
Figure 4.1
Immunofluorescent staining of BHK-21 cells infected with
louping-ill virus
(a) 10-12 hours post infection
(b) 21-24 hours post infection
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Fig.4.lb
2. ADSORPTION OF VIRUS TO CELLS IN A CELL SUSPENSION
(i) The effect of the multiplicity of infection and the concentration
of cells on virus adsorption
BHK-21 cells suspended in BHK virus growth media were mixed with
virus to give (a) an added multiplicity ranging from 0.09 to 95 pfu/ce
6 8
and, (b) a cell concentration of between 10 and 10 cells/ml with a
constant multiplicity of 1.8 pfu/cell.
With an added multiplicity of one and a cell concentration of
0
5 x 10 cells/ml the percentage of infected cells after 60 minutes
adsorption at 37°C was 0.35. Unadsorbed virus was detected in the
cell-free supernatants. Incubation of the virus cell mixture for a
further 60 minutes did not appreciably increase adsorption. Thermal
degradation of virus was not detectable throughout the adsorption
period. At input multiplicities of 0.09, 5 and 95 pfu/cell and cell
7 6 6
concentrations of 10 /ml, 5 x 10 /ml and 10 /ml, 0.38, 2.0 and 4.0
per cent respectively of cells were infected after adsorption for 120
minutes. With a constant input multiplicity of 1.8 pfu/cell and a
7 7 7
cell concentration of 7.5 x 10 /ml, 3.8 x 10 /ml, 10 /ml and 3.8 x
0
10 /ml, 13, 13, 8 and 5 per cent respectively of cells were infected
after 60 minutes adsorption. There was a linear relationship between
the percentage of infected cells and the cell concentration, the
correlation coefficient being 0.99 (p<0.01) (Fig. 4.2). The final
concentration of serum in each adsorbing suspension was constant at
10 per cent.
(ii) Preparation and pretreatment of cell suspensions
Preparation of cell suspensions
Cell suspensions were routinely prepared by trypsinization of
Figure 4.2




cell concentration loc^/ml adsorbing suspension
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cell monolayers using a mixture of trypsin and versene. To investi¬
gate the possibility of deleterious effects brought about by the
use of trypsin and a chelating agent single cell suspensions were
prepared either by mechanical detachment using a rubber policeman or
by trypsinization. Adsorption of virus to each cell suspension was
compared. With an added multiplicity of 3.5 pfu/cell and a cell
5
concentration of 5 x 10 cells/ml, 0.2 per cent of the trypsinized
cells were infected compared with 0.38 per cent of cells prepared by
mechanical detachment.
Pretreatment of cell suspensions
To determine the effect of pretreating cells with DEAE-D and
DMSO on viral adsorption, 9 aliquots of cells were prepared and
resuspended in BHK cell growth media or BHK cell growth media
containing DEAE-D at concentrations of 5 pg/ml, 15 pg/ml, 25 pg/ml
and 50 pg/ml or DMSO at concentrations of 0.5, 2, 5 and 10 per cent
o
(v/v). Suspensions were incubated at 37 C for 60 minutes, the cells
then sedimented by centrifugation at 750g and washed twice with media.
0
All cell suspensions were adjusted to 5 x 10 cells/ml and the
percentage of infected cells assayed after incubation for 60 minutes.
The input multiplicity was 13 pfu/cell. The results are shown in
Table 4.2. The percentage of untreated cells that were infected was
1.7 compared to 2.7 per cent of cells pretreated with 25 pg/ml DEAE-D
and 3.2 per cent of cells pretreated with 10 per cent DMSO.
(iii) The effect of serum on virus adsorption to BHK-21 cells and pig
kidney cells.
Effect of serum on virus adsorption to BHK-21 cells
Eight aliquots of trypsinized BHK-21 cells were resuspended in
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6 different media varying in serum content and concentration. Sheep
serum and adult bovine serum were inactivated prior to use by heating
at 56°C for 35 minutes. Two ml of virus inoculum were mixed with
8ral of each cell suspension to give an input multiplicity of 10 pfu/
6
cell and 1 pfu/cell and a cell concentration of 10 cells/ml and
0
6 x 10 cells/ml respectively. After 60 minutes of adsorption an
aliquot was removed from each cell-virus suspension and assayed (in
duplicate) for the number of infected cells using the plaque assay
method.
The percentage of cells infected and the statistical differences
in the number of cells infected with 8 per cent LS in the adsorbing
suspension compared to the number infected in each of the other
adsorbing suspensions are shown in Table 4.3. There was no
significant difference in virus adsorption with 8 per cent LS or
8 per cent FBS in the adsorbing suspension (input multiplicity of
10 pfu/cell) . However the numbers of infected cells were significantly
higher with 4 per cent LS (p< 0.001), 8 per cent NBCS (p< 0.001),
8 per cent ABS (p<0.01), and 8 per cent SS (p<0.05) in the adsorbing
suspension. Adsorption was most efficient in the presence of 4 per
cent LS and 8 per cent NBCS (24 and 23 per cent of cells respectively
were infected) The data were analysed using an analysis of variance.
With a multiplicity of one, virus adsorption was greater in media
containing 8 per cent ABS (8 per cent of cells infected), than in
media containing 8 per cent LS (one per cent of cells infected).
Adsorption of virus to pig kidney cells
The IB/RS2 pig kidney (PK) cell line was used to compare virus
adsorption to BHK-21 cells and PK cells. The effect of serum and
cell pretreatment on the efficiency of virus adsorption to PK cells
was examined. PK cell suspensions were prepared by trypsinization
of 4-day-old confluent cell monolayers grown in PK cell growth media
containing 10 per cent ABS. Cells were pretreated with 10 per cent
DMSO as described previously. BHK-21 cells suspended in BHK virus
growth media and PK cells suspended in PK virus growth media con¬
taining 10 per cent ABS were each adsorbed with virus. With an
input multiplicity of 2.8 pfu/cell and a cell concentration of 6 x 10
cells/ml 2.8 per cent of untreated and 2.8 per cent of treated BHK-21
cells were infected compared with 16 per cent of untreated and
20 per cent of treated PK cells.
To determine the effect of serum on virus adsorption to PK cells
confluent PK cell monolayers were trypsinized and the cells
resuspended in fresh growth media containing 10 per cent ABS or
10 per cent LS. After a further 24 hours incubation the resultant
monolayers were retrypsinized and the cells resuspended in media
containing the appropriate sera. Virus and each cell suspension were
mixed to give an added multiplicity of 13.6 : 1 and a cell con-
6
centration of 6 x 10 cells/ml. After 60 minutes of adsorption an
aliquot was removed from each cell-virus suspension and assayed (in
triplicate) for the number of infected cells using the plaque assay
method. The data were statistically analysed using a two-sample
g
t-test. The mean number of cells infected (1.6 x 10 pfu/ml) in a
suspension containing a final concentration of 8 per cent ABS was
5
significantly higher (p<(0.01) than the number infected (4.8 x 10
pfu/ml) in a suspension containing a final concentration of 8 per
cent LS.
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Fractionation of whole lamb serum: adsorption in the presence of
three serum fractions
The serum in the growth media specified for virus adsorption and
virus growth in the preparation of louping-ill virus vaccine is
necessarily of ovine origin. To investigate further the apparent
inhibitory effect of lamb serum on virus adsorption, a 3ml volume
of whole lamb serum was applied to a Sephadex G200 2.5cm x 8.5cm
column equilibrated with 0.1 M Tris HC1 and 1M sodium chloride pH 8
buffer. A flow rate of 17ml/hour was applied and the eluate fractions
collected at one minute intervals. Protein present in the eluate
fractions was continuously monitored using a LKB Uvicord II* reading
absorbancy at 280nm, connected to a Vitatron linear recorder (Type
UR404**). Three distinct protein peaks emerged (Fig. 4.3). The
eluate fractions corresponding to each peak were pooled and the
resulting 3 fractions dialysed against polyethylene glycol 6000 for
18 hours and then against BHK cell growth media without serum
overnight. The volume of each was made up to 6ml with cell growth
media minus serum. BHK-21 cell suspensions were prepared by
trypsinizing 3-day-old confluent monolayers and resuspending the
cells in BHK virus growth media containing (i) 10 per cent LS,
(ii) 5 per cent LS, and (iii) fractions 1, 2 and 3 at a concentration
of 20 per cent. Virus (2ml) and cell suspensions (8ml) were mixed
to give a multiplicity of 3 pfu/cell and a cell concentration of
7
10 cells/ml. After 60 minutes of adsorption an aliquot was removed
* LKB Instruments Ltd., Bromma, Sweden.
**Vitatron Dreren, Holland.
Figure 4.3
Protein distribution of normal lamb serum following
fractionation through a Sephadex G200 column
FractionIFraction2r3
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from each cell-virus suspension and assayed (in duplicate) for the
number of infected cells using the plaque assay method.
The statistical differences between the number of cells infected
in a cell-virus suspension with a final concentration of 8 per cent
complete serum and the number infected with a serum content of 4 per
cent complete and 15 per cent fractionated serum (final concentrations)
are shown in Table 4.4. The mean number of cells infected were
5
significantly higher with a 4 per cent complete (7.2 x 10 pfu/ml,
0
p< 0.001), fraction 3 (1.9 x 10 pfu/ml, p^ 0.001), fraction 2 (6.8 x
5 5
10 pfu/ml, p<0.01) and fraction 1 (3.4 x 10 pfu/ml, p<0.05)
serum content in the adsorbing suspension compared to the mean number
5
infected with a serum content of 8 per cent complete (2.0 x 10 pfu/ml).
The data were analysed using an analysis of variance.
An aliquot of complete serum was screened for haemagglutination-
inhibiting antibody activity to louping-ill virus using the method
described in Chapter Two. No activity either in the IgM or IgG
antibody class was detected.
Resuspension of BHK-21 cells in the virus inoculum
The efficiency of adsorption of virus to cells by directly
resuspending the cells in virus was determined. Confluent BHK-21
cell monolayers were trypsinized, the cells washed and resuspended in
the virus inoculum to give input multiplicities of 2.5 pfu/cell,
7
4.4 pfu/cell and 8.6 pfu/cell with cell concentrations of 4 x 10
7 7
cells/ml, 3 x 10 cells/ml and 2 x 10 cells/ml respectively. The
best adsorption (46-56 per cent of cells infected) occurred when
the cells were resuspended directly in the virus inoculum with an
input multiplicity of 8.6 pfu/cell (Table 4.5).
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3. ADSORPTION OF VIRUS TO BHK-21 CELLS IN CELL MONOLAYERS
Confluent cell monolayers were inoculated with one ml of a virus
suspension to give an input multiplicity of 15 pfu/cell. After 90
minutes adsorption 0.6 per cent of cells were shown to be infected.
The effect of pretreating cells in a monolayer with 10 per cent
DMSO was also investigated. The procedure was as described earlier
except that prior to inoculation of the monolayer the media was
decanted from half of the tubes and replaced with BHK cell growth
media plus 10 per cent DMSO. After a further 60 minutes incubation
the media was removed from all tubes and one ml of a virus suspension
added to each tube to give a multiplicity of 1.5 pfu/cell. After 60
minutes adsorption 0.1 per cent of untreated and 0.24 per cent of
pretreated cells were infected.
DISCUSSION
The plaque method was shown to be a significantly more sensitive
method for assaying the proportion of cells infected following
adsorption than the immunofluorescence method. Plaques were
indistinguishable from those produced by free virus and non-infected
cells did not appear to interfere with the assay.
Adsorption of virus to BHK-21 cells and the IB/RS2 PK cell line
was shown to be inhibited by the presence of lamb serum in the
adsorbing mixture and on further investigation it was apparent that
adsorption was specifically inhibited by a component or components
of high molecular weight present in the first and, to a lesser extent,
second protein peaks following Sephadex-G200 fractionation of whole
serum. The serum was screened for HAI antibody activity to louping-ill
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virus and no activity either in the IgM or IgG antibody class could be
detected. It is unlikely therefore that the adsorption inhibiting
factor was a specific immunoglobulin against louping-ill. A visna
virus inhibiting factor (VIF) present in normal sheep sera and cerebro¬
spinal fluid has been reported by Thormar, Wisnieski and Lin (1979).
They showed that the VIF was not an immunoglobulin with specific anti¬
body against visna virus and suggested that it may be a lipoprotein.
The growth of visna virus was shown to be totally inhibited in sheep
cell monolayers containing 90 per cent normal sheep serum. Under the
experimental conditions described here the louping-ill virus
inhibiting factor present in normal lamb serum appears to be specific
to virus attachment and adsorption as replication of virus in cells
grown in media containing 10 per cent lamb serum was unaffected (Part
II). Different batches of lamb serum were used throughout the study and
it is possible that a variation in the degree of adsorption inhibition
existed between batches.
Adsorption of louping-ill virus to BHK-21 cells was shown to be
dependent on the cell concentration and virus input. Raising the cell
concentration and the added multiplicity increased the probability of
adsorption and was most readily effected by resuspending cells directly
in the virus inoculum. In addition under these conditions adsorption
was not adversely affected by the introduction of fresh lamb serum
into the adsorbing preparation. Similarly Davey, Dennett and Dalgarno
(1973) studying the growth kinetics of 2 togaviruses, Semliki Forest
virus and Kunjin virus, showed that increasing the cell concentration
during adsorption increased the percentage of cells infected, and
Rubin, Franklin and Baluda (1957) demonstrated that adsorption of
51.
Newcastle disease virus to chick-embryo-lung epithelium approached
7
a maximum when the total number of cells in the layer was 10 .
It has been suggested that DEAE-D may bind to the cell surface
or complex with virus particles and thus increase the efficiency of
virus adsorption and virus infectivity (Rossi and Kiesel, 1978;
Rossi, 1971 and Shigeko, 1968) . Pretreatment of cells with DEAE-D
has been shown to enhance the infectivity of respiratory syncytial
virus in African green monkey kidney cells and bovine embryonic lung
cultures (Shigeko, 1968; Rossi and Kiesel, 1978), the growth of
rubella virus in BHK-21 cells (Vaheri, Sedwick and Plotkin, 1967)
and plaque production in alphaviruses in chick embryo culture
(Pattyn and Vleesschauwer, 1969). McCutchan and Pagano (1968)
however reported a 20-fold reduction in the infectivity of Simian
virus 40 in the presence of DEAE-D and Stow and Wilkie (1976) showed
that the infectivity of Herpes Simplex virus in BHK-21 cells was
unaffected by treatment with DEAE-D. Cleaver Q974) observed an
increase in plaque size and numbers following addition of DMSO to the
agar overlay of Simian virus 40 plaque assays. It is evident therefore
that depending on the virus-cell system employed, DMSO and DEAE-D may
exert either an enhancing or a depressing effect on virus adsorption.
In the present study treatment of cells with these two chemicals had
little effect on virus adsorption.
In conclusion, the rate of adsorption of louping-ill virus to
BHK-21 cells proved to be a function of the cell concentration, the
input multiplicity and the serum present in the adsorbing preparation.
Adsorption was maximal after 60 minutes incubation at 37°C and was
52 .
more efficient to cells in a cell suspension than to cells in a
monolayer.
The influence of the efficiency of adsorption on virus growth
and virus yield will be discussed in Part II.
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+ 5
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0.8 - 0.9 x 10
+ 5
1 - 0.01 x 10
0.7 - 0.15 x 105










Pretreatment at 37°C for 60 minutes
Adsorption at 37°C for 60 minutes
g
Input multiplicity 13 pfu/cell, cell concentration 5 x 10 cells/ml
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Table 4.4 Adsorption of virus to BHK-21 cells in suspension: the











2.1 - 0.49 x 10"
2 - 0.48 x 105
, 5***
7.2 - 1.5 x 10
3.4 ± 0.9 x 105*
3.5 - 0.79 x 105
7.8 - 1.6 x 105**
6 ± 1.17 x 105
1.4 ± 0.18 x 106***











Input multiplicity 3 pfu/cell, cell concentration 10 cells/ml
o
Adsorption at 37 C for 60 minutes
* p<0.05 significantly higher number of cells infected
** p<0.01 compared to the number infected with 8% LS in the
*** p<. 0.001 adsorbing suspension
^Samples removed from cell-virus suspensions after 60 minutes adsorption
were titrated in duplicate
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PART II PROPAGATION OF LOUPING-ILL VIRUS IN BHK-21 CELLS
MATERIALS AND METHODS
The maintenance and routine handling of BHK-21 cells was carried
out as described in Chapter Two. Unless stated otherwise adsorption
of virus was achieved by resuspending trypsinized cells directly in
o
the virus inoculum and incubating at 37 C for 60 minutes. The
adsorption procedure and infected cell assay is described in Part I.
Following adsorption of virus, cells were sedimented and washed
twice in BHK virus growth media to remove free unadsorbed virus.
The cells were resuspended in the appropriate growth media and
inoculated into the following culture vessels as indicated below.
1. STATIONARY AND ROLLING TUBE CULTURES
Pyrex glass tubes (15 x 150mm) fitted with rubber stoppers were
6
inoculated with 10 cells in a volume of 1.2ml media. The tubes
o
were incubated at 37 C either in stationary racks or on a roller drum
rotating at 0.2rpm and were examined microscopically every 24 hours.
Ten stationary and 10 rolling tubes were sampled daily for 5 days.
The media from each group of 10 was pooled and centrifuged at 750g
o o
for 15 minutes at 4 C. The supernatant was stored at -80 C until
assayed in duplicate for virus infectivity and HA activity.
2. STATIONARY MULTI-TRAY UNIT *
A multi-tray unit consisting of 10 separate chambers with a
2
total surface area for cell growth of 6000cm was inoculated with
9
10 cells in 1800ml BHK virus growth media. The tray was incubated
*Inter-Med, Denmark.
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at 37°C and the culture harvested after 72 hours incubation. The
harvest was stored at -80°C.
3. ROLLING HALF-GALLON BOTTLES*
Half-gallon bottles (length 270mm, diameter 110mm) with a
2
surface area for cell growth of 840cm were each inoculated with
g
1.5 x 10 cells in 200ml BHK virus growth media. The bottles were
incubated at 37°C on a roller rotating at 0.2rpm for 72 hours.
Growth of virus in serum free media (EBA media) was also examined;
8
following adsorption, bottles were inoculated with 1.5 x 10 cells
in 200ml BHK cell growth media supplemented with a further 0.1 per
cent (w/v) sodium bicarbonate. After 24 hours incubation the media
was decanted and the cell monolayer gently washed twice in PBS,
100ml of EBA media was then added and the cultures reincubated for
48 hours. Cultures were then harvested and stored at -80°C.
4. WHEATON ROLLER BOTTLES*
Wheaton roller culture bottles (length 465mm, diameter 110mm)
2
with a surface area for cell growth of 1680cm were each inoculated
g
with 3 x 10 cells in 500ml BHK virus growth media. The bottles
were incubated at 37°C on a roller rotating at 0.3rpm. Growth of
virus in EBA media was also examined as described in 3. Cultures
were harvested 72 hours post infection and stored at -80°C.
Harvests were assayed for infectivity using the plaque assay and
HA test as described in Chapter Two.
*Jencons (Scientific) Ltd., Hemel Hempstead,
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RESULTS
1. STATIONARY AND ROLLING TUBE CULTURES
Propagation of virus using BHK virus growth media
Trypsinized cells were resuspended in virus inoculum to give an
input multiplicity of 8.6 pfu/cell and a cell concentration of
7
2 x 10 cells/ml. Following 60 minutes adsorption 53 per cent of
cells were infected. The adsorbed cells were washed, resuspended
in BHK virus growth media and incubated as stationary and rolling
cultures.
A cytopathic effect (CPE) was first observed 24-48 hours
following infection. As the CPE developed, cells sloughed off and
between 72 and 96 hours after infection detachment of cells was
almost total.
After 24 hours virus titres in the rolling and stationary
7 7
cultures reached 3 x 10 pfu/ml and 4.5 x 10 pfu/ml respectively.
Levels remained relatively constant for up to 120 hours post-
g
infection. Yields were highest (1.1 x 10 pfu/ml) in stationary
cultures incubated for 96 hours (Fig. 4.4). Haemagglutination
titres reached maximum (1/128) in rolling cultures 120 hours post¬
infection and in stationary cultures (1/256) 72 hours post-infection
(Fig 4.4). The full results are tabulated in Appendix 4.1.
The effect on viral replication of varying the concentration of lamb
serum in the adsorption and growth media
Two aliquots of trypsinized BHK-21 cells were washed and
resuspended in BHK virus growth media containing 10 or 5 per cent
lamb serum. Five ml of virus inoculum was added to each cell
Fig. 4.4 Propagation of louping-ill virus in BHK-21 cells using
BHK virus growth media
0 0 infectivity titre (pfu/ml) in rolling
cultures
A A infectivity titre pfu/ml) in stationary
cultures
0 0 reciprocal HA titre in rolling culture
A A reciprocal HA titre in stationary culture
24 48 72 96 120
Hours post infection
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suspension (10ml) to give an input multiplicity of 1.5 pfu/cell and
7
a cell concentration of 2.2 x 10 cells. Following 60 minutes of
adsorption the percentage of infected cells was 7.3 and 10
respectively. The adsorbed cells were washed twice, resuspended in
either 10 or 5 per cent lamb serum growth media and incubated either
as rolling or stationary cultures.
g
The highest infectivity titres (1.2 x 10 pfu/ml) were obtained
from stationary cultures grown in 10 per cent LS growth media for
48 hours (Fig 4.5). Virus levels were maintained for the period of
the experiment. Rolling cultures grown in 10 per cent LS growth
7
media developed maximum titres (4.7 x 10 pfu/ml) after 48 hours
0
incubation, titres then showed a gradual decrease to 1.2 x 10 pfu/ml
at 120 hours post-infection. After 24 hours stationary and rolling
cultures grown in 5 per cent LS growth media produced virus titres
7 7
of 2.7 x 10 pfu/ml and 5.2 x 10 pfu/ml respectively, titres however
progressively declined and by 120 hours had decreased to 2.8 x
2 5
10 pfu/ml and 7.7 x 10 pfu/ml respectively. Virus titres were thus
higher in cells cultured in 10 per cent lamb serum.
A similar pattern was observed in HA activity. The highest HA
titre (1/512) was obtained from stationary cultures grown in 10 per
cent LS media (Fig. 4.6). Titres were lower in stationary and
rolling cultures grown in 5 per cent LS media and; after 96 hours incu¬
bation had declined to undetectable and minimal levels respectively.
The full results are tabulated in Appendix 4.2.
Figure 4.5 The infectivity titre pfu/ml) of louping-ill
virus propagated in
0 0 rolling BHK-21 cell cultures using BHK virus
growth media (10% LS)
A A stationary BHK-21 cell cultures using BHK
virus growth media (10% LS)
• • rolling BHK-21 cell cultures using BHK virus
growth media (5% LS)
▲ ▲ stationary BHK-21 cell cultures using BHK
virus growth media (5% LS)
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24 48 72 96 120
Hours post infection
Fig. 4.6 The reciprocal HA titre louping-ill virus
propagated in
0 0 rolling BHK-21 cell cultures using BHK virus
growth media (10% LS)
A A stationary BHK-21 cell cultures using BHK
virus growth media (10% LS)
• • rolling BHK-21 cell cultures using BHK virus
growth media (5% LS)
▲ A stationary BHK-21 cell cultures using BHK
virus growth media (5% LS)
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Propagation of virus in BHK-21 mycoplasma contaminated cells and
BHK-21 mycoplasma-free cells BHK-21 (R8MF)
Trypsinized BHK-21 and BHK-21 (R8MF) cells were washed and each
resuspended in 8ml virus inoculum to give an input multiplicity of
7
1.6 pfu/cell and a cell concentration of 2 x 10 cells/ml.
Following 60 minutes adsorption 19 and 8 per cent of BHK-21 and
BHK-21 (R8MF) cells respectively were infected. The adsorbed cells
were washed twice, resuspended in BHK virus growth media and incubated
as rolling and stationary cultures in test tubes. After 48 hours
incubation approximately 50 per cent of cells in all cultures
appeared rounded and cell detachment was apparent.
Virus titres were consistently higher in BHK-21 (mycoplasma
contaminated) cells, incubated both as stationary and rolling cultures.
7 7
After 96 hours mean virus titres* of 7.9 x 10 pfu/ml and 2.6 x 10
pfu/ml were demonstrated in stationary and rolling cultures of BHK-21
6 4
cells compared with 1.3 x 10 pfu/ml and 1.1 x 10 pfu/ml in
stationary and rolling cultures of BHK-21 (R8MF) cells (Fig. 4.7).
Virus yields remained constant up to 120 hours in all cultures
except BHK-21 (R8MF) rolling cell cultures. Virus yields from these
g
cells declined from a maximum titre of 9.1 x 10 pfu/ml 24 hours
4
after infection to a titre of 1.1 x 10 pfu/ml after 120 hours.
The HA activity was shown to parallel the infectivity titres.
HA titres were highest (Fig. 4.8) in both stationary and rolling
cultures of BHK-21 cells reaching mean titres of 1/512 and 1/427
*Data collated from two separate experiments carried out under the
same adsorption and growth conditions.
Fig. 4.7 The infectivity titre pfu/ml) of louping-ill
virus propagated in
0 0 rolling cultures of BHK-21 mycoplasma
contaminated cells
A A stationary cultures of BHK-21 mycoplasma
contaminated cells
• • rolling cultures of BHK-21 mycoplasma-free cells
A A stationary cultures of BHK-21 mycoplasma-free
cells
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24 48 72 96 120
Hours post infection
Fig. 4.8 The reciprocal HA titre of louping-ill virus
propagated in
0 0 rolling cultures of BHK-21 mycoplasma
contaminated cells
A A stationary cultures of BHK-21 mycoplasma
contaminated cells
• • rolling cultures of BHK-21 mycoplasma-free
cells
▲ A stationary cultures of BHK-21 mycoplasma-free
cells
67.




respectively 120 hours post-infection. In contrast a maximum titre
of 1/20 was demonstrated in stationary (96 hours p.i.) and rolling
(72 hours p.i.) cultures of BHK 21 (R8MF) cells. The full results
are shown in Appendices 4.3 and 4.4.
2. STATIONARY MULTI-TRAY UNIT
Trypsinized BHK-21 cells were washed and resuspended in 10ml
virus inoculum to give an input multiplicity of 0.5 pfu/cell and a
8
cell concentration of 1.2 x 10 cells/ml. Following adsorption
11 per cent of cells were infected. The adsorbed cells were washed
twice, resuspended in BHK virus growth media and cultured in a
multi-tray unit. After 72 hours incubation the infectivity of the
virus harvest was shown to be 4.5 x 10^ pfu/ml and the HA titre 1/16.
3. ROLLING HALF-GALLON BOTTLE CULTURES
Propagation of virus using BHK virus growth media
Trypsinized BHK-21 cells were resuspended in the virus inoculum
to give input multiplicities ranging from one pfu/cell to 7.5 pfu/cell.
Following adsorption, cells were inoculated into half-gallon bottles
containing 200ml BHK virus growth media.
The infectivity titres of the 72-hour-virus harvests ranged
7 8
from 6 x 10 pfu/ml to 1.1 x 10 pfu/ml with HA titres of 1/128.
Propagation of virus using EBA media
Trypsinized BHK-21 cells were resuspended in the virus inoculum
to give input multiplicities of one pfu/cell. The infectivity
7
titres of the 72-hour-virus harvests ranged from 2.9 x 10 pfu/ml
8
to 1.7 x 10 pfu/ml and HA titres were 1/256 and 1/128 respectively.
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4. WHEATON ROLLER CULTURE BOTTLES
Propagation of virus using BHK virus growth media
Trypsinized cells were resuspended in virus inoculum to give
input multiplicities ranging from 5 to 0.2 pfu/cell.
After 72 hours incubation mean virus titres ranged from 2.8 x
7 8
10 pfu/ml to 3.5 x 10 pfu/ml and mean HA titres were 1/78 to 1/355.
The full results are tabulated in Appendix 4.5.
Propagation of virus using EBA media
The infectivity titres of the 72-hour-virus harvests ranged
8 8
from 1 x 10 pfu/ml to 2 x 10 pfu/ml and HA titres were 1/512 and
1/256.
DISCUSSION
Edward (1948a) proposed that for a formalinized vaccine
prepared from the virus infected tissues of one species to be
effective when inoculated in another species a sufficiently high
concentration of antigen must be present. Louping-ill vaccine,
required primarily for the immunization of sheep and derived from
BHK-21 cells thus presents such a heterologous system. The
necessity therefore for optimizing the growth of louping-ill virus
in BHK-21 cells to consistently produce harvests of maximum
infectivity is a prerequisite in subsequent studies on vaccine
preparation and potency.
Louping-ill virus was shown to propagate to maximum titres,
8
>10 pfu/ml in BHK-21 mycoplasma contaminated cells incubated both
as stationary and rolling cultures in BHK virus growth media or EBA
media. Maximum titres (mouse LD /0.03ml) of louping-ill virus
o u
propagated in other systems for vaccine production have previously
-5.1
been shown to be 10 in sheep kidney cells (Brotherston and Boyce,
g fj ^
1970), 10 in infected mouse brain (Edward, 1948b), 10 ' in
-5
infected chick embryo (Edward, 1947a) and 10 in infected sheep
tissue (Gordon, Brownlee, Wilson and MacLeod, 1962).
The titres of virus achieved in these studies are therefore
greater than any previously described following propagation of virus
in vivo or J^n vitro.
Fluorescent studies indicated that specific antigen was first
apparent 10-12 hours after infection of cells and was localized
around the cell nucleus. By 24 hours post-infection fluorescence
was observed throughout the cytoplasm of all cells. Libikova and
Albrecht (1962) studying the replication of tick-borne encephalitis
(TBE) virus in HeLa cell monolayers similarly observed fluorescent
antigen present in the perinuclear area between 8 and 11 hours post¬
infection; by 17 hours fluorescence was apparent throughout the
cytoplasm of all cells.
Final yields of louping-ill virus, harvested 72 hours post¬
infection were similar regardless of the input multiplicity; Mayer,
Zemla and Albrecht (1962) likewise demonstrated that final yields of
TBE virus propagated in HeLa cells and harvested at 72 hours were
of the same order even though the input multiplicity was varied.
The infectivity titres of virus grown in media containing 10 per
cent lamb serum were similar to titres of virus grown in EBA media.
Under the same conditions however the infectivity of harvests grown
in media containing 5 per cent lamb serum were lower.
BHK-21 clone 13 cells routinely used have been shown to be
contaminated with Mycoplasma arginini and other unidentified
mycoplasmas of human and ovine origin (G. Jones, personal communi¬
cation) . Mycoplasma contamination of cell cultures has been shown
to influence virus growth producing either a decrease or increase in
virus yields. Rouse, Bonifas and Schlesinger (1963) and Singer,
Fitzgerald, Barile and Kirschstein (1970) demonstrated that myco¬
plasmas decreased the yields of adenovirus type 3 and vaccinia virus
respectively by depleting arginine from the growth media. Singer,
Barile and Kirschstein (1969) studying the effect of mycoplasma
infection on the production of interferon and the effect on yields
of Semliki Forest virus in hamster embryonic kidney cells
demonstrated that M. arginini and M. hyorhinis inhibited interferon
production resulting in increased yields of virus. The enhancement
of virus production was however only demonstrated when cells were
infected with a low input of virus and it was postulated that with a
low virus input only a small number of cells are initially infected
leaving most of the cells susceptible to interferon. In cells
contaminated with M. arginini and M. hyorhinis interferon production
was inhibited and uninfected cells remained susceptible to virus
infection and yields were high. In mycoplasma-free cells interferon
production was not inhibited and with a low virus input the remaining
uninfected and interferon-sensitive cells developed a degree of
resistance to virus infection and virus yields were low. With a
high virus input the number of cells infected initially was
substantially increased and the effect of mycoplasma inhibition of
interferon production was thus masked.
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Propagation of louping-ill virus in BHK-21 mycoplasma-
contaminated cells resulted in virus titres 2.3 pfu/ml higher
than titres of virus grown in BHK-21 (R8MF) mycoplasma-free cells.
The virus input was one pfu/cell. Whether the enhancing effect on
virus growth by contaminating mycoplasmas involves interferon and
is thus analogous to the effect described by Singer, Barile and
Kirschstein (1969) is unknown and a more detailed study and a better
understanding of the relationship between virus, cell and mycoplasma
is required.
For commercial production it was found that yields of virus
propagated under the optimal conditions described reached maximal
8
titres, >10 pfu/cell, in both Wheaton roller culture bottles and
half~gallon roller bottles. Yields of virus were considerably lower
from cells grown stationary in a multilayer plate. Production of
the present commercial vaccine utilizes Wheaton roller culture bottles
for propagation of virus in batches up to 40 litres. The obvious
advantage of this culture bottle as opposed to the half-gallon bottle
is the increased surface area for cell growth. Propagation of virus
in BHK-21 cells adapted to grow in suspension was not examined,
although it is recognised that such an investigation would be
particularly pertinent to the need for producing large volumes of
high titred virus for vaccine production.
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CHAPTER FIVE
THE INACTIVATION OF LOUPING-ILL VIRUS BY TREATMENT WITH FORMALIN
INTRODUCTION
An inactivated louping-ill vaccine suitable for commercial
exploitation was first developed by Gordon (1934) using infected
sheep brain, spinal cord and spleen tissues treated with 0.35 per
o
cent formalin (final concentration) for 4 days at 0-5 C. In a
subsequently developed tissue culture-derived louping-ill vaccine
(Brotherston and Boyce, 1970) virus harvests were inactivated by
exposure to 0.1 per cent formalin (final concentration) for 24 hours
at 37°C, This latter method of inactivation is also employed to
inactivate virus propagated in BHK-21 cells during commercial
production of the presently available inactivated louping-ill
vaccine.
The process of inactivation of louping-ill virus by formalin
has not however been studied in detail and this chapter therefore
examines the inactivation of tissue culture-derived louping-ill virus,
describing the dynamics of the inactivation process and the effect on
the rate of inactivation of using lower concentrations of formalin.
The selection of the optimal concentration of formalin with regard
to subsequent vaccine manufacture is also discussed.
MATERIALS AND METHODS
Preparation of virus
Louping-ill virus was propagated in BHK-21 cells grown in BHK
virus growth media and incubated at 37°C as rolling cultures. After
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72 hours incubation the infected supernatants were harvested, samples
removed for infectivity assay and the remainder dispensed in 15ml
volumes in screw-capped bottles.
Virus inactivation
The course of virus inactivation in tissue culture fluids was
followed at 37°C with final formalin* dilutions of 1/1000, 1/2000,
1/4000 and 1/8000. The fluids were kept in screw-capped bottles in
o + o
a 37 - 0.5 C incubator. Virus to which no formalin had been added
was also incubated at 37°C to determine the lability of louping-ill
virus at this temperature. Aliquots were removed from the
preparations immediately following the addition of formalin and
thereafter at various time intervals and assayed for residual virus
and haemagglutination activity. Deformalinization of aliquots was
attempted using a 2.3 per cent aqueous solution of NallSOg in the
ratio lmol NaHSO^ per lmol of formaldehyde. It was shown however
that treatment of live virus with the highest concentration of
NaHS0„ decreased infectivity by 1.5 log pfu/ml and HA activity to
1U
undetectable levels. Inactivated samples were therefore not
deformalinized.
Residual virus assay
Immediately following sampling aliquots were diluted in PK/RA
media and assayed for residual virus using the plaque method
described in Chapter Two.
Haemagglutination assay
Aliquots (0.4ml volume) were dispensed into screw-capped bottles
*Analar Formaldehyde solution (37-40%) BDH Chemicals Ltd.
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and stored at -20°C until completion of the experiment. All samples
were then assayed for haemagglutination activity using the method
described in Chapter Two.
RESULTS
The course of formalin inactivation of louping-ill virus in
tissue culture fluid is illustrated in Fig. 5.1, The curves
obtained show that there was an initial rapid drop in infectivity in
the four hours immediately following addition of formalin. With
formalin dilutions of 1/1000 and 1/2000 infective virus was not
detected after 12 hours incubation at 37°C. The rate of inactivation
with formalin at 1/4000 and 1/8000 was slower and the time required
for complete inactivation of virus was protracted to 24 and 48 hours
respectively.
Haemagglutination activity was not detected after 4 hours and
12 hours exposure of virus to formalin dilutions of 1/1000 and
1/2000 respectively. With formalin dilutions of 1/4000 and 1/8000
HA activity was detectable up until 24 hours and 48 hours of incubation
with corresponding titres of 1/8 and 1/32,
Incubation of virus without formalin at 37°C for 12 hours caused
no appreciable loss in infectivity, after 24 and 48 hours infectivity
was reduced hy 1.0 log and 3.0 logs respectively. Haemagglutination
activity with a titre of 1/128 was maintained throughout the sampling
period.
DISCUSSION
Inactivation of louping-ill virus in tissue culture fluids with
1/1000 and 1/2000 formalin resulted in a loss in detectable
Fig. 5.1 The course of formalin inactivation of louping-ill virus






















infectivity after 12 hours incubation at 37 C. The curve
representing the rate of the formalin inactivation reaction was not
a straight line but biphasic, indicating a higher rate of
inactivation in the first 4 hours following addition of formalin.
A similar biphasic reaction was observed in the inactivation of
Japanese B encephalitis virus with formalin dilutions ranging from
1/1000 to 1/8000 (Darwish and Hammon, 1966a) and also in
inactivation of poliovirus exposed to a formalin concentration
of 1/8000 (Timm, MacLean, Kupsky and Hook 1956). Charney, Fisher
and Machlowitz (1957) studying the inactivation of a purified
poliovirus suspension obtained however straight line inactivation
curves indicating a reaction following first order kinetics.
The lability of louping-ill virus to formalin is characteristic
of a number of togaviruses. Bartelloni, McKinney, Calia, Ramsburg
and Cole C1971) and Maire, McKinney and Cole, (1970) demonstrated
that tissue culture grown Western equine encephalitis virus and
Venezuelan equine encephalitis virus were inactivated by 1/2000
o
formalin at 37 C in less than 24 hours. Danes and Benda (1960)
observed that tick-borne encephalitis virus strain B3 incubated at
o
4 C for 72 hours was inactivated by formalin at a dilution of
1/2000, and Gall (1973) studying the inactivation of tick-borne
encephalitis virus strain B7 showed that incubation with 1/4000
o
formalin for 12 hours at 37 C resulted in loss of detectable
infectivity.
The formalin dilution required in the preparation of an
inactivated vaccine is determined by the need to completely destroy
infectivity yet maintain antigenicity. High concentrations of
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formalin, although causing a rapid loss of infectivity, have been
shown to cause physical damage of virus particles (Schaffer, 1960) and
antigenicity of the inactivated virus suspension may be impaired.
Salk and Gori (1960) have however shown that when very low concen¬
trations of formalin are used most of the formalin will only bind
with the protein surface layer with minimal diffusion to the interior
of the virus particle and this may result in a reversible type of
virus inactivation. In addition low concentrations of formalin also
prolong the incubation period required for complete destruction of
infectivity and the antigenicity of preparations inactivated at
30°C or 37°C may be adversely affected as a result of thermal de-
naturation of the virus particle (Salk and Gori, 1960). Inactivation
at lower temperatures although abrogating thermal denaturation of
virus greatly decreases the rate of inactivation (Darwish and Hammon,
1966c; Robinson, Herman, Lowenthal and Hetrick, 1966; White, Berman
and Lowenthal, 1971), and the period of incubation required for
complete loss of infectivity may be impractical for a vaccine
production schedule. Cole, May and Robinson (1973) have however
shown that the immunogenicity of inactivated Venezuelan equine
encephalitis vaccines remained stable even after treatment with
o
0.1 per cent formalin for 96 hours at 37 C and Danes and Benda
(1960) observed no significant differences in the immunogenicity of
tick-borne encephalitis vaccines inactivated by formalin dilutions
ranging from 1/500 to 1/2000 or in the immunogenicity of formalinized
and the corresponding deformalinized vaccines.
A formalin dilution that is mild yet effective and can be
tolerated in a vaccine without the necessity for subsequent
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elimination by dialysis or chemical means is therefore required. A
formalin dilution of 1/2000 was shown to completely destroy detectable
louping-ill virus infectivity within 24 hours and is therefore as
efficient as a dilution of 1/1000. Treatment with the 1/2000
dilution however constitutes a milder yet equally functional
inactivation process. Higher dilutions of formalin were shown to
require longer incubation periods to completely inactivate virus and
this may adversely affect antigenicity. It is suggested therefore
that for preparation of inactivated louping-ill virus vaccine a
formalin dilution of 1/2000 is optimum.
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CHAPTER SIX
THE IMMUNOGENICITY OF METHANOL-CONCENTRATED AND
UNCONCENTRATED LOUPING-ILL VIRUS VACCINES
INTRODUCTION
Proteins are readily precipitated out of solution by treatment
with organic solvents, and the use of methanol to precipitate
protein from virus infected tissue culture fluids is well established
(Harris, 1964). Methanol precipitation of virus harvests and
subsequent elution of viral protein from non-viral protein without
a significant loss in infectivity has been described with influenza
virus (Cox, Van der Scheer, Aiston and Bohnel, 1947), Eastern equine
encephalitis virus, influenza B virus and Newcastle disease virus
(Pollard, Connolly and Fromm, 1949) and poliomyelitis virus
(Schwerdt and Schaffer, 1956), resulting in concentrated and
partially purified virus preparations.
Concentration of louping-ill virus (propagated in secondary
monolayers of sheep kidney cells) by methanol or acetone
precipitation was shown to produce immunogenic vaccines (Brotherston
and Boyce, 1970). High antibody titres were regularly induced by a
single dose of such vaccines. No attempts were made to elute virus
from the non-viral protein present, rather, the entire protein
precipitate was used as antigen. Vaccines prepared from
unconcentrated harvests were shown to be non-immunogenic even
following the administration of 2 doses.
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For commercial production of louping-ill virus vaccine, virus
is propagated in BHK-21 cell monolayers and virus antigen
concentrated by methanol precipitation (Appendix 3.1). The
concentration procedure employed is essentially that described by
Brotherston and Boyce (1970). Experience has indicated however
that the potency of the commercially produced vaccine is variable
and sometimes considerably lower than the experimental louping-ill
vaccine described by Brotherston and Boyce (1970), Two doses of
commercial vaccine are required to consistently provoke a
satisfactory immune response.
The potency of inactivated vaccines has been shown to be
dependent on the infectivity of the source material (Smorodintsev
and Ilyenko, 1962; White, Berman and Lowenthal, 1972; Levkovich,
1962; Crawford, Dayhuff and White, 1968; Edward, 1948b and Cox,
Van der Scheer, Aiston and Bohnel, 1947). The relationship between
the immunogenicity of louping-ill vaccines and the infectivity titre
of the virus harvest prior to inactivation, and an evaluation of
methanol precipitation as a means of concentrating commercially
produced louping-ill virus are described in this chapter. The
requirement for an effective method of concentrating virus to




1. THE EFFICACY OF METHANOL TREATMENT FOR CONCENTRATING VIRAL
ANTIGEN: A COMPARISON OF THE IMMUNOGENICITY OF VACCINES PREPARED
FROM CONCENTRATED VIRUS HARVESTS AND UNCONCENTRATED VIRUS HARVESTS.
All the vaccines used in this study were derived from inactivated,
concentrated or unconcentrated tissue culture harvest pools prepared
during the commercial production of louping-ill virus vaccine in 1978
and 1979. Inactivation of the harvests and concentration by methanol
precipitation is described in Appendix 3.1.
The data concerning the immunogenicity of vaccines prepared from
the concentrated virus harvest pools were derived from the pre-blend
potency assays described in Appendix 3.1. Essentially, aliquots of
the 10-fold concentrated virus harvest pools (A-F) were diluted to
give 5-, 2.5- and 1.25-fold concentrates using PBS plus 0.5 per cent
(v/v) phenol. Vaccines were prepared by emulsifying each of the
concentrates with Bayol F and Falba oil adjuvant in a ratio of one
part of concentrate to 2 parts adjuvant to give a final volume of
15ml. Emulsification was carried out using a MSE bench type
overhead homogenizer. The vaccines were prepared and assayed for
potency immediately following production of each concentrated virus
harvest pool.
Vaccines were also prepared from aliquots of the corresponding
unconcentrated inactivated virus harvest pools (A-F). Prior to
inactivation, vaccine preparation and potency assay the infected
virus harvest pools had been stored at -20°C for approximately 5
months .
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Various breeds of sheep born either at the Moredun Research
Institute or in other areas free of ticks and aged between 7 months
and 2 years were used to assess vaccine potency. Prior to
vaccination all the sheep were tested for the presence of louping-ill
HAI serum antibodies and all were found to be seronegative. Each
vaccine was injected sub-cutaneously into 5 sheep behind the right
shoulder in a volume of 1ml. All the sheep were then bled weekly for
4 weeks. Twenty-eight days following vaccination sheep inoculated with
vaccines prepared from concentrated and unconcentrated virus harvest
pools E and F were re-injected with a second 1ml dose of vaccine.
These sheep were then bled weekly for a further 4 weeks. Sheep
inoculated with vaccines prepared from unconcentrated virus harvest
pools were also bled 10 and 16 weeks post vaccination. The blood
was allowed to clot and the sera removed and tested for HAI antibody
to louping-ill virus as described in Chapter Two.
Statistical analysis
Reciprocal HAI titres obtained at 7, 14, 21 and 28 days post-
vaccination were converted to log-^Q values and the mean titres
calculated. The responses to vaccines prepared from the 6
concentrated virus harvest pools and concentrate dilutions were
compared with the responses to vaccines prepared from each of the
corresponding unconcentrated virus harvest pools . The data from all
vaccines was composited and similarly compared. Tests used to
analyse the data included (in order of preference) Dunnett's Multiple
Comparison test (Dunnett, 1955); the 2-sample t-test, the Mann
Whitney non-parametric test and the Chi-square test.
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2. IMMUNOGENIC CITY OF VACCINES PREPARED FROM AN UNCONCENTRATED VIRUS
HARVEST E2
An aliquot of an inactivated and unconcentrated virus harvest,
E2, prepared during the commercial production of vaccine was obtained.
8
The infectivity of the harvest prior to inactivation was 3.4 x 10
pfu/ml. The inactivated harvest was diluted 1/3, 1/6, 1/12 and 1/24
using PBS plus 0.5 per cent (v/v) phenol, vaccines were prepared from the
undiluted harvest and the diluted preparations as described earlier.
Each vaccine was injected sub-cutaneously in a 1ml volume into each
of 5 7-month-old seronegative Dorset ewe lambs. The lambs were then
bled weekly for 4 weeks and then again at 8 and 12 weeks. The blood
was allowed to clot, the sera removed and tested for HAI antibody
activity.
RESULTS
1. THE IMMUNOGENICITY OF VACCINES PREPARED FROM CONCENTRATED VIRUS
HARVESTS AND THEIR CORRESPONDING UNCONCENTRATED HARVESTS
The 14 and 28 day antibody responses to vaccines prepared from
the 10-, 5-, 2.5- and 1.25-fold concentrates of each of the harvest
pools (A-D) and to vaccines prepared from the corresponding
unconcentrated harvest pools are illustrated in Figs. 6.1 a-d. The
antibody responses following revaccination with vaccines prepared
from concentrated and unconcentrated virus harvest pools E and F are
illustrated in Figs. 6.le and 6. If. The 28-day mean reciprocal HAI
titres and the statistical differences in HAI responses
elicited by the concentrated and the corresponding unconcentrated
vaccines are indicated in Table 6.1. The infectivity titres of the
Fig. 6ul a-d The 14 and 28 day antibody responses to vaccines
prepared from harvest pools A-D
• unconcentrated vaccine
O 10-fold concentrate vaccine
■ 5-fold concentrate vaccine
□ 2.5-fold concentrate vaccine
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Fig. 6.1 e-f The 28 and 56 day antibody responses to vaccines
prepared from harvest pools E and F
• unconcentrated vaccine
O 10-fold concentrate vaccine
■ 5-fold concentrate vaccine
□ 2.5-fold concentrate vaccine






























































virus harvests (A-F) prior to inactivation ranged from 8.4 1°5^q
pfu/ml to 8.1 log10 pfu/ml (Table 6.1). The composite mean
reciprocal HAI titres (log^) at 14, 21 and 28 days and the
statistical differences in the overall responses are tabulated in
Table 6.2. The full results are given in Appendix 6.1.
Twenty-eight days after vaccination only one out of the 24
concentrated vaccines produced a significantly higher (p<0.01)
response than the corresponding unconcentrated vaccine, this vaccine
had been prepared from Pool A 10-fold concentrate. Twenty-two of
the 24 concentrated vaccines evoked responses that were not
significantly different compared to those produced by the unconcen-
trated vaccines^ and; vaccine prepared from Pool C 2.5-fold concentrate
produced a significantly lower antibody response (p<0.05) than the
corresponding unconcentrated vaccine. The percentage of animals
injected with the unconcentrated vaccines or the concentrated vaccines
and found to be persistently seronegative for up to 28 days post-
vaccination was 3.4 and 19.4 per cent respectively. The highest mean
HAI titre (1/501) was detected in animals injected with unconcentrated
vaccine (harvest pool E) 28 days following vaccination.
Statistical analysis of the composite data indicated that, overall,
7, 14, 21 and 28 days post-vaccination there was no significant
difference between the antibody response induced by the 10- and 5-fold
concentrated vaccines and the unconcentrated vaccines. At 21 and 28
days following vaccination the overall response produced by
unconcentrated vaccine was significantly higher (p< 0.001, p<0.01)
than that produced by 2.5-fold concentrate vaccines and that
produced by 1.25-fold concentrate vaccines (p<! 0.001, P<0.05)
(Table 6.2) .
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The immune responses produced by vaccines prepared from
unconcentrated harvests were maintained for up to 16 weeks post-
vaccination (Table 6.3) and a typical secondary anamnestic response
was detected in sheep revaccinated either with unconcentrated or
concentrated vaccine (Figs. 6.1 e-f).
2. THE IMMUNOGENICITY OF VACCINES PREPARED FROM UNCONCENTRATED
VIRUS HARVEST E2
The infectivity titre of harvest E2 and the equivalent
infectivity titres of the 1/3, 1/6, 1/12 and 1/24 diluted
8 8 7
preparations were 3.4 x 10 pfu/ml, 1.13 x 10 pfu/ml, 5.6 x 10
7 7
pfu/ml, 2.8 x 10 pfu/ml and 1.4 x 10 pfu/ml respectively.
The 14- and 28-day serological responses to vaccines prepared
from harvest E2 and harvest dilutions are illustrated in Fig. 6.2.
The mean reciprocal HAI titres 7, 14, 21, 28, 56 and 84 days
post-vaccination and the numbers of sheep responding to vaccination
are indicated in Table 6.4.
The highest mean HAI titre (1/200) was detected at 21 days in
sheep injected either with vaccine prepared from the undiluted
harvest or vaccine prepared from the 1/3 harvest dilution, and at 28
days mean HAI titres were shown to be 1/200 and 1/100 respectively.
In addition a serological response was demonstrated in all animals
injected with either of these 2 vaccines. Vaccines prepared from the
1/6, 1/12 and 1/24 harvest dilutions produced a detectable serological
response in 40, 80 and 20 per cent of animals 28 days post-
vaccination with corresponding mean HAI titres of 1/19, 1/25 and 1/6.
The relationship between vaccine potency and the preinactivation
Fig. 6.2 The 14 and 28 day antibody responses to vaccines





























infectivity titre of the virus harvest is illustrated in Fig. 6.3.
The correlation coefficient was +0.769 (p<0.001).
DISCUSSION
Brotherston and Boyce (1970) reported that methanol treatment of
formalinized louping-ill virus propagated in secondary cultures of
sheep kidney cells produced experimental vaccines of considerable
immunogenicity, and that vaccines prepared from untreated virus
were non-immunogenic. To assess the efficacy of methanol
precipitation of commercially produced louping-ill virus (propagated
in BHK-21 cells) the comparative immunogenicity of vaccines prepared
from methanol treated virus harvests and untreated virus harvests
was examined.
The concentration of commercially produced virus using methanol
was shown to be inefficient because there was no significant
difference between the potency of unconcentrated vaccines and the
10- and 5-fold concentrate vaccines. Furthermore, the antibody
response to unconcentrated vaccine was significantly higher than
the response to the 2.5- and 1.25-fold concentrate vaccines. The
percentage of persistently seronegative sheep was also considerably
lower in animals vaccinated with the unconcentrated vaccine.
A comparison between the commercial and experimental methods of
vaccine production is required in an attempt to understand the
apparent success of concentrating virus with methanol in the
experimental system, and the overt inefficiency of the same method
when applied to an approximately equivalent system.
Louping-ill vaccine is required primarily for the protection of
sheep against natural infection and the essential difference between
Fig 6.3 The 28 day HAI titres to vaccines prepared from




the two vaccine production methods is that, experimentally, virus
was propagated in sheep tissue (a homologous system) in the absence
of serum, whereas commercially virus is propagated in baby-hamster-
kidney tissue (a heterologous system) in media containing 10 per
cent lamb serum.
The difficulties associated with immunization using virus
derived from heterologous tissue suspensions have long been
recognized (Traub, 1938; Koprowski and Cox, 1946; Maurer, Walker,
Shope, Griffiths and Jenkins, 1946; Edward, 1948b) and the rationale
of Brotherston and Boyce (1970) to propagate louping-ill virus in
homologous cell culture and to further reduce the amount of foreign
protein present by removal of cellular debris may therefore be a
particularly important factor contributing significantly to the
success of their experimental vaccine.
Commercial propagation of virus using a heterologous cell
culture system, media containing serum and the non-removal of cell
debris will inevitably incorporate a greater amount of non-viral
antigenic material than in harvests derived from homologous culture.
Methanol precipitation of commercially produced virus harvests may
therefore concentrate not only specific antigen but also non¬
specific antigens and intermolecular and intramolecular immunogenic
competition and interference may result. In addition, concentration
of the antigens could be unequal, producing an antigenic imbalance
in the final concentrate in favour of non-specific antigen and a
corresponding decrease in specific antigenicity of the final
preparation.
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The use of a heterologous cell system for virus propagation and
the contrasting effect of methanol precipitation on the antigenic
activity of virus derived from homologous and heterologous cell culture
will be discussed further in Chapter Nine.
The potency test specification with respect to commercial
louping-ill vaccine states that out of 6 sheep injected with vaccine
the sera of 5 must contain HAI antibodies at dilutions of 1/10 or
greater. The immunogenicity of vaccines prepared from unconcentrated
virus harvests was shown to be a reflection of the preinactivation
infectivity titre. Vaccines prepared from virus harvests having an
7
antigenic mass equivalent to titres of 5 x 10 pfu/ml and less
produced a serological response in only 80, 40 and 20 per cent of
animals. These vaccines would therefore be unacceptable for
commercial issue. A serological response was however shown in all
animals injected with vaccines prepared from unconcentrated virus
harvests having an antigenic mass equivalent to pre-inactivation
g
titres in excess of 10 pfu/ml. Such vaccines would therefore be
acceptable for commercial issue.
Thus, providing the titre of the source material is in excess
g
of 10 pfu/ml, concentration of antigen is an unnecessary step and
vaccines of satisfactory potency can be prepared from unconcentrated
commercial harvests. Production of such vaccines however demands a
constant supply of high titred source material. As the present
commercial technique employed for virus propagation is a batch
method and titres of individual harvests have been shown to range
8 6
from 10 pfu/ml to 10 pfu/ml, to consistently produce vaccines of
acceptable potency a method of concentrating viral antigen other
than by methanol precipitation would be expedient.
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Table 6.1 The 28 day mean reciprocal HAI titres (log^) elicited
by concentrated and unconcentrated louping-ill vaccines A-F
Harvest Mean Infectivity
Pool of Harvest Pool
A 8.^ - 0.06
B 8.1-0.05
C 8.1 - 0.09
D 8.1-0.07
E 8.4 - 0.02
F 8.2 - 0.04
Vaccine Concentration Factor
Unconc. lOx 5x 2,5x 1,25x
1.6 2.6** 1.8 1.5 1.7
2.0 1.9 1.7 1.5 1.5
2.3 1.6 1.5 1.2* 1.5
2.0 1.8 1.7 1.4 1.2
2.7 2.6 1.8 2.0 1.9
1.8 1.9 1.8 1.2 1.6
ilogl0 Pfu/ml
The statistical differences between the titres elicited by the
concentrated and the corresponding unconcentrated vaccines are indicated
as follows:
* p < 0.05 (data analysed by Dunnett's Multiple Comparison test) and
**P < 0.01 (data analysed by the Mann-Whitney non-parametric test
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Table 6.2 The composite mean reciprocal HAI titres elicited
































The statistical differences between the titres elicited by the
concentrated and the corresponding unconcentrated vaccines are
indicatedas follows:
* p < 0. 05
** p<.0.01 Data analysed by the Dunnett's Multiple Comparison test
*** p<0.001
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Table 6.3 The duration of antibody response in sheep vaccinated with
vaccines prepared from unconcentrated harvest pools A-D
Vaccine Reciprocal HAI titres (log1Q) at days post-vaccination
28 70 112
A 1.6 2.2 - 0.16 1.5 - 0.20
B 2.0 - 0.15 2.6 - 0.17 2.3 - 0.26
C 2.3 - 0.17 2.6 - 0.10 2.2 - 0.16
D 2.0 - 0.23 2.1 - 0.20 1.5 - 0.23
+
Mean titres - s.e.
Table6.4ThmeanreciprocalHAItitres( og^)sheepinj ctedwithvaccinespr paredfrom unconcentratedharvestpoolE2anh rv stdilu ions Preinactivation infectivitvtitre (1°g10Pfu/ml) 8.53 8.04 7.74 7.44 7.150.7 0.7 0.8 0.7 0.714 1.8-0.20 **5/5 1.7-0.15 5/5 1.1-0.20 3/5 0.9-.18 1/5 0.7Dayspost-vaccination 218 2.3-0 18 5/5 2.3-0 10 5/5 1.7-0 18 5/5 1.4-0 24 4/5 1.2-0 4 2/52.3-0 10 5/5 2.0-0.10 5/5 1.2i0.30 2/5 1.4-0.17 4/5 0.8-.05 1/5
56
1.8-0.08 4/4 1.5-0.14 4/4 1.1-0 22 2/5 1.3i0 21 3/4 0,8-.03 1/5
Meantitres-s.e. **Numberofsh epresponding/numberfsh pvaccinated.




CONCENTRATION OF LOUPING-ILL VIRUS BY ULTRAFILTRATION
AND POLYETHYLENE GLYCOL PRECIPITATION
INTRODUCTION
For commercial production of louping-ill virus vaccine, virus is
propagated in BHK growth media containing 10 per cent LS and the
inactivated virus harvest concentrated by methanol precipitation.
The present studies have shown however that methanol precipitation
does not effectively concentrate commercially produced louping-ill
virus harvest. It therefore appeared desirable to investigate
concentration of virus antigen by methods other than methanol
precipitation.
Commercial propagation of virus using a heterologous cell
system with media containing serum and the non-removal of cellular
debris will produce virus harvests considerably more diverse in
antigenic character than the method of virus harvest preparation
described by Brotherston and Boyce (1970). It therefore also seemed
appropriate to investigate the concentration of clarified-virus
harvests propagated in serum-free media by methanol precipitation
and other concentration techniques in an attempt to produce virus
antigen concentrates with reduced non-specific antigenic activity.
Several methods of concentrating viruses have been described.
The technique of adsorbing virus to salts and molecular gels has
been applied to certain viruses, e.g. poliovirus (Sabin, 1932;
Schaeffer and Brebner, 1933), fowl plague virus, Newcastle disease
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virus and mumps virus (Elford, Chu, Dawson, Dudgeon, Fulton and
Smiles, 1948; Frimmhagen and Knight, 1959; Miller and Schelsinger,
1955; Salk, 1941), and enteroviruses (Midulla, Wallis and Melnick,
1965). Concentration by precipitation with polyethylene glycol has
been applied to most groups of viruses including the togaviruses
(Horzinek, 1969; Della-Porta and Westaway, 1972; Inglot, Chudzio and
Albin, 1973; Igarashi, Fukuoka, Sasao, Surimarut and Fukai, 1973).
Physical methods of concentration employing ultracentrifugation and
ultrafiltration techniques have been described for poliovirus
(Guskey and Wolff, 1972), Rift Valley fever virus (Klein, Mahlandt,
Bonner and Lincoln, 1971), foot-and-mouth disease virus (Morrow,
Whittle and Eales, 1974), murine leukaemia and sarcoma viruses
(Rhim, Williams, Huebner and Turner, 1969) and baboon endogenous
virus (Weiss, 1980).
The concentration of commercially produced virus harvests and
clarified virus harvests propagated in serum-free media by ultra¬
filtration and precipitation with polyethylene glycol is examined
in this chapter. The preparation and comparative physical
characteristics of the concentrates are outlined in Part I and the
immunogenicity of vaccines prepared from these concentrates and
commercially prepared vaccine are described and contrasted in Part
II. Particular reference is made to the feasibility of concentrating
large volumes of inactivated louping-ill virus, using these methods,
for production of vaccine on a commercial level.
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PART I PREPARATION AND PHYSICAL CHARACTERISTICS OF THE VIRUS
CONCENTRATES
MATERIALS AND METHODS
Virus was propagated in BHK-21 cells cultured in rolling half-
gallon bottles in either BHK virus growth media containing 10 per
cent LS or in EBA media as described in Chapter Four. Virus was
harvested after 72 hours incubation and the serum-free virus harvests
were clarified by centrifugation for one hour at 3000 rpm. All live
o
virus harvests were stored at -80 C prior to concentration, and virus
inactivat ion, when required, was performed by treatment with 0.1 per
o
cent formalin at 37 C for 24 hours.
CONCENTRATION OF VIRUS BY PRECIPITATION WITH POLYETHYLENE GLYCOL 6000*
Polyethylene glycol 6000 (PEG) was used throughout. Appropriate
amounts of solid PEG were added to live or inactivated virus harvests
previously chilled to 4°C. Small volume preparations (40ml) were
incubated in an ice bath and shaken vigorously initially and again
at regular intervals throughout the incubation. Larger volume
preparations ( >100ml) were incubated at 4°C and stirred
continuously with a magnetic stirrer for the required period. The
resulting precipitates were pelleted by centrifugation at 4000g for
60 minutes at 4°C and resuspended in the required volume (usually
1/10 or 1/20 of the starting volume) of either PBS or PBS plus 0.5
per cent (v/v) phenol. The precipitates thus formed were however
characteristically sticky and difficult to resuspend. In an attempt
to facilitate complete resuspension a live virus concentrate was
*BDH Chemicals Ltd., Poole.
105 .
therefore also subjected to sonication for 30 seconds using a MSE*
150 watt ultrasonic disintegrator.
CONCENTRATION OF VIRUS BY ULTRAFILTRATION
Concentration of live virus by ultrafiltration was not attempted
as the method involved the processing of live virus under pressure,
and the possibility therefore existed of creating aerosols of live
virus.
Concentration of inactivated virus harvests was performed using
a stirred cell ultrafiltration system or a hollow fibre ultra¬
filtration cartridge.
1. Stirred cell ultrafiltration
Small volumes of virus (200ml maximum) were filtered in an
Amicon** stirred cell model 202 through a Diaflo membrane type XM300
with a molecular weight cut-off of 300,000. The procedure was
operated at 4°C with an upstream pressure of 0.68 atm. A serum-
free virus harvest was concentrated 50-fold and the commercial virus
harvests 10-fold. The time required for completion did not exceed
24 hours.
2. Hollow fibre ultrafiltration cartridge
(a) DOW hollow fibre cartridge: 2000ml of a commercially produced
inactivated-virus harvest was concentrated 40-fold using a DOW
cartridge having a molecular weight cut-off of 30,000. The virus
suspension was drawn through the cartridge using water suction at a
pressure of 1.36 atm. High molecular weight material was retained within
the cartridge,and solvent and low molecular weight material was directed
*MSE, Crawley.
**Amicon Ltd., High Wycombe.
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to waste. The time required to concentrate the virus suspension 40-
fold was approximately 2 hours and the procedure was carried out at
room temperature. The concentrated virus material was then poured
from the cartridge, the cartridge washed twice with PBS plus 0.5 per
cent (v/v) phenol and shaken vigorously to release virus adsorbed to
the fibres. The washings were added to the virus concentrate. The
cartridge was refilled with PBS plus 0.5 per cent (v/v) phenol and
rotated overnight at 4°C. This washing was then also added to the
virus concentrate and the volume adjusted to 200ml to give a 10-fold
concentrate.
Washing and sterilizing of the cartridge prior to re-use was
performed according to the manufacturer's instructions. All the
washing solutions were filtered through a 0.45pm filter to remove
fibres and thus reduce clogging of the cartridge.
(b) Amicon hollow fibre cartridge: Commercially produced inactivated-
virus harvests (maximum volume 9000ml) were concentrated 10-fold using
an Amicon Hollow Fibre Concentrator model CH4A. The model was fitted
with an Amicon hollow fibre cartridge type HIP100 with a molecular
weight cut-off of 100,000. The internal diameter of each fibre
within the cartridge was 0.5mm giving a total area for filtration of
2
0.07m . The fibres were constructed of the same non-cellulosic
material as the flat Amicon membranes. The cartridge was fitted with
an in-line pre-filter to remove cellular debris and thus reduce
clogging of the fibre surface. The pre-filter was replaced between
each concentration procedure.
In operation the inactivated-virus suspension was drawn from a
reservoir through the pre-filter and then through the fibre cartridge
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by a built-in peristaltic pump. The pressure within the cartridge
was controlled by a back pressure valve at the cartridge outlet.
Solvent and low molecular weight species were driven through the
fibre walls by the internal cartridge pressure (1-1.75 atm.) and
discarded to waste. Concentrated material was returned to the
reservoir and recycled until a 10-fold concentrate was approximately
achieved. Recirculation of the concentrated material was then
arrested and the system cleared of concentrate. The back pressure
valve was then completely opened, the filtrate outlet closed and 20ml
of PBS recirculated through the system to obtain maximum recovery of
concentrate. The volume of the concentrate was then adjusted with
PBS to give a 10-fold concentrate. On average one litre of virus
harvest was concentrated to 100ml in one hour.
The cartridge was cleaned and resterilized according to the
manufacturer's instructions.
CONCENTRATION OF VIRUS BY PRECIPITATION WITH METHANOL
To compare the concentration of virus using PEG precipitation
and ultrafiltration with the commercial method of concentration, live
and inactivated virus harvests were also concentrated by methanol
precipitation as described in the production of commercial vaccine
(Appendix 3.1). Concentrated preparations derived from live
harvests were however resuspended in PBS without phenol. A live
virus concentrate was also subjected to sonication for 30 seconds as
described previously.
The unconcentrated live virus harvests, the live virus con¬
centrates (prepared by PEG and methanol precipitation) and the
corresponding supernatants were assayed for infectivity and HA
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activity as described in Chapter Two. Protein content was
determined by the Kjeldahl method.
Inactivated virus concentrates, prepared by concentrating
commercially produced virus by methanol precipitation, PEG
precipitation and ultrafiltration were examined by immunodiffusion
using the double diffusion and the single radial diffusion methods
as described in Chapter Two.
RESULTS
CONCENTRATION OF VIRUS BY PRECIPITATION WITH PEG 6000
1. Concentration of virus propagated in BHK virus growth media
(10 per cent LS)
The results of concentrating a live commercial virus harvest
with PEG 6000 at concentrations ranging from 3-8 per cent (w/v) are
given in Table 7.1. The protein content of the unconcentrated virus
harvest was 5.8 mg/ml. The precipitates formed were characteristically
sticky and some difficulty in resuspending was encountered. With
each polymer concentration the virus harvest was concentrated by a
factor of 10 with respect to volume.
Precipitation of viral activity as measured by HA activity
commenced with a 3 per cent concentration of polymer. Maximum
recovery of activity (80 per cent) was achieved following pre¬
cipitation with PEG concentrations of 6, 7 and 8 per cent. No
residual HA activity was detectable in the corresponding supernatants.
Maximum recovery of infectivity (24 per cent) was attained with
concentrations of 7 and 8 per cent and less than 1 per cent of the
original infectivity was detected in the corresponding supernatant.
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Precipitation of protein increased with increasing polymer concen¬
trations, ranging from 0.6 to 20 per cent recovery following
treatment with 3-8 per cent PEG respectively.
Sonication of a virus concentrate prepared by precipitating
virus with a 7 per cent concentration of polymer did not affect
HA recovery but did result in an increase in infectivity recovery
from 36-58 per cent. No residual HA activity and less than one per
cent of the original infectivity were detected in the supernatant.
2. Concentration of virus propagated in serum-free media
The results of concentrating serum-free virus harvests by PEG
at concentrations ranging from 3-8 per cent are given in Table 7.2.
Prior to concentration the virus harvest was clarified to remove
cell debris. The protein content of the unconcentrated harvest was
4.5 mg/ml. The precipitates formed were less viscous than the
commercial virus harvest precipitates but again resuspension was
difficult. With each polymer concentration the virus harvest was
concentrated to a factor of 20 with respect to volume.
Precipitation of HA activity commenced with a 4 per cent
concentration of PEG and maximum recovery (80 per cent) was achieved
with concentrations of 7 and 8 per cent. Maximum recovery of
infectivity (26 per cent) was also similar to that obtained with
commercial virus harvest. In contrast to the concentration of
commercial virus harvest, however, increasing the polymer
concentration did not appreciably increase protein precipitation and
the average recovery was 0.6 per cent.
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CONCENTRATION OF VIRUS BY ULTRAFILTRATION
Commercially produced louping-ill virus harvest was concentrated
10-fold using either a stirred cell or a hollow fibre ultrafiltration
system. Recovery of protein ranged from 70-100 per cent. Inactivated
virus propagated in serum-free media was concentrated 50-fold using
a stirred cell ultrafiltration system.
CONCENTRATION OF VIRUS BY PRECIPITATION WITH METHANOL
The results of concentrating live virus according to the
commercial method of concentration (described in Appendix 3.1) are
shown in Table 7.3. Maximum recovery of virus activity as determined
by HA and infectivity was 20 and 0.4 per cent respectively. No
residual HA activity and less than 0.001 per cent of the original
infectivity were detected in the supernatant. Sonication of a
concentrated virus preparation did not enhance recovery of viral
activity. The recovery of protein following methanol precipitation
of 3 inactivated virus harvests ranged from 7-14 per cent.
Precipitation of live virus propagated in EBA serum-free media was
not investigated.
Inactivated virus concentrates prepared by methanol precipitation,
PEG precipitation and ultrafiltration were examined by immunodiffusion
using the methods described in Chapter Two. A 7 per cent con¬
centration of PEG was employed and ultrafiltration was carried out
using a hollow fibre system. Sonicated preparations of the methanol
and PEG concentrates were also tested.
No reaction was detected between a 1/8 dilution of sheep hyper¬
immune serum and the methanol and PEG inactivated virus concentrates
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using a double diffusion method (Fig. 7.1a). Inactivated virus
concentrated 10-fold and 5-fold by ultrafiltration however showed a
reaction of identity with the reference antigen producing a single
continuous line of precipitin (Fig. 7.1b).
A normal mouse brain preparation, the concentrated BHK cellular
extracts (concentrated 10-fold by each of the concentration methods)
and the BHK virus growth media did not react with the antibody.
The single radial diffusion method was shown to be of limited
value in attempting to quantify the relative antigenic activity of
each of the three concentrates.
Optimal conditions were described when antibody was incorporated
into the gel at a final dilution of 1/100 and a 1/5 dilution of
reference antigen used. The concentrated BHK cellular extracts and
normal mouse brain preparation did not react with antibody. Only
virus harvest concentrated 10-fold by ultrafiltration produced a
ring of precipitin (Fig. 7.2), thus as the PEG and methanol 10-fold
virus harvest concentrates did not react with antibody, the
comparative antigenicity of the three concentrates could not be
determined.
DISCUSSION
Concentration of commercially produced live louping-ill virus
by methanol precipitation resulted in almost total loss of viral
activity with regard to both haemagglutination and infectivity. A
likely explanation is that methanol caused physical alteration to,
or denaturation of, the virus particle. It is also possible
therefore that the activity of surface antigenic sites was similarly
Fig. 7.1 Immunodiffusion of concentrated virus preparations
(a) Ab anti louping-ill sheep serum
Mb infected mouse brain
M methanol 10-fold virus antigen concentrate
P PEG 10-fold virus antigen concentrate
BHKM methanol concentrated BHK cell extract
BHKP PEG concentrated BHK cell extract
(b) AlOx ultrafiltration 10-fold virus antigen concentrate
A5x ultrafiltration 5-fold virus antigen concentrate





Fig. 7.2 Radial immunodiffusion of concentrated virus preparations
p PEG 10-fold virus antigen concentrate
a ultrafiltration 10-fold virus antigen concentrate
m methanol 10-fold virus antigen concentrate
b infected mouse brain




diminished following treatment with methanol. The need for an
alternative method of concentrating virus is thus further emphasised.
Of the wide variety of concentration methods available
precipitation with polyethylene glycol 6000 and ultrafiltration were
chosen for further examination.
Polyethylene glycol is a high molecular weight, water soluble
polymer and a method of concentrating and purifying viruses using
an aqueous PEG dextran sulphate 2-phase system was first developed
by Philipson, Albertsson and Frick (1960), and Norrby and Albertsson
(1960). Studies by Hebert (1963) and Leberman (1966) indicated that
PEG alone or in combination with sodium chloride could be effectively
used to concentrate plant viruses and bacteriophages. Subsequently
this method of concentration has been applied to representatives of
the Rhabdoviridae (McSharry and Benzinger, 1970), the Herpetoviridae
(Adams, 1973); the Retroviridae (Bronson, Elliott and Ritzi, 1975),
the Myxoviridae (Kanarek and Tribe, 1967), the Picornaviridae
(Wagner, Card and Cowan, 1970), and the Papovaviridae (Friedmann and
Haas, 1970). Precipitation of the Togaviridae with PEG has been
described by Horzinek (1969); Della-Porta and Westaway (1972);
Igarashi, Fukuoka, Sasao, Surimarut and Fukai (1973); Inglot, Chudzio
and Albin (1973), and Heinz and Kunz (1977a).
Heinz and Kunz (1977a) studying the concentration and puri¬
fication of tick-borne encephalitis virus demonstrated that pre¬
cipitation with PEG at concentrations of 5-8 per cent resulted in
maximum recoveries of HA activity and infectivity (100 and 60 per
cent respectively), and Horzinek (1969) reported that concentration
of Venezuelan equine encephalitis virus using a polymer concentration
115 .
of 10 per cent combined with a sodium chloride concentration of 0.25M
resulted in 100 per cent recovery of infectivity. Infectivity of
3 other togaviruses ranged from 23-60 per cent. An average recovery
of 60 per cent of infectivity and 100 per cent HA activity was
obtained following precipitation with a PEG concentration of 8 per
cent with Japanese B encephalitis, Kunjin, Murray Valley encephalitis,
St. Louis encephalitis and West Nile viruses (Della-Porta and Westaway,
1972) and Igarashi, Fukuoka, Sasao, Surimarut and Fukai (1973)
demonstrated complete recovery of HA activity and a 30-75 per cent
recovery of the infectivity of Japanese encephalitis virus following
treatment with 8 per cent PEG and a sodium chloride concentration of
0.5M.
Precipitation of louping-ill virus was examined using con¬
centrations of PEG ranging from 3-8 per cent. Concentration by
precipitation with polymer at concentrations of 7 and 8 per cent
resulted in maximum recovery of HA activity (80 per cent) and
infectivity (24-36 per cent) although the precipitates formed were
viscous and resuspension was difficult. Sonication of a virus
concentrate precipitated with a 7 per cent concentration of polymer
increased infectivity but had no effect on HA recovery.
Wagner, Card and Cowan (1970) demonstrated that optimal
recovery from foot-and-mouth disease virus was achieved witl> virus
propagated in serum-free media. Addition of serum to the growth
medium decreased infectivity recovery and produced precipitates
that were difficult to dissolve. It was concluded that such a loss
in infectivity was probably due to entrapment of the virus in
proteinaceous debris.
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PEG precipitation of Rous sarcoma virus propagated in media
containing 10 per cent serum and 10 per cent TPB also caused
aggregation of particles (Bronson, Elliott and Ritzi, 1975), and it
was proposed that proteinaceous materials from medium supplements
were responsible for aggregation and the subsequent loss in foci-
forming units.
As sonication of a louping-ill virus concentrate increased
infectivity recovery it is possible that loss of detectable
infectivity recovery following precipitation of virus with PEG may
also be attributed to aggregation of virus particles caused by
medium supplements.
The technique of ultrafiltration has been employed for a number
of years to concentrate a variety of substances within the
pharmaceutical and food industries. More recently Van Wezel (1974)
described its use for concentrating tetanus toxin, poliovirus and
vaccinia virus on a large scale for vaccine production.
Concentration of large volumes of foot-and-mouth disease virus
using an Amicon hollow-fibre ultrafilter resulted in CF antigen
recoveries of between 70 and 100 per cent (Morrow, Whittle and Eales,
1974) and Klein, Mahlandt, Bonner and Lincoln (1971), using a
stirred-cell ultrafiltration system to concentrate Rift Valley fever
virus, obtained recoveries ranging from 40-100 per cent. Ultra¬
filtration of murine leukemia and sarcoma viruses produced
quantitative concentration of antigen activity as measured by CF
activity and focus forming activity (Rhim, Williams, Huebner and
Turner, 1969).
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Concentration of live louping-ill virus using ultrafiltration
techniques was not attempted due to the hazards involved.
Concentration of inactivated virus harvest was however easily
accomplished and no difficulties were encountered.
Immunodiffusion tests showed that only virus concentrated by
ultrafiltration reacted with antibody and a single continuous line
of identity with the reference antigen was produced. No reaction
was observed between antibody and virus harvest concentrated by
methanol and PEG precipitations. A valid comparison of the antigenic
activity of the 3 concentrates using this test cannot be established
as it is possible that precipitation of virus with methanol and PEG
(particularly the latter) resulted in aggregation of virus and the
production of non-diffusable antigens.
The 2 methods of concentration under consideration both appear
to be readily adaptable to the concentration of large volumes of
virus. A possible advantage of the PEG method was that concentration
also resulted in partial purification. A disadvantage of this
technique however was that the precipitates formed were difficult to
dissolve and aggregation of virus particles occurred; this may have
an adverse effect on the immunogenicity of subsequent vaccine.
Ultrafiltration is a physical method of concentration and the
probability of denaturing the virus particle is small. A hollow
fibre ultrafiltration system is particularly well suited for scale-
up for the processing of large volumes of virus. The cartridges can
be re-used repeatedly without loss of filtration efficiency and the
concentration procedure is simple and inexpensive in terms of both
operation and manpower.
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The comparative immunogenicity of vaccines prepared from PEG
concentrates, ultrafiltration concentrates and methanol concentrates
will be examined and discussed in Part II.
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PART II THE IMMUNOGENICITY OF VACCINES CONCENTRATED BY POLYETHYLENE
GLYCOL PRECIPITATION, ULTRAFILTRATION AND METHANOL PRECIPITATION
MATERIALS AND METHODS
Inactivated virus propagated in either BHK virus growth media
containing 10 per cent LS or EBA serum-free media was concentrated
by each of the 3 methods described in Part I.
The concentrates were stored at -20°C. V/hen required vaccines
were prepared from each of the concentrates and concentrate
dilutions by emulsification with Bayol F and Falba oil adjuvant in
a ratio one part concentrate to two parts adjuvant to give, unless
otherwise stated, a final volume of 15ml. Emulsification was
carried out using a MSE bench type overhead homogeniser.
The pre-blend potency vaccines and final potency vaccine
derived from the commercial vaccine production 1978-79 (Appendix
3.1) were also made available for comparative purposes.
Vaccine potency v/as determined initially in either mice or
chickens and on the basis of the results obtained, selected vaccines
were then further assayed in sheep and cattle.
1. ANTIBODY RESPONSE IN MICE
Schneider Swiss White random bred mice, C57 black inbred mice,
athymic Nu. Nu. mice and litter mates were used to assess vaccine
potency. The mice were bred and housed at the Moredun Research
Institute and were inoculated at approximately 3 weeks of age with
0,5ml of vaccine. The vaccine was injected intra-peritoneally (i.p.) .
Athymic mice and litter mates were housed in plastic isolators.
Animals vaccinated with pre-blend potency vaccines derived from the
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1978-79 commercial vaccine production were revaccinated at 21 days
with a further 0.5ml, and 3 weeks later were killed and the blood
collected by heart puncture. Animals vaccinated with the experimental
vaccines received one dose of vaccine only, were killed at 21 days
and the blood collected. The blood was allowed to clot, the serum
collected and tested for HAI antibody to louping-ill as described in
Chapter Two.
2. ANTIBODY RESPONSE IN CHICKENS
One-day-old chicks were purchased from a local hatchery and
housed at the Moredun Research Institute. At 10 days of age they
were injected intra-muscularly (i.m.) with 0.5ml of vaccine. The
birds received either the pre-blend potency vaccines (commercial
vaccine production 1978-79) or experimental vaccine prepared from
virus propagated in serum-free media and concentrated by stirred
cell ultrafiltration. Each vaccine was injected into 5 chicks.
After 14 days the birds were bled from the right jugular vein and a
further 0.5ml of vaccine injected i.m. They were then bled weekly
for 3 weeks, 2ml of blood being withdrawn from each bird on each
occasion. The blood was allowed to clot, the serum removed and
tested for HAI antibody activity (Chapter Two).
3. ANTIBODY RESPONSE IN SHEEP
Various breeds of sheep, aged between 7 months and 2 years, and
born either at the Moredun Research Institute or in other areas
free of ticks, were used to assess vaccine potency. Prior to
vaccination all the sheep were tested for the presence of louping-ill
HAI serum antibodies and all were found to be seronegative. The
animals were injected sub-cutaneously Cs,c.) behind the right
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shoulder with 1ml oi vaccine and each vaccine was injected into
groups of 4, 5, 6 or 12 sheep depending on availability. Animals
vaccinated with batches of final potency commercial vaccine were
bled weekly for 3 weeks, revaccinated with a further 1ml dose and
then bled weekly for a further 4 weeks. Sheep vaccinated with the
experimental vaccines received one 1ml dose only and were bled
weekly for 4 weeks following inoculation. On each occasion
approximately 10ml of blood was withdrawn from each animal.
The blood was allowed to clot and the serum collected and
tested for HAI antibody activity.
4. ANTIBODY RESPONSE IN CATTLE
Thirteen Jersey calves aged between 12 and 18 months and
21 Hereford cows were inoculated with vaccine. Prior to
vaccination the animals were tested for the presence of louping-ill
HAI serum antibodies and all were found to be seronegative. The
animals were injected s.c. in the right side of the neck and each
vaccine was injected into groups of 4, 5 or 6 animals depending on
ayailability, Calves vaccinated with a batch of final potency
commercial vaccine received an initial 2ml dose, followed by a
further 2ml after 21 days. Animals inoculated with the experimental
vaccines received an initial 1ml dose followed 28 days later by a
second 1ml dose. Following revaccination the animals were bled
weekly for at least 4 weeks, approximately 10ml of blood being
withdrawn from each animal. The blood was allowed to clot, the
sera removed and tested for HAI activity.
Five of the calves inoculated with a vaccine prepared from
virus propagated in BHK virus growth media containing 10 per cent LS
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and concentrated by ultrafiltration were subjected to hyper¬
sensitivity tests 176 days after initial vaccination. The vaccine
used for the tests had been prepared on a commercial scale and had
been concentrated 10-fold using an Amicon Hollow Fibre Ultrafilter.
Calves X846 and X849 were injected s.c. in the left side of the
neck with 2ml and 1ml respectively of the emulsified vaccine.
Calves X843, X845 and V516 were injected s.c. with 5ml, 2.5ml and
lml respectively of the 10-fold concentrate (not emulsified) and
intradermally (i.d.) with 0.5ml. The calves were observed for a
4-hour period immediately following injection and skin thickness
measured at 0.5, 2.5, 24, 48 and 96 hours.
Statistical analysis
Reciprocal HAI titres were transformed into logarithms to the
base 10. Titres of 2.10 were deemed to have a logarithmic value of
0.7. The data were analysed using either a Mann-Whitney non-
parametric test or a 2 sample t-test.
RESULTS
1. ANTIBODY RESPONSE IN MICE
Commercial vaccine
The 1978-79 pre-blend potency vaccines concentrated 10- and
2.5-fold were injected into both the random bred and inbred strains
of mice. The vaccines were prepared and tested immediately following
production of the 10-fold concentrates. The mice were inoculated with
2 0.5ml doses of vaccine and each vaccine was injected into 10 mice.
The mean reciprocal 42-day HAI titres are given in Table 7.4.
126 .
There was no significant difference between the serological
responses detected in the random-bred and the inbred strains of
mice. The maximum mean antibody titres following vaccination with
the 10- and 2.5-fold concentrate vaccines was 1/25 and 1/8 respectively.
Experimental vaccines
Experimental vaccines were routinely assessed using the random-
bred strain of mice only. A 50-fold concentrate (BAU) prepared from
virus propagated in serum-free media and concentrated by stirred
cell ultrafiltration was diluted accordingly with PBS plus 0.5 per
cent (v/v) phenol to give 10-, 5-, 2- and 1-fold concentrates.
Vaccines were prepared and tested immediately following production
of the 50-fold concentrate. Each vaccine was injected into 10 mice.
Following a single dose of 50-, 10-, 5-, 2- and 1-fold concentrate
vaccines the mean 21-day HAI titres were 1/630, 1/316, 1/256, 1/8
and 1/6 respectively (Table 7.5). The preinactivation infectivity
8
titre of the unconcentrated harvest was 1.2 x 10 pfu/ml and the
HA titre was 1/512.
The serological response following a single dose of the 10-fold
BAU concentrate vaccine was therefore approximately 13-fold higher
than the response following a double vaccination of commercial
vaccine of equivalent concentration. Preparation of the BAU
concentrate vaccine differed from that of the commercial vaccine in
2 respects; the method of virus propagation and the concentration
technique. The following experiments were therefore performed in
an attempt to determine whether the rationale of growing virus in
serum-free media, thereby reducing non-specific antigenic competition
and interference, and/or the method of virus antigen concentration
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were contributory to the immunogenicity of the vaccine.
(1) Non-specific antigenic interference
(a) Addition of media supplements
Lamb serum and TPB were treated with 0.1 per cent formalin at
37°C for 24 hours. A mixture containing equal volumes of serum and
TPB was likewise formalinized. The 50-fold virus antigen
concentrate (BAU) was diluted to a 10-fold concentrate with each of
these formalinized preparations. The concentrate was also diluted
with PBS plus 0.5 per cent (v/v) phenol. Vaccines were prepared and
each injected into 10 Swiss White mice. The addition of
formalinized supplements did not affect significantly the immuno¬
genicity of the BAU concentrate -vaccine (Table. 7.6).
(b) Addition of methanol concentrated BHK cellular extract
BHK-21 cells were grown in rolling culture in BHK virus growth
o
media containing 10 per cent LS. After 3 days incubation at 37 C
the cell culture was frozen and thawed 3 times and then treated with
a 1/1000 concentration of formalin. The formalinized cell extract
was concentrated 10-fold by methanol precipitation. The 50-fold
BAU concentrate was diluted to a 10-fold concentrate with either the
10-fold methanol concentrated BHK cell extract or PBS plus 0.5 per
cent (v/v) phenol. Vaccines were prepared accordingly and each
injected into 10 mice. The addition of methanol concentrated BHK
cellular extract did not affect significantly the immunogenicity of
the BAU concentrate vaccine (Table 7.6).
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(2) Concentration of virus propagated in serum-free media by
methanol precipitation and PEG precipitation
The serum-free virus harvest (preinactivation infectivity titre
g
of 1.2 x 10 pfu/ml and HA of 1/512) was also concentrated 10-fold
by PEG precipitation and methanol precipitation. The resulting 10-
fold concentrates (BAP- BAM) were diluted with PBS plus 0.5 per cent
(v/v) phenol to give 5- and 1-fold concentrates; the 50-fold BAU
concentrate was similarly diluted. Vaccines were prepared and each
injected into 5 or 7 mice. The 21-day HAI results are shown in
Table 7.7. Statistical analysis of the results using the Mann-
Whitney nomparametric test indicated that the antibody responses
evoked by 10- and 5-fold BAU concentrate vaccines were significantly
higher (p<0.01; p<0.05) than the response produced by the 10- and
5-fold BAP and BAI.I concentrate vaccines. The maximum mean HAI
antibody titre was 1/501 and was elicited by 10-fold BAU concentrate
vaccine. The lowest mean HAI titres were consistently detected in
response to the methanol concentrated vaccines.
The results indicated therefore that immunogenicity was
significantly affected by the technique of concentration employed
and was not influenced by the presence of cellular debris and
proteinaceous material.
The immunogenicity of vaccines prepared by propagating virus in
BHK growth media containing 10 per cent LS and concentrated by
ultrafiltration was therefore investigated and a comparative
assessment with respect to the PEG and methanol methods of
concentration determined.
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(3) Concentration of virus propagated in BHK virus growth media
containing 10 per cent LS
g
A virus harvest (preinactivation infectivity titre 4 x 10
pfu/ml) propagated in BHK virus growth media containing 10 per cent
LS was concentrated 10-fold by PEG precipitation (LSP), methanol
precipitation (LSM), and ultrafiltration (LSU). The concentrates
were diluted with PBS plus 0.5 per cent (v/v) phenol, vaccines
prepared and each inoculated into 5 or 3 mice. The 21-day HAI
titres are given in Table 7.8. The results were analysed using
a Mann-Whitney non-parametric test; the serological responses
evoked by the 10- and 5-fold LSU concentrate vaccines were
significantly higher (p<0.05) than the responses produced by the
PEG and methanol vaccines of equivalent concentration. The maximum
mean antibody titre was 1/398 and was produced in response to 10-fold
LSU concentrate vaccine.
There was no significant difference between the serological
responses produced by vaccines concentrated by ultrafiltration and
prepared from virus propagated in either serum-free media or in BHK
virus growth media (Tables 7.7, 7.8).
The antibody response in athymic Nu Nu mice and litter mates
Vaccination of athymic Nu Nu mice with either 2 doses of
commercial vaccine or a single dose of experimental vaccine did not
produce a detectable antibody response. Vaccination of the hairy
litter mates with 2 doses of commercial vaccine or a single dose of
BAU concentrate vaccine produced a mean antibody response of 1/10 or
1/794 respectively. The results suggest that louping-ill antigen is
a thymus-dependent antigen.
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2. ANTIBODY RESPONSE IN CHICKENS
Commercial vaccine
To assess the antibody response in chickens to commercial
louping-ill vaccine the pre-blend potency vaccines (1978-79) were
injected i.m. into 10-day-old birds. The chicks were inoculated
with 2 doses of vaccine, the total volume being 1ml. Vaccines were
tested immediately following emulsification of the virus antigen
concentrate.
The maximum mean HAI titres 14 days following primary
vaccination and 21 days following revaccination were 1/13 and 1/40
respectively (Table 7.9).
Experimental vaccine
A 50-fold virus antigen concentrate (BAU) was diluted and
vaccines prepared. Each vaccine was inoculated into 5 chicks as
described previously. The results are given in Table 7.9. The
mean HAI titres evoked by the 10-fold concentrate vaccine 14 days
after vaccination and 21 days following revaccination were 1/1995
and 1/19952 respectively.
3. ANTIBODY RESPONSE IN SHEEP
Commercial vaccine
The antibody responses in sheep to the 6 final batches of
commercial vaccine (concentration factor between 2- and 5-fold) are
illustrated in Table 7.10. The vaccines were tested immediately
following emulsification of the virus antigen concentrates. Prior
to emulsification the concentrates had been stored at -20°C for
periods ranging from 6-22 months. The mean antibody titres
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following a single inoculation and a double inoculation ranged from
1/6 to 1/50 and 1/8 to 1/200 respectively.
Experimental vaccine
A 50-fold virus antigen concentrate (BAU) which had been stored
for 4 weeks at -20°C was diluted and vaccines prepared. Each
vaccine was injected into 4 7-month-old Greyface sheep. The sheep
received one inoculation of 1ml only. The 28-day HAI results are
shown in Table 7.11. All animals injected with the 10- and 5-fold
BAU concentrate vaccines were seropositive at 14 days and the mean
28-day antibody titres were 1/251 and 1/129 respectively. Titres
remained relatively constant for up to 126 days post-vaccination
(Table 7.11) .
Vaccination of mice with the experimental louping-ill vaccines
indicated that immunogenicity was dependent on the technique of
concentration and independent of the method of virus propagation.
To test the validity of this observation in sheep a virus harvest
propagated in BHK virus growth media containing 10 per cent LS and
8
with a pre-inactivation infectivity titre of 10 pfu/ml and HA
activity of 1/128 was concentrated by methanol precipitation (LSM),
PEG precipitation (LSP), and by hollow fibre ultrafiltration (LSU).
The 10-fold virus concentrates were diluted as described previously,
vaccines prepared and each injected into 5 9-month-old Crossbred
Suffolk and Blackface lambs . The 28-day HAI results are shown in
Table 7.12. All animals inoculated with 10- and 5-fold LSU
concentrate vaccine were seropositive by 14 days and the 28-day mean
HAI titres were 1/126 and 1/251 respectively. Twenty-eight days
132.
after vaccination with the PEG and methanol 10-fold concentrate
vaccines, 75 and 80 per cent of animals respectively were sero¬
positive with corresponding mean antibody titres of 1/63 and 1/50.
It is apparent therefore that concentration of virus by ultra¬
filtration produces vaccines of higher immunogenicity than the
commercial method of concentration or by precipitation with PEG.
To assess the efficiency of scaling up the ultrafiltration
process for commercial production, a total 18 litres of virus
suspension propagated in BHK virus growth media containing 10 per
cent LS was concentrated using an Amicon CH4 hollow fibre filter.
The maximum volume of virus concentrated in one run was 9 litres.
The harvest was concentrated to 1800ml and then diluted with PBS
plus 0.5 per cent (v/v) phenol to give a 4.5-fold concentrate.
This was divided into 2 lots of equal volume and each emulsified
with adjuvant using an Atomix* laboratory blender to give 2 x
6000ml batches of final vaccine. The final vaccine was distributed
in 50ml volumes in bottles fitted with rubber flanges and aluminium
seals,
One bottle was withdrawn at random from each batch and injected
into 6 12-month-old Blackface ewes. The sheep received one injection
of 1ml. All animals were found to be seropositive 14 days after
inoculation and the mean 28-day HAI titres detected in sheep
vaccinated with Batch A and Batch B vaccine were 1/316 and 1/158




4. ANTIBODY RESPONSE IN CATTLE
Commercial vaccine
Four calves were inoculated with 2 2ml doses of commercial
vaccine Batch I. At 21 days post-primary vaccination antibody was
detected in only 2 animals and the mean HAI titre was 1/16. Twenty-
eight days following revaccination 3 of the 4 animals were sero¬
positive and the mean HAI titre was 1/32, but 67 days later titres
were reduced to undetectable levels in 3 animals and the mean HAI
titre was 1/8.
Experimental vaccine
A virus harvest propagated in BHK virus growth media containing
10 per cent LS and with a pre-inactivation infectivity titre of
g
10 pfu/ml and an HA titre of 1/128 was concentrated 10-fold by
methanol precipitation (XSM) , and hollow fibre ultrafiltration (LSU) .
Vaccines were prepared and each injected into 5 or 6 heifers. Two
JLml doses of vaccine were administered as indicated in Table 7.14.
At 28 days post-primary vaccination all animals inoculated with the
LSM concentrate vaccines were seronegative; 33 and 20 per cent of
animals injected with the 5- and 2.5-fold LSU concentrate vaccines
were seropositive with mean HAI titres of 1/10 and 1/13 respectively.
Twenty-eight days following revaccination all animals inoculated with
the LSU concentrate vaccines were seropositive and the mean HAI
titres were 1/501 and 1/158 respectively. Antibody was detected in
only 20 and 40 per cent of animals inoculated with 2 doses of the
LSM concentrate vaccines and the mean 56-day KAI antibody titres were
1/6.
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Vaccines concentrated 10-and 5-fold by ultrafiltration (LSU)
were also injected into 9 12- to 18-month-old calves. At 28 days
post-vaccination an antibody response was detected in all animals
receiving the 10-fold concentrate vaccine and in 50 per cent of
those receiving the 5-fold concentrate vaccine with corresponding
mean antibody titres of 1/25 and 1/10. Four weeks after re-
vaccination all animals were seropositive and mean HAI titres were
1/398 and 1/158 (Table 7.15).
Although no untoward reactions were observed following
inoculation of cattle with vaccine concentrated by ultrafiltration
production of the vaccine does involve propagation of virus in media
containing 10 per cent lamb serum and concentration of virus by
ultrafiltration also concentrates the serum. It therefore appeared
pertinent to assess if the cattle had been hypersensitized. Five
of the 9 calves were therefore given a further injection of a
vaccine concentrated 10-fold by hollow fibre ultrafiltration.
Calves X846 and X849 were re-injected s.c. with 2ml and 1ml
respectively of the emulsified vaccine, receiving therefore 0.67ml
and 0.33ml respectively of the 10-fold concentrate. Calves X843,
X845 and V516 were injected s.c. with 5ml, 2ml and 1ml respectively
of the 10-fold concentrate. In addition all the animals were
injected i.d. with 0.5ml of the 10-fold concentrate.
Thirty minutes following injection calf X845 showed signs of
respiratory distress manifested by rapid and shallow breathing and
serious lacrimation and swelling around the eyes. A plaque 30mm
in diameter was evident at the site of inoculation, within 3 hours
however the animal appeared to have recovered completely. Immediately
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following injection skin thickness readings increased in all animals
except calf X846. Maximum readings were detected 30 minutes following
injection and the fold increase ranged from 9 (calf X843) to 3 (calf
X849). Skin thickness gradually decreased over the following 96 hours.
DISCUSSION
The immunogenicity of vaccines prepared from virus grown in
either serum-free media or media containing 10 per cent serum and
concentrated by methanol precipitation, PEG precipitation or ultra¬
filtration was examined and compared with the commercial 1978-79
louping-ill vaccine.
The serological responses in mice, sheep and cattle to a single
dose of vaccine prepared from virus propagated in both types of media
and concentrated 10- and 5-fold by ultrafiltration were consistently
higher than the responses evoked by a single dose of experimental
vaccine concentrated 10- and 5-fold with PEG or methanol or a double
dose of commercial louping-ill vaccine. Furthermore, in contrast to
vaccination with a single dose of the PEG and methanol experimental
vaccine (10- and 5-fold concentrate), all sheep inoculated with a
single dose of vaccine similarly concentrated by ultrafiltration,
responded to vaccination within 14 days. Some sheep (17 - 83 per cent)
injected with the 1978-79 final batches of commercial vaccine were
found to be persistently seronegative even after administration of a
second dose.
The responses evoked by vaccines prepared by ultrafiltration of
virus harvests propagated in either of the growth media described
were not significantly different and the immunogenicity of the
serum-free vaccine was not affected by the addition of media
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supplements or cellular extracts. Concentration of virus propagated
in both types of media by methods other than ultrafiltration did
however decrease immunogenic!ty. It would therefore appear that
these concentration methods are less efficient with regard to
recovery of viral antigen than the ultrafiltration technique.
Vaccine immunogenicity thus appears to be dependent on the method of
virus antigen concentration and is unaffected by the presence of non¬
specific antigenic determinants in the virus antigen concentrate.
It was apparent from the studies described in Part I that con¬
centration of live virus by PEG precipitation resulted in a high
recovery of HA activity but with a corresponding loss in infectivity.
Sonication of the virus concentrate increased infectivity recovery,
and it was proposed that the loss in detectable infectivity was
attributable, at least in part, to aggregation of virus particles.
PEG precipitation of louping-ill virus propagated in both types
of media produced vaccines of lower immunogenicity than the corres¬
ponding vaccines concentrated by ultrafiltration. If aggregation of
louping-ill virus does occur following PEG precipitation and if the
aggregates persist throughout the vaccine production then it is
probable that a proportion of the antigenic determinant sites will
be effectively masked within the proteinaceous aggregates and the
potency of resulting vaccines will therefore be reduced. This
effect will also be exacerbated as the amount of protein precipitated
from solution increases and may therefore account for the lower
antibody responses produced by PEG vaccines prepared from virus
grown in media containing serum compared to PEG vaccines prepared
from virus grown in serum-free media.
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The use of sonicated virus concentrates for subsequent vaccine
production was not investigated and the adaptability of the PEG
precipitation method for commercial scale vaccine production was not
further pursued.
The lowest antibody titres were consistently demonstrated in
animals inoculated with the experimental vaccines concentrated by
methanol precipitation and the 1978-79 commercial vaccines. The
results obtained from the 1978-79 commercial vaccines, prepared
from virus antigen concentrate preparations that had been stored at
-20°C for 6 months or longer, also indicated that under such storage
conditions the concentrate preparations lost antigenicity.
The responses evoked by vaccines prepared by concentrating by
methanol precipitation! virus from both the methods of propagation
described were not significantly different.
The technique of concentrating louping-ill virus antigen by
ultrafiltration has been described previously (Wells and P.eid, 1978) .
However in contrast to the studies reported here the inactivated virus,
grown in serum-free media, was first concentrated 10-fold using a
stirred cell ultrafiltration system and then extracted by acetone
precipitation. The resultant vaccine was used solely to study the
antibody response in newborn lambs. No attempts were made to omit
the precipitation stage from the vaccine production schedule or to
concentrate commercially produced virus.
That concentration of louping-ill virus by ultrafiltration was
readily adaptable to a commercial scale of vaccine production was
evident from the production of 12 litres of emulsified vaccine. The
scale-up of tire procedure from an experimental to a commercial level
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was effective in terms of vaccine efficiency as measured by the
serological responses evoked in sheep.
Louping-ill vaccine is designed primarily for the protection
of sheep, however cattle are also susceptible to infection and
require protection by vaccination. Vaccines prepared by ultra¬
filtration of virus harvests grown in media containing serum produced
higher antibody titres in cattle than equivalent vaccines concen¬
trated by methanol and the 1978-79 commercial vaccine. Antigen
incorporated in oil adjuvant did not induce any signs of anaphylaxis
but it is recognised that any future injections of lamb serum could
be hazardous.
In conclusion therefore concentration of louping-ill virus by
ultrafiltration produced vaccines of superior immunogenicity
compared to corresponding vaccines concentrated by PEG and methanol
precipitation. In addition vaccines concentrated 10- and 5-fold
by ultrafiltration provoked a satisfactory immune response in sheep
and cattle as defined in the British Pharmacopoeia (Veterinary)
following a single 1ml dose in sheep and 2 1ml doses in cattle.
In contrast, 2 1ml doses of the presently available commercial
vaccine were required for sheep and 2 2ml doses for cattle.
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Table 7.4 Antibody response in an inbred strain of mice (C57 black)
and a random-bred strain of mice (Schneider Swiss White)
to vaccine prepared during the commercial production of
1978-79.














































*Pre-blend potency vaccines (Appendix 3.1)
Antibody response following a double dose of vaccine
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Table 7.9 Geometric mean reciprocal HAI antibody titres in




















































*Pre-blend potency vaccines from commercial production 1978-79.
BAU: virus propagated in serum-free media; concentrated by stirred
cell ultrafiltration
Revaccination at 14 days post primary vaccination
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Table 7.10 Geometric mean reciprocal HAI antibody titres in
sheep to final batches of commercial vaccine 1978-79
Period of storage
Vaccine of antigen concentrate
at -20 C (months)






























*Revaccinated with a further 1ml of vaccine
**Number of animals responding/number vaccinated
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Geometric mean recinrocal HAI antibody titres in
cattle vaccinated with virus propagated in BHK virus
growth media
Concentration Days after primary vaccination
Factor 28* 56 125
5x 10 501 100
2/6** 6/6 ' 6/6
2. 5x 13 158 100
1/5 5/5 5/5
5x 5 6 16
0/5 1/5 2/4
2. 5x 5 6 6
0/5 2/5 2/5
g
Unconcentrated virus harvest: infectivity 10 pfu/ml
HA 1/128
*revaccinated with a further 1ml of vaccine
**Number of animals responding/number vaccinated
LSU(HF) virus harvest concentrated by hollow fibre ultrafiltration
LSM " " " " methanol precipitation
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Table 7.15 Reciprocal HAI antibody titres in calves vaccinated
with virus propagated in BHK virus growth media and
concentrated by hollow fibre ultrafiltration
Virus Concentration Calf Number Days after primary vaccination












































Unconcentrated virus harvest:infectivity 10
pfu/ml HA 1/128
8
♦revaccinated with a further 1ml of vaccine




THE STABILITY OF LOUPING-ILL-VIRUS VACCINES
INTRODUCTION
Traditionally the demand for louping-ill vaccine occurs in the
early spring and late summer immediately preceding the periods of
maximum tick activity.
The policy adopted for storage of vaccine is that directly
following production, the 10-fold virus antigen concentrate
(concentrated by methanol precipitation) is stored at -20°C. When
a demand for vaccine is anticipated the concentrate is removed,
diluted to the appropriate concentration as determined by the pre-
blend potency test (Appendix 3.1), emulsified and, prior to
commercial issue, subjected to final potency testing.
The minimum required storage life of emulsified vaccine is
therefore approximately 6 months. As vaccine production presently
operates on an annual or biannual basis the minimum required storage
life of the virus antigen concentrate is 12 months.
The stability characteristics of the commercially produced 10-
fold virus antigen concentrate and of the final emulsified vaccine
preparation are undetermined. On numerous occasions, however,
vaccine prepared from stored virus-antigen concentrate has failed to
produce the expected antibody response as judged by the pre-blend
potency test, and it has also been observed that the antigenic
activity of concentrates (as reflected by the immunogenicity of the
resulting vaccines) progressively diminishes as the period of
o
storage at -20 C increases (Chapter Seven).
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A requirement therefore exists for a comprehensive study of the
stability of both antigen concentrate and emulsified vaccine.
The immunogenicity of experimental louping-ill vaccines
prepared by PEG precipitation or ultrafiltration has been
previously described (Chapter Seven) . To further assess the
efficacy of these experimental vaccines for commercial use, an
evaluation of antigenic stability is also necessary.
Virus-antigen concentrates prepared by PEG precipitation and
methanol precipitation contain phenol at a final concentration of
0.5 per cent (v/v), phenol is not however incorporated into the
virus-antigen concentrates prepared by ultrafiltration. It would
therefore also appear expedient to determine the effect, if any, of
the presence of phenol on antigenic stability.
This chapter therefore examines the stability of commercially
produced and experimentally produced virus-antigen concentrates and
corresponding final vaccine preparations under defined storage
conditions.
MATERIALS AND METHODS
PREPARATION OP VIRUS ANTIGEN CONCENTRATES AND EMULSIFIED VACCINE
Two louping-ill virus harvests (Batch 1 and 2), each 6 litres in
volume, and a third harvest (Batch 3), 15 litres in volume, were
prepared according to the method described in Chapter Four using
Wheaton roller culture bottles and BHK virus growth media. Aliquots
were removed from each of the 3 virus harvests and assayed for virus
infectivity and HA activity. The harvests were then inactivated by
treatment with 0.1 per cent formalin as described in Appendix 3.1.
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Samples were removed from the inactivated virus suspensions and
assayed for innocuity and sterility, as described in the commercial
manufacturing protocol.
The 3 batches were each divided into 3 aliquots of equal volume
and the aliquots concentrated 10-fold either by methanol (M) pre¬
cipitation (as described in Appendix 3.1), PEG (P) precipitation or
ultrafiltration (U). PEG precipitation was achieved using a 7 per
cent (w/v) concentration of PEG 6000 and ultrafiltration was
performed using an Amicon CH4 hollow fibre filter (Chapter Seven) .
Vaccines were prepared by emulsifying 80ml of each of the batch 1
and 2 virus antigen concentrates (IM, IP, IU, 2M, 2P and 2U) and
120ml of the batch 3 virus antigen concentrates (3M, 3P ,and 3U) with
160ml and 240ml respectively of Bayol F and Falba oil adjuvant
using an Atomix laboratory blender. The vaccines, 9 in total, were
dispensed in either 40ml or 20ml volumes in bottles fitted with
rubber flanges and aluminium seals or in screw-capped bottles.




Sixty ml of each of the batch 3 virus-antigen concentrates (3M,
3P and 3U) and 120ml of each of the corresponding emulsified vaccine
preparations were stored at -20°C using a domestic type deep-freeze
cabinet.
2. 4°C
One hundred and eighty ml of each of the batch 1, 2 and 3 virus-
antigen concentrates (9 antigen concentrate preparations in total)
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and 360ml of each of the corresponding emulsified preparations were
stored in a 4°C cold room fitted with a continuous recording device.
3. 'Cool temp'
One hundred and twenty ml of each of the batch 1, 2 and 3 virus-
antigen concentrates and 240ml of each of the resultant vaccine
preparations were stored in an unheated room. The air temperature
was recorded daily using a maximum-minimum thermometer. The mean
temperature over a 24 week period was 17.6°C with a maximum recorded
o o
temperature of 26 C and a minimum temperature of 8 C.
4. 30°C
Sixty ml of each of the batch 1, 2 and 3 virus-antigen
concentrates and 120ml of each of the corresponding emulsion
+ o
preparations were incubated in a 30 - 0.5 C waterbath. To determine
the effect of phenol on the antigenic stability of concentrate
preparations 75 pi were added to 15 ml of batch 3U virus antigen
concentrate to give a final concentration of 0.5 per cent. An equal
volume of PBS was added to a further 15ml volume of 3U antigen
concentrate. The 2 concentrate preparations were also incubated at
30°C.
Aliquots of virus antigen concentrates and of emulsified vaccine
o
preparations were removed after one and 2 weeks storage at 30 C and
after 4, 8, 12 and 24 weeks storage at 4°C, 'cool temp' and -20°C,
EVALUATION OF VACCINE AND VIP.US-ANTIGEN CONCENTRATE STABILITY
Immediately prior to storage the immunogenicity of each of the
9 emulsified vaccine preparations was determined in mice. Immuno¬
genicity of stored preparations was subsequently also evaluated in
mice. After 24 weeks storage, selected emulsified vaccine
155 .
preparations and virus antigen concentrates were also assayed for
potency in sheep.
1. Antibody response in mice
A 6ml volume of each of the emulsified vaccine preparations and
a 5ml volume of each of the 10-fold virus antigen concentrates were
removed from storage as required. Each virus-antigen concentrate was
emulsified with oil adjuvant in a ratio of one part concentrate to
2 parts adjuvant. Potency of all vaccine preparations was evaluated
by inoculating 3-week-old Swiss White mice i.p. with 0.5ml of vaccine.
Each vaccine was injected into 8 mice. After 21 days 4 mice,
selected at random from each group of 8, were killed and the blood
collected by heart puncture. The remaining mice were then
revaccinated with a further 0.5ml of the appropriate vaccine and 3
weeks later were killed and the blood collected. The blood was
allowed to clot, the serum collected and tested for HAI antibody to
louping-ill as described in Chapter Two. During the period between
the initial vaccination and revaccination all vaccine preparations
under test were stored at 4°C.
Mice inoculated with vaccine prepared from either 3U virus-
antigen concentrate supplemented with 0.5 per cent (v/v) phenol or
an equivalent phenol-free concentrate preparation received one
injection of vaccine only.
2. Antibody response in sheep
Eighteen-month-old seronegative Greyface and Blackface sheep
were used to assess the potency of vaccine preparations.
Phosphate buffered saline was emulsified with oil adjuvant in a
ratio of one part PBS to 2 parts adjuvant. Equal volumes of 1U, 2U
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and 3U emulsified vaccine preparations stored at either 4°C or at
a 'cool temperature' for 24 weeks were pooled and added to an equal
volume of emulsified PBS to give a 5-fold concentrate vaccine
preparation. A volume of 3U emulsified vaccine stored at -20°C
for 24 weeks was likewise diluted to a 5-fold concentrate vaccine.
Emulsified vaccine preparations concentrated by methanol precipitation
and stored at 4°C, 'cool' and -20°C were similarly sampled.
Aliquots (5ml) of 3U virus antigen concentrate were also
removed after storage at -20°C and 4°C for 24 weeks and emulsified
with oil adjuvant in a ratio one part concentrate to 2 parts
adjuvant to give 10-fold concentrate vaccine preparations.
Sheep were injected s.c. behind the right shoulder with 1ml of
vaccine and each vaccine was injected into 6 sheep. The animals
were bled weekly for 4 weeks. The blood was allowed to clot, the
serum collected and tested for HAI antibody activity.
Statistical analysis
For statistical analysis the data obtained from each of the 3
preparations concentrated by the same process (e.g. 1U, 2U, 3U) at
each storage temperature were combined. Reciprocal HAI titres were
transformed into logarithms to the base 10. Titres of -CIO were
deemed to have a logarithmic value of 0.7.
In instances where the rate of decline appeared to be a first-
order-reaction standard statistical techniques were applied to
calculate linear regressions and to assess the significance of the
regression coefficients. The decrease in immunogenicity of several
vaccine preparations concentrated by methanol or PEG precipitation
did not follow first-order reaction kinetics. In-such cases the significance
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of decline was assessed using the 2-sample t-test. The 2-sample
t-test was also used to determine the significance of the decrease
in potency of vaccine preparations stored at 30°C for 2 weeks.
RESULTS
The mean 42-day HAI titres produced in mice by the pre-storage
emulsified vaccine preparations concentrated by methanol precipitation,
PEG precipitation and ultrafiltration were 1/79, 1/251 and 1/2511
respectively.
The effects of storage at refrigerated and room temperatures on
the immunogenic stability of emulsified and non-emulsified virus
antigen preparations concentrated by methanol precipitation, PEG
precipitation and ultrafiltration are illustrated in Figs. 8.1 a-d.
THE STABILITY OF VIRUS ANTIGEN PREPARATIONS CONCENTRATED BY METHANOL
PRECIPITATION
The stability characteristics, as determined by potency testing
in mice, of emulsified and non-emulsified louping-ill virus-antigen
concentrated by methanol precipitation are indicated in Table 8.1.
There was a significant decline (p< 0.001) in the imrauno-
genicity of virus antigen preparations stored at 30°C for 2 weeks.
The data were analysed using a 2-sample t-test.
The immunogenicity of virus-antigen concentrate and emulsified
vaccine significantly declined (p< 0.001) following storage at'cool'
or -20°C for one or 4 weeks respectively. A significant decline in
the potency of emulsified vaccine held at 4°C for 4 weeks was also
observed (p< 0.001). The data were analysed by a 2-sample t-test.
The rate of decline in the immunogenicity of virus antigen
Fig. 8.1 a-d The stability characteristics of non-emulsified
louping-ill virus antigen concentrates and
emulsified final vaccines at refrigerated and
room temperatures.
.... virus antigen concentrated by ultra¬
filtration
virus antigen concentrated by PEG
precipitation





























concentrate stored at 4 C for 6 months was deemed to be that of a
first order reaction and the regression coefficient was -0.04
(p<0.001) .
The antibody responses in sheep to emulsified virus-antigen
o o
preparations previously stored at either 'cool', 4 C or -20 C for
6 months are given in Table 8.4. All animals vaccinated with
emulsified virus-antigen stored at 'cool' were serologically non-
responsive. Of the animals inoculated with emulsified virus-antigen
° o
stored at 4 C or -20 C, 17 per cent seroconverted with mean 28-day
HAI titres of 1/10 and 1/8 respectively.
THE STABILITY OF VIRUS ANTIGEN PREPARATIONS CONCENTRATED BY PEG
PRECIPITATION
The stability characteristics of emulsified and non-emulsified
virus-antigen concentrated by PEG precipitation are shown in Table 8.2.
There was a significant decline (p<0.001) in the potency of
virus-antigen preparations stored at 30°C for 2 weeks. The immuno-
genicity of emulsified vaccines stored at 'cool' for one week or at
4°C and -20°C for 4 weeks also significantly decreased (p<0.001,
p<0.01). The data were analysed by a 2-saraple t-test. The
inactivation curves obtained from virus-antigen concentrates stored
at 'cool', 4°C or -20°C were assessed as being linear and the
regression coefficients were -0.05 (p< 0.001) - 0.04 (j> <0.001) and
-0.06 (p<0.01) respectively.
Stored virus-antigen preparations concentrated by PEG
precipitation were not potency tested in sheep.
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THE STABILITY OF VIRUS-ANTIGEN PREPARATIONS CONCENTRATED BY
ULTRAFILTRATION
The stability characteristics of emulsified and non-emulsified
virus antigen concentrated by ultrafiltration are shown in Table 8.3.
There was a significant decline (p<0.001) in the immunogenicity
of virus-antigen preparations stored at 30°C for 2 weeks. The data
were analysed using the 2-sample t-test.
The rate of decline in the immunogenicity of all other vaccine
preparations followed first-order reaction kinetics. The regression
coefficients are given in Table 8.3. The decline in vaccine potency
over a 6 month storage period was significant (p <0.001, P<0.01) for
all preparations except for virus antigen concentrate stored at -20°C
(p > 0.05) .
The antibody responses in sheep to emulsified virus-antigen
preparations stored for 6 months at 'cool', 4°C and -20°C are
given in Table 8.4. There was no detectable antibody response in
animals vaccinated with emulsified virus antigen previously stored at
'cool'. Of the animals inoculated with emulsified virus-antigen
preparations stored at either 4°C or -20°C, 50 per cent seroconverted
with mean 28-day HAI titres of 1/10 and 1/13 respectively.
The antibody responses in sheep to vaccines prepared from non-
emulsified virus antigen concentrate preparations previously stored
at -20°C or 4°C for six months are also shown in Table 8.4. All
animals inoculated with vaccine prepared from non-emulsified virus-
antigen concentrate stored at -20°C seroconverted with a mean 28-day
HAI titre of 1/398. Of the animals given vaccine derived from non-
emulsified virus antigen stored at 4°C, 83 per cent were seropositive
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and the mean 28-day HAI titre was 1/100.
The results are tabulated in full in Appendices 8.1-5.
THE EFFECT OF PHENOL ON THE STABILITY CHARACTERISTICS OF VIRUS
ANTIGEN CONCENTRATES (NON-EMULSIFIED) PREPARED BY ULTRAFILTRATION
There was no significant difference in the antibody titres of
mice injected with vaccines prepared from non-emulsified virus-
antigen concentrates supplemented with either 0.5 per cent Cv/v)
PBS or 0.5 per cent (v/v) phenol and stored at 30°C for 14 days
(Table 8.5). The data were analysed by the 2-sample t-test,
DISCUSSION
The stability characteristics of the commercial and experimentally
prepared louping-ill virus vaccines stored at refrigerated and room
temperatures for a period of up to 6 months were evaluated.
Potency tests in mice indicated that the immunogenicity of
commercially produced virus-antigen concentrate and final emulsified
vaccine rapidly declined to non-detectable levels within weeks of
storage at both refrigerated and room temperatures. Potency tests
in sheep further emphasised the antigenic instability of
commercially produced emulsified final vaccine following storage for
6 months at refrigerated temperatures.
At present, the storage policy for commercial louping-ill vaccine
concentrated by methanol precipitation is that bulk virus-antigen
concentrate is maintained at -20°C and emulsified final vaccine at
4°C; the minimum required storage life of virus-antigen concentrate
and final vaccine being 12 and 6 months respectively.
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I found, however, that under these storage conditions
commercially produced virus-antigen concentrate and final vaccine
were antigenically unstable.
With respect to the storage characteristics of the experimentally
produced virus-antigen concentrates and final vaccine preparations
concentrated by PEG precipitation and ultrafiltration, potency testing
both in mice and sheep indicated that only virus antigen prepared
by ultrafiltration and stored as the concentrate at -20°C retained
immunogenicity for a period of at least 6 months.
Although vaccine prepared from louping-ill virus antigen
concentrated by ultrafiltration and stored as the concentrate at
o
4 C for 6 months also produced an acceptable antibody response in
sheep, statistical analysis of the antibody response in mice did
however indicate a significant decline in immunogenicity over this
period.
Louping-ill virus antigen concentrated by ultrafiltration and
emulsified with oil adjuvant was shown to be antigenically unstable
following subsequent storage at refrigerated temperatures. Potency
tests in mice indicated a significant decline in the immunogenicity
of emulsified vaccine concentrated by ultrafiltration and stored
for a period of 6 months at 4°C or -20°C, and the serological
responses in sheep to such preparations also failed to comply with
the louping-ill final vaccine potency test specifications.
All emulsified louping-ill vaccines, regardless of the method
used to concentrate viral-antigen, and virus-antigen concentrates
prepared either by methanol or PEG precipitation, contain phenol at
a final concentration of 0.5 per cent (v/v). Only virus antigen
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concentrate prepared by ultrafiltration is phenol-free and of all
the vaccine preparations studied only this virus-antigen concentrate
was antigenically stable over a prolonged storage period. An attempt
to determine whether phenol exerts an adverse effect on the stability
of louping-ill virus antigen failed. The conditions under which the
investigation was performed, however, were limited both with respect
to the temperature of storage and the duration of storage and a
further more comprehensive study is required.
A review of the literature indicated that information relating
to the storage characteristics of inactivated togavirus vaccines,
other than louping-ill-virus vaccine, is negligible. The stability
characteristics of the only established live togavirus vaccine,
yellow fever vaccine, are however well documented (Burfoot, Young
and Finter, 1977) .
To conclude, therefore, both the commercially produced virus-
antigen concentrate and the commercial emulsified vaccine were shown
to be antigenically unstable following storage at refrigerated and
room temperatures. These findings further emphasise the inadequacy
of this method of vaccine production.
Although virus-antigen concentrated by ultrafiltration and
stored as concentrate at -20°C retained antigenicity, emulsification
of the concentrate and subsequent storage at refrigerated temperatures
resulted in loss of immunogenicity. The implications of the instability
of emulsified vaccine prepared from louping-ill virus-antigen
concentrated by ultrafiltration with regard to the use of this
concentration technique for commercial production of vaccine is
discussed further in Chapter Nine,
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Table 8.5 The effect of phenol on the stability of virus-antigen
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Louping-ill is probably the most important virus infection of
sheep in Scotland and Northern England and recent appearance of the
disease in areas where it had hitherto been unrecognised, together
with the increasing demand for vaccine, emphasises the need for
effective prophylactic control.
Control of arthropod-transmitted viral disease can be effected
by 2 basic methods; control of the vector or the immunization of the
susceptible host population through large-scale vaccination. In the
majority of instances control by the latter method is most practical
and vaccines have been, or are in the process of being, developed
(Table 9.1).
The animals most susceptible to louping-ill infection are
(i) hoggs returning from overwintering to tick-infected pasture,
(ii) purchased animals, and (iii) lambs (Pool, Brownlee and Wilson,
1930). Losses may also be experienced in all ages of sheep when
louping-ill is first encountered on a farm (C. Bannatyne, personal
communication). Immunization of susceptible animals is presently
effected using a formalin-inactivated, methanol-precipitated, oil
adjuvant vaccine derived from virus infected BHK-21 culture.
Production of this vaccine is based on the methodology developed
by Brotherston and Boyce (1970) in the experimental preparation of
highly immunogenic louping-ill vaccine propagated in primary sheep
kidney cell culture. A single dose of this vaccine was shown to be
sufficient to provoke a satisfactory immune response in sheep.
In contrast however the immunogenic!ty of the presently
available vaccine, based on propagation of virus in BHK-21 cells,
is low and often considerably variable and 2 doses are required to
produce a satisfactory immune response in sheep. Furthermore it
has also been observed that even following the recommended 2 dose
schedule a number of animals persistently remain seronegative or
seroconvert to minimal HAI antibody titres only.
Studies undertaken by the author and reported here demonstrated
that following experimental challenge animals immunized with this
vaccine were protected against clinical disease. Circulation of
virus was nevertheless demonstrated in those animals exhibiting
minimal or undetectable levels of specific humoral antibody. The
intensity of viraemia was however insufficient to cause clinical
disease and below the threshold titre required to establish virus
in the tick. It is evident therefore that despite the absence of a
detectable serological response, the immune system of such animals
is nevertheless sufficiently sensitized to protect against clinical
disease following experimental challenge.
Under field conditions however vaccination may not always induce
an optimal immune response; concurrent infection of mice (Buxton,
Reid and Pow, 1979) and sheep (Reid, Buxton, Pow and Finlayson, in
press) with Toxoplasma gondii has been shown to reduce the antibody
response to louping-ill vaccine and studies with tick-borne fever
(TBF) have shown that infected sheep have depressed immune responses
to para-influenza-3 virus (M. Batungbacal, personal communication).
Animals concurrently infected with TBF may therefore be also less
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able to respond to louping-ill vaccine. It is possible therefore
that under certain conditions the immune responsiveness in a
proportion of sheep will be suboptimal and following immunization
with low potency vaccine the response may be insufficient to protect
the animals from clinical disease following natural challenge. In
addition animals immunized with a low potency vaccine may therefore
develop viraemias of sufficient intensity to reinfect the tick
vector and transmission and maintenance of the virus in nature will
be unaffected by vaccination.
The initial protection of lambs born at or around the peak
period of the spring phase of tick activity depends entirely upon
maternal antibody acquired from colostrum within the first 36 hours
of birth (Brambell, 1958). Reid and Boyce (1976) demonstrated that
lambs with titres of maternal antibody in excess of 1/40 are
refractory to infection and protection persists for at least 3 weeks
following the decline of maternal HAI antibody to undetectable
levels. Experimentally the titres of louping-ill HAI antibodies
in the sera of lambs receiving colostral antibodies from immune ewes
were shown to parallel the titres of the dams (Williams and Thorburn,
1961; Brotherston, Bannatyne, Mathieson and Nicholson, 1971). Under
field conditions however transfer of antibody may not be as efficient.
Thus, at lambing, ewes vaccinated 3 or 15 months previously with
vaccine of low potency may, unless exposed to natural infection in
the intervening period, exhibit only minimal levels of specific anti¬
body. Transfer of maternal immunity to the lamb will therefore also
be minimal and, as the half-life of colostrum-derived HAI antibody
is 13.5 days (Brotherston - cited by Reid, PhD Thesis, 1975), such
animals may therefore become susceptible to infection within weeks of
birth and prior to the cessation of the spring/summer period of tick
activity.
Similarities between the present vaccine and the inactivated
brain tissue vaccine that was available up until the 1960s are
evident; the immunogenicity of the brain tissue vaccine was also low
and a single dose likewise failed to induce a serological response.
In addition the apparent priming of the immune system in the absence
of a detectable serological response, as evident from the vaccination
studies reported here, is comparable to the suggested mode of action
of the brain tissue vaccine (Gordon, 1934; Gordon, Brownlee, Wilson
and MacLeod, 1962; Edward, 1947b; Smith McMahon, O'Reilly, Wilson and
Robertson, 1964; Smith, 1969; Brotherston, Bannatyne, Mathieson and
Nicolson, 1971).
During the period when this brain tissue vaccine was the only
method of prophylaxis a considerable mortality in lambs due to
louping-ill was reported on 2 separate occasions (Gordon, 1934;
Smith, McMahon, O'Reilly, Wilson and Robertson, 1964) and Smith et al
(1964) expressed concern over the use of a low potency vaccine which,
although preventing clinical infection in ewes may however fail to
provide a substantial maternal immunity in lambs.
It is evident therefore that for effective and practical
prophylactic control of louping-ill within the farming industry the
use of a vaccine capable of eliciting the highest possible serological
response following a single inoculation is particularly desirable.
There is also evidence to suggest that, under the recommended storage
conditions, the commercial vaccine is immunologically unstable.
Stability studies have confirmed this observation as both virus
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antigen concentrate and emulsified vaccine were immunologically
unstable following storage at refrigerated temperatures for periods
of less than 6 months.
The principal aim of this project was therefore to develop a
one dose vaccine antigenically stable and capable of consistently
producing a satisfactory immune response in sheep.
Optimal conditions for the growth of louping-ill virus in BHK-21
cell monolayer cultures were determined experimentally and, using
this technique under commercial conditions, titres of individual
harvests were found to range from 6.1 log-^Q pfu/ml to 8.5 log^ pfu/ml.
A direct correlation between the pre-inactivation infectivity titres
of virus suspensions and the immunogenicity of the resulting vaccines
was demonstrated and a threshold titre of 8.0 l°g10 pfu/ml determined;
harvests with titres below this produced unacceptable vaccines. The
immunogenicity of louping-ill vaccine is thus dependent on the
pre-inactivation infectivity titre of the virus harvest.
The titre of louping-ill virus propagated in secondary monolayers
-7
of sheep kidney cells was 10 mouse LD /ml (Brotherston and Boyce,
OU
1970), and vaccines prepared from these inactivated unconcentrated
virus harvests were likewise shown to be non-immunogenic.
That vaccine potency is determined by the antigenic mass of the
source virus suspension has been well illustrated for other members
of the Togaviridae (Levkovich, 1962; Smorodintsev and Ilyenko, 1962;
Crawford, Dayhuff and White, 1968), and Darwish and Hammon (1966b),
developing an inactivated Japanese B encephalitis virus vaccine
derived from hamster kidney cell culture, also demonstrated a direct
correlation between the pre-inactivation infectivity titre of the
source virus suspension and vaccine immunogenicity.
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The failure to produce highly immunogenic vaccine against the
alphavirus, Chikungunya virus, from chick embryo monolayer cultures
(Harrison, Binn and Randall, 1967) was partially attributed to low
pre-inactivation infectivity titres. White, Berman and Lowenthal
(1972), using chick embryo suspension cultures, however, propagated
virus to considerably higher titres and subsequently produced highly
potent vaccines .
The growth of louping-ill virus in other cell culture systems
was not examined, although recently Malewicz and Jenkin (1979)
propagated Dengue virus type 2 in BHK-21 cells adapted to shaker
culture to higher infectivity titres than had been previously
reported in other cell systems. It is possible therefore that a
similar technique adapted for the growth of louping-ill virus may
also significantly increase virus yields.
Using the present method of propagation the infectivity titre
of the commercially produced louping-ill virus harvests will
approximate to the threshold titre of 8.0 pfu/ml. Concentration
of louping-ill viral antigen is thus a particularly necessary and
important stage in the production of potent vaccine.
Production of the presently available vaccine involves the
concentration of viral antigen by methanol precipitation. The
studies described here however demonstrate that this method of
concentrating commercially produced virus antigen was ineffective.
There was no increase in the immunogenicity of concentrated virus
harvests compared to unconcentrated harvests and in several instances
the concentration procedure actually resulted in vaccines of
decreased potency.
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In contrast Brotherston and Boyce (1970) reported that methanol
concentration of louping-ill virus antigen derived from sheep kidney
cells was particularly effective and produced highly potent vaccines.
Vaccine immunogenicity could not however be wholly attributed to
the concentration process as dilution of the concentrates to volumes
in excess of the original volume still produced immunogenic vaccine.
It was suggested therefore that in addition to concentrating viral
antigen, methanol precipitation also enhanced surface antigenicity
by releasing or 'unmasking' hidden antigen.
The efficacy of this method of concentrating louping-ill virus
antigen is thus apparently dependent on the method of virus
propagation, concentration is effective with virus derived from
homologous cell culture (sheep kidney cells) but ineffective when
applied to virus propagated in a heterologous cell culture system
(BHK-21 cells).
In an attempt to offer an explanation for this discrepancy
between the results reported by Brotherston and Boyce (1970) and
the work described here, a review of the current knowledge relating
to the surface morphology and antigenicity of the Togaviridae is
necessary.
Togaviruses are small RNA viruses constructed of a spherical
nucleocapsid and surrounded by an outer lipoprotein envelope
carrying glycoprotein projections on its surface. Togavirus
morphogenesis is entirely cytoplasmic although alphaviruses and
flaviviruses differ with respect to viral maturation. The envelope
of the alphaviruses is acquired as the nucleocapsid buds through
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the marginal membrane, whereas flaviviruses emerge from internal
vacuolar membranes (Horzinek, 1973).
Analysis of the structural proteins of the togaviruses by
polyacrylamide gel electrophoresis has revealed 2 glycoproteins in
the viral envelope (Schlesinger, Schlesinger and Burge, 1972;
Garoff, Simons and Renkonen, 1974). That the envelope glycoproteins
are the principal determinants of HA activity and surface anti¬
genicity has been well illustrated (Mussgay, Weiland, Weiland and
Hhrtner, 1976; Kennedy, 1974; Appleyard, Oram and Stanley, 1970;
Bose and Sagik, 1970; Pedersen and Eddy, 1974; Pederson, Slocum and
Eddy, 1973; Heinz and Kunz, 1977b; Kitano, Suzuki and Yamaguchi,
1974). Kitano, Suzuki and Yamaguchi (1974) further demonstrated
that antigenicity is specifically associated with the glycoproteins
of the surface projections of Japanese encephalitis virus, although
activity could not be definitively assigned to either the sugar or
polypeptide component of the glycoprotein. Mussgay, Weiland, Weiland
and Hhrtner (1976) and Kennedy (1974), studying the alphavirus,
Semliki Forest virus, suggested that it is the polypeptide portion
rather than the carbohydrate residues that determine surface anti¬
genicity and haemagglutination activity and that the integrity of
this component is essential for expression of these properties.
Carbohydrate is a universal constituent of the lipoprotein
membrane of all classes of enveloped viruses and is thought to be
associated with the membrane protein of the viral envelope (Strauss,
Burge and Darnell, 1970). Burge and Huang (1970) working with a
togavirus (Sindbis virus) and a rhabdovirus (vesicular stomatitis virus
suggested that the carbohydrate moiety of the envelope glycoprotein
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may be specified principally by the host cell.
X-ray diffraction studies of Sindbis virus (Harrison, David,
Jumblatt and Darnell, 1971) indicated that the lipids in the lipo¬
protein envelope are arranged as a bilayer. The polar groups
orientate towards the centre of the virus whilst the outer groups
are associated with the peripheral envelope glycoprotein. The
suggestion that at least part of the glycoprotein surface pro¬
jections pass through the lipid bilayer was proposed by Brown,
Smale and Horzinek (1974); Utermann and Simons (1974) ; Garoff (1974);
and Garoff and Simons (1974).
Whether the lipid component is host cell determined or a
reflection of the lipid affinities of the viral envelope polypeptide
is not established. David (1971), studying the lipid patterns of
Sindbis virus grown in either chick embryo fibroblasts or BHK-21
cells, proposed that the lipid composition is determined by the
viral protein. Conversely, Heydrick, Comer and Wachter (1971)
demonstrated that Venezuelan equine encephalitis virus propagated
in L cells of mouse origin had a lipid composition different from
virus grown in chick embryo culture. Laine, Kettunen, Gahmberg,
Khdriainen and Renkonen (1972) also observed that the fatty acids
of the different lipid classes present in Semliki Forest virus and
host BHK-21 plasma membranes were similar. Furthermore when the
phospholipids of members of 3 different groups of viruses (toga,
paramyxo and leukoviruses) grown in the same host cell species were
compared, similar patterns were observed (Quigley, Rifkin and Reich,
1971) .
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If the lipid and carbohydrate composition of the viral envelope
is specified by the host cell, it may not be unreasonable to assume
that louping-ill virus propagated in different cell systems may also
differ in the chemical make-up of both the lipid and carbohydrate
constituents of the virus envelope.
A dissimilarity in the lipid composition of Venezuelan equine
encephalitis virus propagated in L cells or chick embryo cell
culture was also reflected by a difference in the sensitivity of
virus to thermal inactivation (Heydrick, Comer and Wachter, 1971);
it is possible therefore that further biochemical characteristics may
also be modified by an alteration in lipid composition.
Louping-ill virus propagated in sheep kidney cell culture and
BHK-21 cell culture may therefore not only differ with respect to
lipid and carbohydrate composition but also in the sensitivity to
treatment with organic solvents.
That methanol is capable of modifying the surface spatial
arrangement of enveloped viruses has been demonstrated (Jensen,
Kemeny and Stone, 1979), They observed that following methanol
treatment, a loss of peplomers from the surface of the virus of
transmissible gastroenteritis of pigs, a member of the coronaviridae,
was apparent and it was suggested that this was due to an interaction
between methanol and the lipid component of the virus envelope. That
such an alteration in surface morphology was adversely associated
with immunogenicity of the virus was demonstrated by Garwes and
Pocock (1975).
It is therefore possible that methanol treatment of louping-ill
virus may also produce distinct morphological changes in the antigenic
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determinant sites according to the composition of the lipid bilayer
and reflected in the surface antigenic activity. As proposed by
Brotherston and Boyce (1970), methanol precipitation of virus
propagated in sheep kidney cell culture may therefore generate
modifications in the surface structure that subsequently augment
antigenicity and vaccine potency. In contrast, however, it is
suggested that methanol treatment of louping-ill virus derived from
BHK-21 cell culture may, as a consequence of a variance in lipid
composition, produce changes in the surface morphology that
adversely affect antigenic activity resulting in vaccines of inferior
immunogenicity.
Burge and Strauss (1970) and Strauss, Burge and Darnell (1970)
studying the alphavirus, Sindbis virus, have evidence to suggest
that all viral carbohydrate is covalently bound to the virus
specified envelope protein although the function of the carbohydrate
remains unknown. If, as suggested by Burge and Huang (1970), the
virus carbohydrate is determined by host cell enzymes then the
glycoprotein may therefore represent a host modification of a virus
determined protein and behave as a hybrid antigen, part host specified
and part virus specified. Although the immunological consequences
of such a situation are not obvious the use of a heterologous rather
than a homologous cell culture system for propagating virus required
for subsequent vaccine production may therefore adversely affect the
specific antigenic activity determined by the surface glycoproteins
and thus the immunogenicity of resulting vaccine preparations.
The low potency characteristic of the presently available
louping-ill vaccine may therefore be attributable to:
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(1) the use of a heterologous cell culture system for virus propagation.
(2) the concentration of viral antigen by the method of methanol
precipitation
(3) vaccine instability
and a re-evaluation of each of these features of vaccine production is
therefore paramount to the production of a louping-ill vaccine of
improved quality.
As the use of homologous primary cell cultures is not feasible
for the large-scale production of commercial vaccine and a homologous
cell line is unavailable, the use of BHK-21 cells for culturing virus
inevitably remains an integral feature of vaccine production.
Louping-ill virus antigen prepared from infected BHK-21 cell
cultures was successfully and efficiently concentrated by the
technique of ultrafiltration. The potencies of resulting vaccines
prepared under both experimental and commercial conditions of
production were consistently higher than corresponding vaccines
prepared hy concentrating viral antigen by methanol precipitation.
In addition, the immunogenicity of vaccines concentrated either 10- or
5-fold by ultrafiltration provoked a satisfactory immune response in
sheep and cattle in compliance with the potency test specification
following a single 1ml dose and 2 1ml doses respectively.
Ultrafiltration is a purely physical method of concentration,
essentially approximating to the simple process of de-watering and
removal of low molecular weight salts. It is thus a particularly
mild method of concentrating viral antigen and it is probably this
characteristic of the technique that allows for effective
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concentration and recovery of viral antigen and the subsequent
production of highly potent vaccines.
The indiscriminant nature of the concentration process may
however be a potential criticism of this technique as in addition
to the concentration of specific viral antigen, non-viral proteins
derived from the cell substrate and media constituents of an
equivalent or higher molecular weight will also be simultaneously
concentrated. Antigenically therefore the resulting concentrate may
be particularly heterogenous in character. Inhibition of, or inter¬
ference with the immune response to specific antigen by non-specific
protein was not however evident in the studies reported here.
The advantages of concentrating commercially prepared louping-
ill virus antigen by ultrafiltration as opposed to methanol
precipitation are numerous: from the farmers' and veterinary
practitioners' point of view a single dose vaccine is preferable
to a double dose vaccine, both with respect to the practical and
managerial aspects of vaccination and the vaccine purchasing costs.
In addition the serological responses evoked by vaccines concentrated
by ultrafiltration have been sufficiently high to suggest that:
(1) vaccinated ewes will transfer a substantial maternal antibody
to the lamb
(2) in those animals failing to produce an optimal serological response
to vaccination, the level of circulating antibody evoked will
nevertheless be sufficient to protect against clinical infection, and
(3) replication of virus in vaccinated animals following natural
exposure to virus will be minimal and less than the infection threshold
titre in ticks. Systematic immunization using a vaccine concentrated
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by ultrafiltration will therefore abrogate virus transmission to the
tick and be instrumental in reducing the natural reservoir of virus.
From the manufacturer's point of view ultrafiltration is
unequivocably a more favourable method both in terms of simplicity
of vaccine production, overall manufacturing costs and safety.
The technique is simple in operation and; in contrast to the
methanol method, demands on manpower resources are minimal.
Expenditure is limited to the initial purchase of an appropriate
hollow fibre ultrafiltration system and as the hollow fibre cartridges
are reusable over an extended period without loss of filtration
efficiency, further costs are negligible.
Commercial vaccine production involves the use of large volumes
of inflammable solvent thus constituting a serious fire hazard. In
contrast the technique of ultrafiltration can be used without risk.
The preparation of louping-ill vaccine using this technique of
ultrafiltration to concentrate viral antigen appears therefore to
satisfy the demands cited earlier, i.e. the development of a highly
immunogenic vaccine capable of eliciting a satisfactory immune
response in sheep following a single dose.
With respect to the stability of such vaccines, assessment of
the storage characteristics of the virus antigen concentrate is
necessarily an on-going study. However, potency testing in sheep
has so far indicated that the concentrate retains antigenicity for
at least 6 months stored at either 4°C or -20°C. In contrast
however storage of the emulsified vaccine for a period of 6 months
at either 4°C or -20°C resulted in almost total loss of immunogenicity.
As the minimum required storage life of emulsified vaccine is 6 months,
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it is apparent therefore that the storage characteristics of the
emulsified vaccine under such conditions are inadequate.
Equivalent vaccine preparations concentrated by PEG
precipitation were also subjected to stability studies and both the
concentrate and the emulsified vaccine were found to be non-
immunogenic when tested in mice or sheep after 6 months storage at
o o
4 C or -20 C. Commercially produced virus antigen concentrate,
prepared by methanol precipitation and the resulting emulsified
vaccine were similarly non-immunogenic following equivalent stability
tests.
Thus of all the vaccine preparations examined only virus antigen
concentrate prepared by ultrafiltration retained potency following
prolonged storage periods. A distinctive feature of this preparation
was the absence of phenoL Virus antigen precipitated by methanol and
PEG were routinely resuspended in PBS which, for bactericidal purposes,
was supplemented with 0.5 per cent (v/v) phenol and all antigen
concentrates were emulsified with oil adjuvant also supplemented with
an equivalent concentration of phenol.
Attempts to determine whether exposure to phenol produced an
adverse effect on vaccine immunogenicity were inconclusive.
Nevertheless the possibility that during prolonged storage the
continuous exposure of antigen to phenol or the oxidation products
of phenol may be detrimental to antigenic activity cannot be excluded.
It is of interest to note that in the production of highly
potent louping-ill vaccine derived from primary sheep kidney cell
culture (Brotherston and Boyce, 1970), the methanol precipitated
protein was resuspended in PBS supplemented with 10 per cent
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inactivated sheep serum and the resulting concentrates were emulsified
with oil adjuvant containing phenol at a concentration of 0.3 per cent
(v/v). The concentration of phenol in this vaccine was thus less than
in the presently available vaccine. Unfortunately however the effect
of long term storage on the antigenic stability of either concentrate
or emulsified vaccine was not determined.
Despite the antigenic instability of the vaccine emulsion,
commercial production of louping-ill vaccine using the technique of
ultrafiltration to concentrate viral antigen must be regarded as a
very attractive alternative to the present method of production.
Further studies outwith this project are however required to improve
the storage characteristics of the vaccine emulsion and it is
suggested that these be designed to assess the stability of phenol-
free vaccine emulsions and to evaluate the use of alternative adjuvants,
preservative agents and storage conditions.
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PREPARATION AND POTENCY TESTING OF COMMERCIAL LOUPING-ILL VIRUS
VACCINE
PREPARATION
Louping-ill virus is propagated in monolayer cultures of BHK-21
cells in BHK virus growth media and incubated as rolling cultures
at 37°C. After 72 hours the supernatants are harvested in 4- or
8-litre volumes in 5- or 10-litre bottles. Samples are removed for
infectivity titration using the plaque assay method. Formalin is
added to the harvests to give a final concentration of 1/1000 and
thoroughly mixed by shaking. After 24 hours incubation at 37°C
samples are removed from the harvests and assayed for innocuity,
sterility and residual formalin. The harvests are chilled at 4°C and
cold methanol added (45ml methanol to each 100ml of harvest). The
preparation is stirred continuously with a bar magnet for 24 hours at
4°C. The resulting precipitate is centrifuged at lOOOg for 60
minutes at 4°C and resuspended to one tenth of the original volume
in PBS pH 7.2 containing 0.5 per cent (v/v) phenol. Samples are
removed from the 10-fold concentrate and tested for pre-blend potency.
The bulk 10-fold concentrates are stored at -20°C until required.
POTENCY TESTING
Pre-blend potency test
Two-fold dilutions (1/2, 1/4 and 1/8) of the 10-fold concentrate
samples are prepared in PBS +0.5 per cent (v/v) phenol and separately
emulsified with Bayol F and Falba oil adjuvant supplented with 0.5
per cent (v/v) phenol in a ratio 2 parts adjuvant to one part
concentrate in a final volume of 15ml. Each preparation is then
207.
potency tested according to the potency test specification.
The response in sheep to these preparations determines to what extent
the 10-fold concentrates can be diluted to prior to emulsification
and preparation of the bulk vaccine.
Final potency test
The 10-fold concentrates are diluted and emulsified as and when
required and a final potency test then carried out on a sample of the
final containerized vaccine.
Prior to February 1979 the potency test specification stated that:
"Not less than 6 healthy sheep devoid of louping-ill haemagglutination-
inhibiting antibodies are each injected with 1.0ml of vaccine. Between
28 and 56 days after the injection the sera of at least 5 of the
sheep must contain HAI antibodies at dilutions of 1/10 or greater ...".
However batches of final vaccine have repeatedly failed to produce
an immune response in accordance with this specification, and, to
ensure protection following vaccination it was found necessary to
recommend a double dose vaccination schedule and to revise the potency
test specification as follows: "Not less than 6 healthy sheep devoid
of louping-ill haemagglutination inhibiting antibodies are each
injected with 1.0ml of vaccine. A second injection of 1.0ml of
vaccine is given between 3 weeks and 6 months after the first.
Between 15 and 56 days after the second injection the sera of at
least 5 of the sheep must contain HAI antibodies at dilutions of 1/10
or greater ...".
The current recommendation for protection of sheep states that
2 1ml doses of vaccine should be administered and spaced not less than
3 weeks and not more than 6 months apart. The current recommendation
208.
for the protection of cattle states that 2 2ml doses of vaccine should
be administered and spaced not less than 3 weeks and not more than
6 months apart.
209.
































































Appendix 3.3 The reciprocal HAI titres of Group II-VIII sheep






revaccination 7 14 21 28 84
II X543 <10 < 10 10 <10 <10 20
X351 < 10 D
X342 < 10 < 10 <10 <10 <10 20
X530 < 10 < 10 10 <10 <10 <10
V860 < 10 20 40 40 40 80
X533 < 10 < 10 10 <10 <10 10
X346 < 10 40 20 20 <10 20
X505 < 10 640 640 640 160 80
V877 < 10 < 10 20 20 10 40
X471 < 10 320 320 160 160 160
Geometric mean 5 20 20 22 15 29
III X302 160 640 640 640 1280 640
V692 20 640 320 160 320 640
X335 160 1280 1280 640 1280 1280
X515 40 80 80 80 80 160
X432 <10 80 160 160 160 80
X478 20 320 320 160 160 80
X343 20 160 160 80 80 20
X548 < 10 < 10 < 10 <10 <10 <10
X511 160 160 160 160 160 640
V864 < 10 20 10 <10 10 20
Geometric mean 26 138 129 91 120 120
jy V896 10 160 80 1280 40 10
X595 < 10 20 80 160 80 640
V888 20 1280 640 640 320 80
V858 80 2560 1280 640 640 640
X297 < 10 80 80 80 40 10
X457 < 10 <10 <10 <10 <10 <10
X300 80 640 640 1280 640 640
V688 < 10 160 160 80 40 <10
X565 < 10 40 20 40 <10 <10
X563 < 10 <10 <10 <10 <10 <10
Geometric mean 11 98 85 120 49 32
y X467 < 10 40 80 <10 40 <10
V893 10 160 80 80 40 80
V863 10 320 320 80 160 20
X484 20 160 320 80 80 40
X469 20 640 640 160 640 80
V861 40 640 640 320 640 160
X485 160 2560 2560 1280 2560 320
X338 80 2560 10240 2560 2560 640
V885 40 320 640 320 1280 1280
X512 320 1280 10240 2560 2560 2560








revaccination 7 14 21 28 84
Group VI X309 < 10 20 C10 <10 <10 <10
X464 1280 2560 2560 5120 5120 20480
X463 320 1280 5120 5120 10240 10240
X492 160 640 2560 2560 2560 10240
X495 80 320 640 160 320 320
X525 < 10 40 40 20 20 80
X536 < 10 160 80 80 40 <10
X547 < 10 < 10 <10 <10 < 10 20
X586 < 10 40 20 20 <10 10
V883 20 160 80 40 40 40
:ric mean 28 138 138 112 105 158
Group VII X549 20 80 320 160 320 160
X545 < 10 80 80 40 160 < 10
X578 < 10 160 80 80 320 10
X157 < 10 160 160 320 1280 40
X579 640 320 640 640 2560 640
X553 < 10 < 10 20 20 80 <10
X490 < 10 80 40 40 160 <•10
X577 10 80 40 40 640 20
X359 20 160 160 80 160 <10
X431 < 10 320 160 160 640 40
Geometric mean 11 98 105 91 363 21
Group VIII X560 < 10 1280 160 640 160 <10
X155 10 40 80 320 40 10
X436 10 160 160 640 320 20
V695 D
V689 < 10 160 80 320 160 20
X524 < 10 160 160 640 160 <10
V869 10 20 40 160 160 40
X466 20 640 640 2560 640 80
X462 10 80 160 320 80 20
X569 40 320 160 320 320 40
Geometric mean 10 158 137 468 170 18
D: died through natural causes.
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Appendix 3.4 The titres of virus (l°g10 pfu/ml) detected in sheep
plasmas following inoculation with louping- ill virus
Sheep Days post-inoculation
No. i_ 2_ _3_ _4_ x _6
Unvaccinated X333 1.4 NT 4.3 3.7 3.6 N
controls X477 N N N 0.7 N N
X497 0. 4 2.0 2.0 2.3 N N
X501 N N N N N N
X520 1.4 2.0 2.6 3.2 1.6 N
X538 2.0 2.9 4.9 4.9 3.3 N
V875 1.1 2.7 4.6 6.9 5.4 2.
V876 0.7 0.4 1.5 2.8 3.6 N
V894 1.6 2.5 3.7 3.4 N N
V897 1.0 2.4 3.9 5.8 2.4 N
Vaccinates: X475 N N N N N N
titre <10 at V889 1.4 2.1 4.2 4.5 4.0 N
challenge X342 N N N 1.1 N N
X543 N N N 2.3 1. 1 N
X548 1.0 1.2 2.8 1.7 1.7 N
V864 N 1.5 2.9 3.8 N N
X565 N N 3.1 1.4 N N
X563 1.1 1.3 2.6 N N N
X586 N 1.9 3.6 3.0 3.4 N
X490 N 1.0 0.9 N N N
X553 N N N N N N
Vaccinates: X467 1.4 1.9 2.6 2.4 0.9 N
titre ^10 at V893 N N N N N N
chal lene-e X309 0.4 N 0.9 N N N
X155 N N N N N N
X462 N N N N N N
N = virus not detected
NT = plasma not tested


































































































































































































































































Appendix 4.1 Infectivity titres (loB10 pfu/ml) and reciprocal
HA (log^) titres of virus harvests propagated in

























































Samples removed at each time interval were assayed for virus
infectivity in triplicate and for HA activity in duplicate















































7.7 7.7 7.3 7.4 6.1 6.5 6.2 6.2 5.9 5.9
1.2 1.2 1.5 1.8 1.5 1.5 1.2 1.2 0.6 1.2
Samplesremov dtachtiinter alwereassayedfovirusi f c ivitynHActindupli ate
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Appendix 4.3 The infectivity titres (log^0 pfu/ml) of virus harvests
propagated in BHK-21 cells and BHK-21 (R8MF) cells in







24 ! 7.6 7.7 6.3 6.4
7.5 7.7 6.1 6.3
7.4 7.6 5.8 5.6
7.5 7.7 6.0 5.6
48 7.4 7.6 6.0 6.2
7.5 7.7 6.1 6.2
7.4 7.3 6.0 5.2
7.3 7.1 5.8 5.3
72 7.6 7.6 5.5 5.6
7.4 7.3 5.5 5.7
7.6 7.3 4.9 4.1
7.6 7.5 5.0 4.1
96 8.0 7.5 6.6 5.0
8.0 7.7 6.7 5.1
7.9 7.3 5.5 3.0
7.8 7.2 5.6 3.1
120 7.9 7.4 6.4 5.1
7.9 7.5 6.5 5.0
7.4 7.0 4.4 3.1
7.5 7.2 4.3 3.0
Data collated from two separate experiments carried out under the
same adsorption and growth conditions
In both experiments the samples removed at each time interval were
assayed for virus infectivity in duplicate
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Appendix 4.4 The reciprocal HA titres virus harvests
propagated in BHK-21 cells and BHK-21 (R8MF) cells








































































Data collated from two separate experiments carried out under the same
adsorption and growth conditions
In both experiments the samples removed at each time interval were
assayed for HA activity in duplicate
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Appendix 4.5 Infectivity titres pfu/ral) and reciprocal HA
(logjg) litres virus harvests propagated in Wheaton
roller bottles for vaccine production 1978-79
A1 Harvest A2 Harvest A3 Harvest
Infectivity HA Infectivity HA Infectivity HA
8.2 2.4 7.7 2.4 8.2 2.1
8.4 2.7 7.9 2.4 8.4 2 . 1
8.2 2.7 8.0 2.4 8.5 2.1
8.5 2.7 7.7 2.4 8.7 2.4
7.7 2.4 8. 1 2.4 8.6 2.4
8.0 2.4 7.8 2.4 8.4 2.1
7.7 2.4 7.9 2.4 8.4 2.4
8.2 2.7 ^0.06 8.4 2.4
8.1 2.6 8.4 2.3
-0. 10 -0.06 -0.05 -0.06
B1 Harvest B2 Harvest B3 Harvest
Infectivity HA Infectivity HA Infectivity HA
7.6 2.1 8.0 2..4 8.2 2.4
7.8 2.4 8. 3 2,,4 8.3 2.4
7.9 2.4 8.2 2.. 4 8.4 2.4
7.9 2.7 8.3 2.,4 8.5 2.7
7.9 2.7 8.3 2..4 8.3 2.4
8.0 2.7 8.4 2,.4 8.4 2.4
7.7 3.0 8.6 2.. 1 8.5 2.7
7.7 2.1 8.2 2 , 7 7.2 2.4
7.9 2.7 8.3 2,, 4 8.6 2.7
7.9 2.7 8.4 2_j_7 8.5 2.4
+7.8 2.6 8.3 2,I . 4 8.3 2.5































































































































































Replicate samples: The number of replicate samples withdrawn from each
harvest was dependent on the total harvest volume.
Mean titre - s.e.




















































1.25x 0.7 1.1 -0.26 1.3 -0.3 1.7 -0.23 1.25x 0.7 1.2 -0.30 1.3 -0.25 1.5 ±0.26
evokedbyconcentratea dunconce ted HarvestPoolB Unconc.lOx5x2.51.25x 0.91 1.7 -0.15-0.37 1.56.74 -0.27±0.49-0.10.37-0.60 2.01 76.54 ±0.1748-0.15-0.3227 2.01 9.75 -0.15±0.5.22357 HarvestPoolD Unconc.lOx5x2.51.25 0.91 20.7 ±0.10.257 1.87.51 ±0.259. 713 2.01 75.2 ±0.23981 2.01 87.42 ±0.237419. 8
Appendix6.1co t'd. Dayspost- vaccination 7 14 21 28* 42 56
HarvestPoolE
Unconc. 1.1 ±0.13 2.2 ±0.24 2.6 ±0.17 2.7 ±0.06 3.3 ±0.06 3.8 ±0.13
lOx 1.1 ±0.26 2.3 ±0.18 2.3 ±0.16 2.6 ±0.21 3.7 ±0.22 3.5 ±0.13
5x 0.8 ±0.10 2.0 ±0.21 1.7 ±0.18 1.8 ±0.27 2.9 ±0.24 2.8 ±0.22
2.5x 0.7 1.9 ±0.31 1.9 ±0.31 2.0 ±0.28 2.6 ±0.16 3.1 ±0.18
1.25x 0.7 2.0 ±0.31 1.7 ±0.25 1.9 ±0.28 2.8 ±0.30 3.1 ±0.30
*Sheeprevaccinatedwithfurt r1mlofvac i e
HarvestPoolF
Unconc. 0.8 ±0.06 1.5 ±0.21 2.0 ±0.31 1.8 ±0.27 2.6 ±0.15 3.0 ±0.13
lOx 1.2 ±0.18 2.1 ±0.26 2.2 ±0.30 1.9 ±0.26 2.9 ±0.28 2.4 ±0.31
5x 1.0 ±0.27 2.0 ±0.27 2.2 ±0.25 1.8 ±0.17 2.8 ±0.10 2.4 ±0.15
2.5x 0.7 1.2 ±0.26 1.2 ±0.27 1.2 ±0.27 2.1 ±0.34 2.0 ±0.33
1 ■25x 0.7 1.7 ±0.32 1.9 ±0.28 1.6 ±0.34 2.8 ±0.25 2.6 ±0.23
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Appendix 8.1 The reciprocal HAI titres nice in response

































Me an - s . e.
Antibody titres 21 days post-revaccination
Vaccines tested immediately following production
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Appendix 8.2 The reciprocal HAI titres (log^) in mice following
vaccination with louping-ill virus vaccines previously
o
stored at -20 C as emulsion or antigen concentrate
Weeks of Emulsion
Storage 3M 3P 3U 3M 3P 3U
4 1.3 1.3 2.5 1.0 1.9 2.5
1.0 1.3 3.1 1.0 2.2 2.8
0.7 1.0 3.1 1.0 1.6 3.1
0.7 0.7 2.8 0.7 0.7 3.1
0.9 1.1 2.9 0. 9 1.6 2.9
Mean^s.e. -0. 14 -0.14 -0. 14 -0.08 -0.32 -0.14
8 0.7 1.3 2.8 1.0 1.3 3.7
1.0 1.6 3. 7 0.7 1.6 3.1
1.0 1.3 3.1 0.7 1.9 3.7
0.7 1.0 3.4 0.7 2.2 2.8
+0.9 1.3 3.3 0.8 1.8 3.3_i_
Mean-s.e. -0.08 -0. 12 -0. 19 -0.08 -0.19 -0.23
12 1.0 0. 7 2.2 0.7 1.3 3.1
1.0 0.7 3.1 1.0 1.0 3.7
1.0 0.7 2.5 0.7 1.0 3.7
1.0 0.7 2.5 1.0 1.0 3.1






























Antibody titre 21 days post-revaccination
M: concentrated by methanol precipitation
P: concentrated by PEG precipitation
U: concentrated by ultrafiltration
NT: not tested
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12 Concentrate 2.5 2.5 2.5 2.2 3.1 2.5 3.1 2.8 3.1 2.8 2.2 2,5 2.7 -0.09
Emulsion 0.7 2.2 1.9 2.5 2.5 3.7 1.9 NT 2.5 2.8 2.8 1.6 2.3 -0.23
Concentrate 2.5 1.0 1.9 2.2 1.9 0.7 2.8 1.9 2.5 1.9 2.8 1.9 2.0^0.19
Appendix8.4ThereciprocalHAItitresmicefollow ngva ci ationw thlou ing-ill virusaccinesstoredt'cool' semulsionantigc centra Vaccine 1M 2M 3M + Mean-s.e.1_ 1£ 1.0 NT1.0 NT1.6 NT0.7 0.7 0.7 0.7 0.7 0.71 0 1.6NT 1.3NT 1.3NT 1.00 9 -0.12±0.10_2 £ 0.71 0 0.71 0 0.71 9 1.03 1.06 1.63 1.30 1.0 0.71 0 1.0 1.30 1.30 1.02 ±0.09ilWeeksof 4_ £c 1.3 0.71 0 0.71 0 0.71 0 1.06 1.03 0.71 0 0.71 0 1.96 1.63 0.71 0 0.71 0 1.0.2 ±0.1207_8 EC 0.71 9 0.71 6 0.71 0 0.7 0.7 0.7 0.7 1.30 7 1.0 0.71 9 0.71 0 0,71 6 0.81 1 ±0.0514
12
EC_
0.7 0.71 0 1.00 7 1.00 7 1.0 1.0 0.71 0 1.0 0.7 1.0 0.7 NT0.7 0.9 ±0.054
24
E_C
1.00 7 0.7 1.0 0.71 0 1.00 7 0.7 1.00 7 1.00 7 0.7 0.7 0.7 0.7 0.8 ±0.043







































































































































































































































































































































































































E=mulsion C=oncentrate Antibodytitres21daypost-revaccination U=concentratedbyultrafiltration
to to to
230.
Appendix 8.5 The reciprocal HAI titres in mice following
vaccination with louping-ill virus vaccines stored
o
at 30 C as emulsion or antigen concentrate
Vaccine Weeks of storage
Emulsion Concentrate Emulsion Concentrate
1M 1.3 1.3 1.3 1.3
0.7 1.0 1.0 1.3
1.9 1.0 1.3 1. 0
1.3 1.0 1.3 1.0
2M 1.6 0.7 1.3 1.3
0.7 0.7 1.3 1.3
1.6 0.7 0.7 1.0
1.9 1.6 1.0 1.3
3M 1.6 0.7 0.7 1.0
1.6 1.0 1.0 1.0
1.3 0.7 1.0 1.3
1.3 1.9 1.0 1.9
1.4 1.0 1.1 1.2
±0. 11 ±0.11 -0.07 ±0.07
IP 1.6 1.3 0.7 1.0
1.6 0.7 1.0 1.0
1.0 1.3 1.0 1.3
0.7 0.7 1.0 1.0
2P 1.0 1.3 1.0 0.7
0.7 0.7 1.0 0.7
0.7 0.7 1.0 0.7
0.7 0.7 1.0 0.7
3P 0.7 0.7 0.7 1.0
0.7 1.6 1.0 1.0
0. 7 1.0 1.6 0.7
0.7 1.0 1.3 0.7
0.9 1.0 1.0 0.9
Me an - s .e. -0.10 ±0.09 °lol+i ±0.06
Antibody titres 21 days following revaccination
M = concentrated by methanol precipitation
P = concentrated by PEG precipitation
231.
Appendix 8.5 cont'd
Vaccine Weeks of storage
1_ _2_
Emulsion Concentrate Emulsion Concentrate
ru 0.7 2.5 1.9 2.5
2.2 2.8 2.8 2.8
3.4 2.8 2.2 1.9
3.1 3.4 0.7 2.2
2U 2.2 2.8 1.9 3.1
2.8 3.1 3.4 2.5
1.6 3.1 1.9 2.8
2.5 3.4 1.9 3.4
3U 3.4 3.1 1.9 2.2
3.4 3.7 2.2 2.2
2.5 3.1 2.5 2.2
3.4 3.7 1.9 3.1
2.6 3.1 2.1 2.6
Mean - s.e. -0.24 -0.10 -0.19 -0.13
Antibody titres 21 days following revaccination
U = concentrated by ultrafiltration
